

# CITATION REPORT

List of articles citing

p53 mutations in human cancers

DOI: 10.1126/science.1905840  
Science, 1991, 253, 49-53.

**Source:** <https://exaly.com/paper-pdf/22066505/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2281	Aberrant protein folding as the molecular basis of cancer. <b>2003</b> , 232, 67-76		25
2280	p53 mutation in hepatocellular carcinoma after aflatoxin exposure. <b>1991</b> , 338, 1356-9		387
2279	Tumor suppressor genes. <i>Science</i> , <b>1991</b> , 254, 1138-46	33.3	1346
2278	Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. <b>1991</b> , 65, 1083-91		367
2277	From The Lancet. <b>1991</b> , 338, 1359		4
2276	Prognostic significance of molecular genetic markers in childhood brain tumors. <b>1991</b> , 17, 245-50		31
2275	Mutations in p53 as potential molecular markers for human breast cancer. <b>1991</b> , 88, 10657-61		189
2274	Dose-dependent differences in the profile of mutations induced by an ultimate carcinogen from benzo[a]pyrene. <b>1991</b> , 88, 11227-30		84
2273	Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. <b>1991</b> , 88, 8405-9		161
2272	A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. <b>1991</b> , 88, 10124-8		1800
2271	DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. <i>Science</i> , <b>1991</b> , 254, 1001-3	33.3	1098
2270	Chromosome 17- and p53 changes in lymphoma. <b>1991</b> , 79, 575-82		29
2269	Use of PCR amplification of cDNA to study mechanisms of human cell mutagenesis and malignant transformation. <b>1991</b> , 18, 239-44		2
2268	p53 alterations in all stages of breast cancer. <b>1991</b> , 48, 260-7		26
2267	Genes associated with tumor suppression and growth control in the human nervous system. <b>1991</b> , 10, 281-7		2
2266	Primary hepatocellular carcinoma. <b>1991</b> , 325, 729-31		112
2265	Gene specific DNA repair. <b>1991</b> , 12, 1983-92		144

2264	Molecular Epidemiology and the Genetics of Environmental Cancer. <b>1991</b> , 266, 681		88
2263	Molecular mechanisms of genetic deregulation in toxicity and carcinogenesis. 6th Aspen Cancer Conference. Aspen, Colorado, July 20-25, 1991. Abstracts. <b>1991</b> , 19, 625-69		
2262	Transgenic models of tumor development. <i>Science</i> , <b>1991</b> , 254, 1161-7	33.3	281
2261	Overview: Recent Aspects of Transgene Technology. <b>1991</b> , 1, 1821-1841		1
2260	Toward the primary prevention of cancer. <i>Science</i> , <b>1991</b> , 254, 1131-8	33.3	315
2259	Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. <i>Science</i> , <b>1991</b> , 253, 665-9	33.3	1592
2258	Mutational spectra and immunohistochemical analyses of p53 in human cancers. <b>1992</b> , 101, 19S-20S		25
2257	The HIV/AIDS epidemic: a current picture. <b>1992</b> , 8, 695-707		
2256	Mutations in the p53 gene at codon 249 are rare in squamous-cell carcinoma of the head and neck. <b>1992</b> , 1, 253-6		1
2255	Barretts carcinoma in a 25-year-old man with point mutation of the p53 tumor suppressor gene. <b>1992</b> , 1, 271-5		
2254	Ras and p53 expression in non-small-cell lung-cancer patients - p53 over-expression correlates with a poor prognosis. <b>1992</b> , 1, 403-13		13
2253	The p53 tumor-suppressor gene. <b>1992</b> , 326, 1350-2		116
2252	Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. <b>1992</b> , 77, 295-301		158
2251	Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. <b>1992</b> , 84, 1156-60		101
2250	p53 expression in lymphatic malignancies. <b>1992</b> , 45, 1011-4		32
2249	Canine malignant lymphoma and 2,4-dichlorophenoxyacetic acid herbicides. <b>1992</b> , 84, 271		3
2248	Search for Ha-ras codon 61 mutations in liver tumours caused by hexachlorobenzene and Aroclor 1254 in C57BL/10ScSn mice with iron overload. <b>1992</b> , 13, 1917-20		17
2247	PCR detection of a neutral CGA/CGG dimorphism in exon 6 of the human p53 gene. <b>1992</b> , 20, 928		16

2246	Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. <b>1992</b> , 20, 5565-70	114
2245	Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. <b>1992</b> , 326, 1309-15	320
2244	Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses. <b>1992</b> , 20, 3435-41	13
2243	Conformational effects of selected cancer-related amino acid substitutions in the p53 protein. <b>1992</b> , 10, 253-64	9
2242	Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. <b>1992</b> , 6, 1886-98	191
2241	Phosphorylation sites in the amino-terminal region of mouse p53. <b>1992</b> , 89, 4231-5	73
2240	Overlap of the p53-responsive element and cAMP-responsive element in the enhancer of human T-cell leukemia virus type I. <b>1992</b> , 89, 5403-7	29
2239	Oncology. <b>1992</b> , 268, 391	
2238	Wild-type p53 is a cell cycle checkpoint determinant following irradiation. <b>1992</b> , 89, 7491-5	1552
2237	Oncogenes and tumor suppressor genes: new biochemical tests. <b>1992</b> , 29, 269-305	13
2236	Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. <b>1992</b> , 89, 9622-6	79
2235	Genotypic analysis of N-ethyl-N-nitrosourea-induced mutations by Taq I restriction fragment length polymorphism/polymerase chain reaction in the c-H-ras1 gene. <b>1992</b> , 89, 5331-5	28
2234	Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. <b>1992</b> , 89, 3439-42	227
2233	Nucleotide sequence analysis of an HTLV-I isolate from a Chilean patient with HAM/TSP. <b>1992</b> , 8, 1201-7	22
2232	The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. <b>1992</b> , 13, 1273-5	47
2231	The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers. <b>1992</b> , 10, 417-29	7
2230	The rat genome contains a p53 pseudogene: detection of a processed pseudogene using PCR. <b>1992</b> , 1, 251-4	15
2229	Abstracts. <b>1992</b> , 20, 655-670	

2228	Genotypic analysis of mutations in Taq I restriction recognition sites by restriction fragment length polymorphism/polymerase chain reaction. <b>1992</b> , 89, 890-4	34
2227	Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. <b>1992</b> , 89, 4207-9	58
2226	p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. <b>1992</b> , 45, 1007-10	66
2225	Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. <b>1992</b> , 102, 1220-1228	134
2224	p53 gene mutations in gastric and esophageal cancers. <b>1992</b> , 103, 892-6	61
2223	Will molecular genetic markers help predict the clinical behavior of colorectal neoplasia?. <b>1992</b> , 102, 1419-21	4
2222	Germline mutations in the p53 tumour suppressor gene: scientific, clinical and ethical challenges. <b>1992</b> , 66, 424-6	21
2221	Increased expression and mutation of p53 in choroidal melanoma. <b>1992</b> , 66, 900-4	36
2220	The molecular and genetic characterization of human soft tissue tumors. <b>1993</b> , 60, 75-120	10
2219	Genomic instability and tumor progression: mechanistic considerations. <b>1993</b> , 60, 121-56	120
2218	Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. <b>1992</b> , 89, 6413-7	76
2217	An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. <b>1992</b> , 89, 6516-20	120
2216	Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. <b>1992</b> , 89, 7262-6	478
2215	Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. <b>1992</b> , 12, 5581-92	328
2214	Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. <b>1992</b> , 89, 2759-63	102
2213	A rapid somatic genotoxicity assay in <i>Drosophila melanogaster</i> using multiple mutant mutagen-sensitive ( <i>mus</i> ) strains. <b>1992</b> , 7, 399-405	8
2212	p53 expression in human breast cancer. <b>1992</b> , 59, 69-88	32
2211	A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. <b>1992</b> , 89, 6693-7	91

2210	Excision repair at individual bases of the Escherichia coli lacI gene: relation to mutation hot spots and transcription coupling activity. <b>1992</b> , 89, 11031-5	66
2209	Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae. <b>1992</b> , 12, 1357-65	118
2208	Rat p53 gene mutations in primary Zymbal gland tumors induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen. <b>1992</b> , 89, 4850-4	70
2207	A mammalian cell line deficient in activity of the DNA repair enzyme 5-hydroxymethyluracil-DNA glycosylase is resistant to the toxic effects of the thymidine analog 5-hydroxymethyl-2'-deoxyuridine. <b>1992</b> , 12, 5536-40	47
2206	DNA damage and mutation in human cells exposed to nitric oxide in vitro. <b>1992</b> , 89, 3030-4	821
2205	Mutations of p53 gene in human colorectal tumor in Japan: molecular epidemiological aspects. <b>1992</b> , 167, 243-5	4
2204	A comparative immunohistochemical study of p53 and heat shock protein expression in microwavefixed, paraffin-embedded sections of colorectal tumors.. <b>1992</b> , 25, 583-590	4
2203	Tumor suppressor genes in the cell cycle. <b>1992</b> , 4, 155-60	25
2202	Inherited cancer genes. <b>1992</b> , 2, 53-7	10
2201	Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. <b>1992</b> , 339, 576-80	251
2200	Detection of single DNA base mutations with mismatch repair enzymes. <b>1992</b> , 14, 249-55	39
2199	Formation of 8-hydroxydeoxyguanosine within DNA of mouse keratinocytes exposed in culture to UVB and H2O2. <b>1992</b> , 13, 2003-7	97
2198	Tumours of the liver. <b>1992</b> , 192, 39-42	19
2197	Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. <b>1992</b> , 89, 4495-9	750
2196	Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. <b>1992</b> , 6, 1143-52	286
2195	The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. <b>1992</b> , 69, 1237-45	2637
2194	Carcinogens leave fingerprints. <b>1992</b> , 355, 209-10	130
2193	Mutations in the P53 tumour suppressor gene in primary lung cancer in Japan. <b>1992</b> , 183, 1139-46	21

2192	Metal carcinogenesis: mechanistic implications. <b>1992</b> , 53, 31-65	263
2191	Metabolic activation of carcinogens. <b>1992</b> , 54, 17-61	207
2190	Human papillomavirus infections in the respiratory tract. <b>1992</b> , 13, 210-25	19
2189	Renal allograft rejection and antibodies to epithelial cells. <b>1992</b> , 339, 503	1
2188	Oncogenes and cancer suppressor genes. <b>1992</b> , 8, 30-9	13
2187	Genetics of hypertension. <b>1992</b> , 339, 1142-1143	1
2186	Relieving the pain of pressure sores. <b>1992</b> , 339, 503-4	12
2185	Commentary: Biomarkers in Occupational Cancer Epidemiology: Considerations in Study Design. <b>1992</b> , 98, 149	
2184	Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to HBV infection and hepatocellular carcinoma in The Gambia and Thailand. <b>1992</b> , 64-65 Spec No, 455-61	38
2183	Cis and trans mechanisms of DNA repair. <b>1992</b> , 4, 385-95	10
2182	Screening for colorectal cancer by stool DNA analysis. <b>1992</b> , 339, 1141-1142	4
2181	Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. <b>1992</b> , 339, 502-3	69
2180	Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. <b>1992</b> , 117, 271-5	45
2179	The p53 gene in human cancer. <b>1992</b> , 28, 293-5	15
2178	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. <b>1992</b> , 70, 923-35	1242
2177	p53 function and dysfunction. <b>1992</b> , 70, 523-6	2010
2176	Regulation of the specific DNA binding function of p53. <b>1992</b> , 71, 875-86	917
2175	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. <b>1992</b> , 71, 587-97	2767

2174	1,4-Dioxane: prediction of in vivo clastogenicity. <b>1992</b> , 280, 245-51	7
2173	A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas. <b>1992</b> , 64, 178-82	10
2172	Cancer risk assessment: the science that is not. <b>1992</b> , 16, 10-20	8
2171	Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. <b>1992</b> , 28B, 67-76	125
2170	Examination of Tetrahydro- and Dihydrobisfuran Formation in Aflatoxin Biosynthesis: From Whole Cells to Purified Enzymes. <b>1992</b> , 141-154	8
2169	Significant existence of deleted mitochondrial DNA in cirrhotic liver surrounding hepatic tumor. <b>1992</b> , 182, 913-20	53
2168	Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. <b>1992</b> , 225, 577-83	202
2167	Genes in the diagnosis of malignant disease. <b>1992</b> , 209, S15-26	1
2166	Progressing toward a molecular description of colorectal cancer development. <b>1992</b> , 6, 2783-90	128
2165	Role of proto-oncogene activation in carcinogenesis. <b>1992</b> , 98, 13-24	78
2164	Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction. <b>1992</b> , 98, 183-5	13
2163	p53: the ultimate tumor suppressor gene?. <b>1992</b> , 6, 3169-76	203
2162	Biomarkers in occupational cancer epidemiology: considerations in study design. <b>1992</b> , 98, 149-54	6
2161	Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research. <b>1992</b> , 98, 167-78	65
2160	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.. <b>1992</b> , 11, 3935-3940	98
2159	Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest.. <b>1992</b> , 11, 2115-2121	78
2158	Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation.. <b>1992</b> , 11, 3513-3520	88
2157	p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.. <b>1992</b> , 11, 1383-1390	178



2156	The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.. <b>1992</b> , 11, 5013-5020	269
2155	Detection of malignant potential in Barrett's epithelium. <b>1992</b> , 5, 45-50	4
2154	Oncogenes in Ovarian Cancer. <b>1992</b> , 6, 813-827	16
2153	High Incidence of Nuclear Accumulation of p53 Protein in Gastric Cancer. <b>1992</b> ,	
2152	Molecular Genetic Aspects of Myelodysplastic Syndromes. <b>1992</b> , 6, 557-570	35
2151	Cancer as a mechanism of hypermutation. <b>1992</b> , 40, 31-40	1
2150	The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. <b>1992</b> , 11, 141-8	85
2149	Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. <b>1992</b> , 89, 445-9	45
2148	Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. <b>1992</b> , 166, 389-94	160
2147	p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. <b>1992</b> , 168, 29-33	60
2146	Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours. <b>1992</b> , 168, 237-42	26
2145	Expression of the p53 protein in a spectrum of astrocytic tumours. <b>1992</b> , 168, 383-6	38
2144	The molecular biology of urological tumors. <b>1992</b> , 4, 159-69	6
2143	Clonal expansion of p53 mutant cells is associated with brain tumour progression. <b>1992</b> , 355, 846-7	571
2142	Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. <b>1992</b> , 356, 215-21	4031
2141	Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. <b>1992</b> , 357, 82-5	510
2140	Cancer. p53, guardian of the genome. <b>1992</b> , 358, 15-6	4118
2139	Amplification of a gene encoding a p53-associated protein in human sarcomas. <b>1992</b> , 358, 80-3	1759

2138	Wild-type p53 activates transcription in vitro. <b>1992</b> , 358, 83-6	556
2137	APC mutations occur early during colorectal tumorigenesis. <b>1992</b> , 359, 235-7	1567
2136	Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. <b>1992</b> , 21, 404-8	98
2135	High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. <b>1992</b> , 83, 978-84	96
2134	Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. <b>1992</b> , 83, 1030-6	37
2133	Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. <b>1992</b> , 83, 1184-91	43
2132	Sensitive detection of p53 gene mutations in esophageal endoscopic biopsy specimens by cell sorting combined with polymerase chain reaction single-strand conformation polymorphism analysis. <b>1992</b> , 83, 1253-6	19
2131	p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. <b>1992</b> , 83, 1293-8	111
2130	p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. <b>1992</b> , 66, 583-8	88
2129	Increased p53 protein content of colorectal tumours correlates with poor survival. <b>1992</b> , 66, 758-64	130
2128	Definition of a consensus binding site for p53. <b>1992</b> , 1, 45-9	1782
2127	Is local failure a cause of or a marker for metastatic dissemination in carcinoma of the uterine cervix?. <b>1992</b> , 24, 377-80; discussion 387	16
2126	p53 point mutations in primary human gastric carcinomas. <b>1992</b> , 119, 67-70	68
2125	Chemical carcinogenesis of the urinary bladder--a status report. <b>1992</b> , 118, 411-9	12
2124	The Norman Nigro Lectureship. New paradigms of oncogenesis and their implications for surgery in the twenty-first century. <b>1992</b> , 35, 627-34	2
2123	Worrying about p53. <b>1992</b> , 2, 581-3	37
2122	Three-dimensional conformal radiation therapy at the Memorial Sloan-Kettering Cancer Center. <b>1992</b> , 2, 274-289	66
2121	An Escherichia coli plasmid-based, mutational system in which supF mutants are selectable: insertion elements dominate the spontaneous spectra. <b>1992</b> , 270, 219-31	36

2120	Cellular and molecular advances in elucidating p53 function. <b>1992</b> , 277, 163-71	17
2119	Description of a new amplifiable shuttle vector for mutagenesis studies in human cells: application to N-methyl-N'-nitro-N-nitrosoguanidine-induced mutation spectrum. <b>1992</b> , 272, 101-10	21
2118	Structural alterations of the p53 gene in human leukemias. <b>1992</b> , 16, 1105-12	8
2117	Will a tumor metastasize? Quantitate, semi-quantitate or pseudo-quantitate? A brief review of the microscopic prediction of tumor metastasis. <b>1992</b> , 22, 129-32	1
2116	Antibodies to the p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. <b>1992</b> , 25, 445-9	21
2115	Low p53 protein expression in salivary gland tumours compared with lung carcinomas. <b>1992</b> , 421, 415-20	60
2114	Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. <b>1992</b> , 421, 223-8	51
2113	Concepts and strategies for human gene therapy. <b>1992</b> , 208, 211-25	65
2112	Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. <b>1992</b> , 16, 1362-6	91
2111	Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. <b>1992</b> , 16G, 137-41	58
2110	Modulation of gene expression as a biomarker in colon. <b>1992</b> , 16G, 151-7	10
2109	Indicators of increased breast cancer risk in humans. <b>1992</b> , 16G, 175-82	27
2108	TP53 tumor suppressor gene: a model for investigating human mutagenesis. <b>1992</b> , 4, 1-15	431
2107	p53 expression and prognosis in gastric carcinoma. <b>1992</b> , 50, 859-62	280
2106	Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. <b>1992</b> , 51, 47-52	66
2105	Is the inhibition of protein phosphatase 1 and 2A activities a general mechanism of tumor promotion in human cancer development?. <b>1992</b> , 5, 91-4	42
2104	p53 gene mutations in human endometrial carcinoma. <b>1992</b> , 5, 250-3	69
2103	Kinds of mutations induced by aflatoxin B1 in a shuttle vector replicating in human cells transiently expressing cytochrome P4501A2 cDNA. <b>1992</b> , 6, 140-7	43

2102	p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. <b>1992</b> , 6, 148-58	64
2101	Alterations in the structural gene and the expression of p53 in rat liver tumors induced by aflatoxin B1. <b>1992</b> , 6, 159-72	28
2100	Mutational analysis of a dominant oncogene (c-Ki-ras-2) and a tumor suppressor gene (p53) in hamster lung tumorigenesis. <b>1992</b> , 6, 199-202	18
2099	Molecular genetics of colorectal carcinoma. <b>1992</b> , 70, 1216-21	78
2098	Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathologic features. <b>1993</b> , 71, 306-14	73
2097	Recessive oncogenes. <b>1993</b> , 71, 1179-86	26
2096	Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction. <b>1993</b> , 71, 1933-7	44
2095	p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. <b>1993</b> , 72, 355-60	65
2094	The molecular biology of carcinogenesis. <b>1993</b> , 72, 962-70	124
2093	Mutations of p53 and human papillomavirus infection in cervical carcinoma. <b>1993</b> , 72, 1272-80	80
2092	Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. <b>1993</b> , 72, 1386-93	120
2091	Screening for human papillomavirus infections in esophageal squamous cell carcinomas by in situ hybridization. <b>1993</b> , 72, 2525-30	46
2090	Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors. <b>1993</b> , 72, 3732-8	38
2089	Cellular oncogenes and suppressor genes as prognostic markers in cancer. <b>1993</b> , 26, 439-47	34
2088	Discerning the function of p53 by examining its molecular interactions. <b>1993</b> , 15, 703-7	28
2087	Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. <b>1993</b> , 2, 58-66	92
2086	Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). <b>1993</b> , 2, 112-7	130
2085	Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). <b>1993</b> , 2, 274-85	38

2084	ras gene mutations and HPV infection are common in human laryngeal carcinoma. <b>1993</b> , 53, 22-8	45
2083	p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. <b>1993</b> , 53, 51-5	78
2082	Genetic damage and escape from proliferation control. <b>1993</b> , 53, 161-177	
2081	K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. <b>1993</b> , 53, 250-6	129
2080	p53 mutations in sporadic adrenocortical tumors. <b>1993</b> , 54, 408-10	114
2079	In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. <b>1993</b> , 54, 531-5	26
2078	Mutation and expression of the p53 gene in malignant melanoma cell lines. <b>1993</b> , 54, 693-9	76
2077	p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. <b>1993</b> , 54, 759-64	172
2076	Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. <b>1993</b> , 55, 453-8	58
2075	Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. <b>1993</b> , 55, 562-5	92
2074	Alterations of the p53 tumor-suppressor gene in transformed mouse liver cells. <b>1993</b> , 55, 952-6	11
2073	p53 protein accumulation and gene mutations in human glioma cell lines. <b>1993</b> , 55, 982-7	63
2072	Carcinogen biomarkers related to smoking and upper aerodigestive tract cancer. <b>1993</b> , 17F, 27-35	38
2071	Oncogene mutations as intermediate markers. <b>1993</b> , 17F, 184-7	3
2070	The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the $\beta$ -fetoprotein status. <b>1993</b> , 18, 559-565	51
2069	Selecting DNA fragments for mutation detection by temperature gradient gel electrophoresis: application to the p53 gene cDNA. <b>1993</b> , 14, 561-5	10
2068	Cell growth regulation in epithelial ovarian cancer. <b>1993</b> , 71, 1597-601	66
2067	Spectrum of spontaneous HPRT- mutations in TK6 human lymphoblasts. <b>1993</b> , 22, 138-46	29

2066	No germline TP53 mutations detected in familial and bilateral testicular cancer. <b>1993</b> , 6, 92-7	65
2065	Characterization of two 11q23.3-11q24 deletions and mapping of associated anonymous DNA markers. <b>1993</b> , 7, 67-73	5
2064	Application of denaturing gradient gel blots to detect p53 mutations in X-ray-transformed mouse C3H 10T1/2 clones. <b>1993</b> , 7, 190-6	10
2063	No point mutation of Ha-ras or p53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. <b>1993</b> , 8, 49-57	38
2062	Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. <b>1993</b> , 8, 74-80	180
2061	Comparison of pulmonary O6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. <b>1993</b> , 8, 177-85	59
2060	Association of tumorigenic and nontumorigenic (immunogenic) variants in a mouse T-cell lymphoma with two distinct p53 mutations. <b>1993</b> , 8, 221-7	6
2059	Dependence of induction of osteocalcin gene expression on the presence of wild-type p53 in a murine osteosarcoma cell line. <b>1993</b> , 8, 299-305	16
2058	Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. <b>1993</b> , 8, 306-11	38
2057	Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. <b>1993</b> , 8, 312-8	73
2056	Quest for excellence: the ultimate goal of the radiation oncologist: ASTRO Gold Medal Address, 1992. <b>1993</b> , 26, 567-80	7
2055	Cancer vaccines. <b>1993</b> , 14, 310-6	140
2054	Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer. <b>1993</b> , 3, 293-298	13
2053	Genetics of cancer predisposition and progression. <b>1993</b> , 71, 488-502	9
2052	Hypomelanosis of Ito in a girl with plexus papilloma and translocation (X;17). <b>1993</b> , 90, 611-3	25
2051	Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma. <b>1993</b> , 91, 455-8	26
2050	Distribution of p53 protein expression in gliosarcomas: an immunohistochemical study. <b>1993</b> , 85, 222-6	17
2049	Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. <b>1993</b> , 91, 6-12	23

2048	A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations. <b>1993</b> , 91, 25-30	23
2047	p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. <b>1993</b> , 85, 611-6	42
2046	Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. <b>1993</b> , 169, 21-6	59
2045	p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. <b>1993</b> , 170, 67-72	79
2044	Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. <b>1993</b> , 171, 105-14	73
2043	Mutant p53 expression in prostate carcinoma. <b>1993</b> , 22, 23-30	65
2042	Toward a molecular understanding of human breast cancer: a hypothesis. <b>1993</b> , 25, 83-94	45
2041	Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan. <b>1993</b> , 27, 247-52	19
2040	Prognostic significance of p53 gene alterations in node-negative breast cancer. <b>1993</b> , 26, 225-35	92
2039	Clinical management of women at increased risk for breast cancer. <b>1993</b> , 28, 195-210	28
2038	Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. <b>1993</b> , 28, 231-9	20
2037	William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. <b>1993</b> , 27, 95-102	43
2036	p53 is required for radiation-induced apoptosis in mouse thymocytes. <b>1993</b> , 362, 847-9	2565
2035	Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. <b>1993</b> , 362, 857-60	1286
2034	Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. <b>1993</b> , 363, 281-3	318
2033	Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. <b>1993</b> , 67, 1274-84	118
2032	Prognostic significance of TP53 alterations in breast carcinoma. <b>1993</b> , 68, 540-8	144
2031	Tumourigenesis associated with the p53 tumour suppressor gene. <b>1993</b> , 68, 653-61	106

2030	p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. <b>1993</b> , 68, 1029-35	80
2029	Clustered base substitutions in CTP synthetase conferring drug resistance in Chinese hamster ovary cells. <b>1993</b> , 3, 317-22	41
2028	Gain of function mutations in p53. <b>1993</b> , 4, 42-6	739
2027	Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. <b>1993</b> , 5, 225-9	482
2026	Demonstration of Baeyer-Villiger oxidation and the course of cyclization in bisfuran ring formation during aflatoxin B1 biosynthesis. <b>1993</b> , 3, 653-656	19
2025	Mutation of the tumor suppressor gene TP53 is not detected in psoriatic skin. <b>1993</b> , 101, 100-2	12
2024	The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas. <b>1993</b> , 22, 383-6	24
2023	DNA content in gallbladder carcinoma: a flow cytometric study of 96 cases. <b>1993</b> , 23, 459-64	9
2022	Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. <b>1993</b> , 23, 465-70	9
2021	Aberrant p53 protein expression in cervical intra-epithelial neoplasia. <b>1993</b> , 23, 471-4	17
2020	p53 protein expression in benign and malignant skin tumours. <b>1993</b> , 128, 237-41	87
2019	Variation in K-ras codon 12 point mutation rate with histological atypia within individual colorectal tumors. <b>1993</b> , 84, 388-93	30
2018	p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. <b>1993</b> , 84, 394-401	80
2017	Genetic alterations in thyroid tumor progression: association with p53 gene mutations. <b>1993</b> , 84, 526-31	74
2016	p53 protein in aggressive and non-aggressive basal cell carcinoma. <b>1993</b> , 20, 429-34	35
2015	p53 immunoreactivity in cutaneous PUVA tumors is similar to that in other non-melanoma skin neoplasms. <b>1993</b> , 20, 435-41	7
2014	TP53 tumor-suppressor gene and human carcinogenesis. <b>1993</b> , 2, 99-105	4
2013	Mutations of the p53 gene in carcinomas of the urinary system. <b>1993</b> , 43, 745-50	1



2012	The pathogenesis of pituitary adenomas. <b>1993</b> , 38, 559-70	29
2011	P53 protein expression in Hodgkin's disease. <b>1993</b> , 101, 689-94	8
2010	The genetics of colon cancer. <b>1993</b> , 3, 2-7	
2009	Analysis of germline and in vivo somatic mutations in the human adenine phosphoribosyltransferase gene: mutational hot spots at the intron 4 splice donor site and at codon 87. <b>1993</b> , 287, 217-25	17
2008	Genetics, molecular biology and colorectal cancer. <b>1993</b> , 290, 3-12	19
2007	DNA methylation and mutation. <b>1993</b> , 285, 61-7	241
2006	Evidence for high-frequency allele loss at the aprt locus in TK6 human lymphoblasts. <b>1993</b> , 289, 245-54	6
2005	Genotypic mutation analysis by RFLP/PCR. <b>1993</b> , 288, 113-21	56
2004	Ionizing radiation, genetic risk estimation and molecular biology: impact and inferences. <b>1993</b> , 9, 79-84	21
2003	The tumor suppressor p53. <b>1993</b> , 1155, 181-205	104
2002	p53 overexpression as a marker of malignancy in gastric biopsies. <b>1993</b> , 2, 321-4	3
2001	p53 and breast cancer. <b>1993</b> , 2, 8-10	7
2000	In search of the functions of normal p53 protein. <b>1993</b> , 3, 46-9	26
1999	Analysis of the p53 gene in patients with isochromosome 17q and Ph1-positive or -negative myeloid leukemia. <b>1993</b> , 17, 533-9	24
1998	Molecular mechanism of stomach carcinogenesis. <b>1993</b> , 119, 265-72	299
1997	Molecular and cellular features of esophageal cancer cells. <b>1993</b> , 119, 441-9	194
1996	Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. <b>1993</b> , 119, 172-8	60
1995	Summary of a Meeting. <b>1993</b> , 14, 47-93	

1994 Vaccination. **1993**, 119, S33-S33

1993	Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS). <b>1993</b> , 67, 223-6	12
1992	Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. <b>1993</b> , 423, 265-71	44
1991	Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. <b>1993</b> , 422, 271-6	65
1990	Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. <b>1993</b> , 16, 125-33	10
1989	p53 gene mutations in gastric adenomas. <b>1993</b> , 63, 191-5	47
1988	p53-mediated cell death: relationship to cell cycle control. <b>1993</b> , 13, 1415-23	321
1987	p53: at the crossroads of molecular carcinogenesis and risk assessment. <i>Science</i> , <b>1993</b> , 262, 1980-1	33.3 410
1986	WAF1, a potential mediator of p53 tumor suppression. <b>1993</b> , 75, 817-25	7436
1985	p53 mutations in lung cancers from non-smoking atomic-bomb survivors. <b>1993</b> , 342, 1520-1	89
1984	The role of hepatitis B virus in development of primary hepatocellular carcinoma: Part II. <b>1993</b> , 8, 95-106	15
1983	Tumour suppressor genes and colorectal neoplasia. <b>1993</b> , 8, 174-84	6
1982	The functions of the p53 gene and gene product. <b>1993</b> , 8, S5-S11	
1981	8-Hydroxydeoxyguanosine as a urinary biomarker of oxidative DNA damage. <b>1993</b> , 40, 391-404	167
1980	Respiratory tract epithelium and neoplasia. <b>1993</b> , 87, 175-81	1
1979	High incidence of mutations of the p53 gene detected in ovarian tumours by the use of chemical mismatch cleavage. <b>1993</b> , 68, 83-9	17
1978	Mechanisms of carcinogenesis: chemical exposure and molecular changes. <b>1993</b> , 29A, 1344-7	8
1977	A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. <b>1993</b> , 3, 229-35	102

1976	Oncogenes and onco-suppressor genes in lung cancer. <b>1993</b> , 87, 413-20	14
1975	The p53-mdm-2 autoregulatory feedback loop. <b>1993</b> , 7, 1126-32	1362
1974	p53 mutations in human immortalized epithelial cell lines. <b>1993</b> , 14, 833-9	364
1973	The Xiphophorus fish: A model for molecular mechanisms of environmental Carcinogenesis § Abbreviations Used: A, adenosine; AAAS, American Association for the Advancement of Science; AACR, American Association for Cancer Research; BC, backcross generations; BL, black light; BNL, Brookhaven National Laboratory; C, cytosine; C?C,C?T,T?T, cyclobutane pyrimidine dimers; cDNA, complementary deoxyribonucleic acid; GCC, deleted colon cancer gene; GNA, deoxyribonucleic acid; G, guanosine; kb, kilobase; L1, length; <b>1993</b> , 11, 12-161	5
1972	Molecular biomarkers for human chemical carcinogen exposures. <b>1993</b> , 6, 764-70	40
1971	K-ras and p53 point mutations in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced hamster lung tumors. <b>1993</b> , 14, 451-5	57
1970	Mutagenesis by the (+)-anti-diol epoxide of benzo[a]pyrene: what controls mutagenic specificity?. <b>1993</b> , 32, 1759-69	84
1969	The tumor suppressor genes. <b>1993</b> , 62, 623-51	429
1968	p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. <b>1993</b> , 85, 1657-69	386
1967	p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. <b>1993</b> , 14, 987-92	201
1966	Endogenous DNA adducts: potential and paradox. <b>1993</b> , 6, 771-85	262
1965	Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. <b>1993</b> , 90, 3221-5	123
1964	Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. <b>1993</b> , 29A, 881-6	33
1963	Doing the right thing: feedback control and p53. <b>1993</b> , 5, 214-8	23
1962	Germ-line p53 mutation is uncommon in patients with triple primary cancers. <b>1993</b> , 73, 51-7	21
1961	Low prevalence of expression of p53 oncoprotein in oral carcinomas from Sri Lanka associated with betel and tobacco chewing. <b>1993</b> , 29B, 147-50	29
1960	p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. <b>1993</b> , 69, 151-60	166
1959	Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. <b>1993</b> , 169, 690-4	52

1958	Predictive testing for germline mutations in the p53 gene: are all the questions answered?. <b>1993</b> , 29A, 1361-5	26
1957	The molecular biology of soft tissue sarcomas. <b>1993</b> , 29A, 2054-8	9
1956	Expression of p53 protein in benign and malignant epidermal pathologic conditions. <b>1993</b> , 29, 741-8	35
1955	Molecular Analysis of Mutations Induced at the hisD3052 Allele of Salmonella by Single Chemicals and Complex Mixtures. <b>1993</b> , 101, 207	3
1954	Abnormal Chromosome Repair and Risk of Developing Cancer. <b>1993</b> , 101, 303	5
1953	Mechanisms of carcinogenesis and molecular epidemiology. <b>1993</b> , 29A, 1226-7	2
1952	Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France. <b>1993</b> , 29A, 1476-8	8
1951	Tumor suppressor genes in urologic tumors. <b>1993</b> , 42, 461-6; discussion 466-7	8
1950	Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?. <b>1993</b> , 75, 765-78	734
1949	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. <b>1993</b> , 74, 957-67	2622
1948	Metachronous multifocal development of urothelial cancers by intraluminal seeding. <b>1993</b> , 342, 1087-8	170
1947	Cancer vaccines. <b>1993</b> , 14, 202-8	21
1946	p53 mutation in fresh lymphocytes, B-lymphoblastoid cell lines and their transformed cell lines originating from Bloom syndrome patients. <b>1993</b> , 68, 70-3	4
1945	p53: the promising story continues to unfold. <b>1993</b> , 24, 455-6	19
1944	p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. <b>1993</b> , 24, 463-8	139
1943	p53 accumulation in ovarian carcinomas and its prognostic implications. <b>1993</b> , 24, 1175-9	94
1942	Localization of p53 protein and human papillomavirus in anogenital squamous lesions: immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia. <b>1993</b> , 24, 1238-42	23
1941	Clinical implications of the p53 tumor-suppressor gene. <b>1993</b> , 329, 1318-27	1186

1940	Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. <b>1993</b> , 29A, 1199-207	102
1939	p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. <b>1993</b> , 698, 114-9	7
1938	A locus on chromosome 17p13.3, associated with a high S-phase index is distinct from the p53 gene in breast cancer. <b>1993</b> , 698, 120-5	1
1937	Molecular and biochemical reprogramming of oncogenesis through the activity of prooxidants and antioxidants. <b>1993</b> , 686, 262-78; discussion 278-9	77
1936	Immunotherapeutic strategies for cancer using poxvirus vectors. <b>1993</b> , 690, 292-300	11
1935	Genetically engineered tumor vaccines. <b>1993</b> , 690, 301-10	16
1934	DNA adducts, mutations and cancer. <b>1993</b> , 14, 2007-12	171
1933	Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. <b>1993</b> , 14, 1085-9	173
1932	Functional evidence for a breast cancer growth suppressor gene on chromosome 17. <b>1993</b> , 2, 1921-7	40
1931	Regulation of the human hsp70 promoter by p53. <i>Science</i> , <b>1993</b> , 259, 84-7	33-3 271
1930	Sensitive two-stage PCR of p53 genomic DNA exons 5-9. <b>1993</b> , 2, 250-2	12
1929	The p53 protein is an unusually shaped tetramer that binds directly to DNA. <b>1993</b> , 90, 3319-23	223
1928	Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor. <b>1993</b> , 90, 1416-9	66
1927	Clinical aspects of glycoprotein biosynthesis. <b>1993</b> , 30, 65-151	37
1926	Regulation of apoptosis by the transforming genes of the DNA tumor virus adenovirus. <b>1993</b> , 204, 30-9	68
1925	Aberrations of p53 gene in human hepatocellular carcinoma from China. <b>1993</b> , 14, 169-73	110
1924	Mutational specificity of the (+)-anti-diol epoxide of benzo[a]pyrene in a supF gene of an Escherichia coli plasmid: DNA sequence context influences hotspots, mutagenic specificity and the extent of SOS enhancement of mutagenesis. <b>1993</b> , 14, 373-83	105
1923	Denaturing gradient gel electrophoresis (DGGE) assay for K-ras and N-ras genes: detection of K-ras point mutations in human lung tumour DNA. <b>1993</b> , 2, 639-44	17

1922	The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence?. <b>1993</b> , 85, 1554-7	40
1921	Enzymic removal of 5-methylcytosine from DNA by a human DNA-glycosylase. <b>1993</b> , 21, 5323-7	66
1920	Structure of the rat p53 tumor suppressor gene. <b>1993</b> , 21, 713-7	78
1919	Effect of ascorbate and 5-aminosalicylic acid on light-induced 8-hydroxydeoxyguanosine formation in V79 Chinese hamster cells. <b>1993</b> , 14, 2431-3	51
1918	The genetics of tobacco-induced malignancy. <b>1993</b> , 119, 1198-205	24
1917	p53, retinoblastoma, and human papillomavirus in squamous cell carcinoma and adjacent normal mucosa of the upper aerodigestive tract. <b>1993</b> , 119, 1125-31	26
1916	Biological activities of p53 mutants in Burkitt's lymphoma cells. <b>1993</b> , 74 ( Pt 5), 803-10	35
1915	p53 domains: identification and characterization of two autonomous DNA-binding regions. <b>1993</b> , 7, 2575-86	203
1914	Retrieval of p53 protein in paraffin-embedded head and neck tumor tissues. <b>1993</b> , 119, 1206-9	27
1913	Wild-type p53 in cellular-transformation - a reassessment. <b>1993</b> , 3, 23-7	
1912	Accumulation of mutant p53 protein correlates with elevation of serum afp in human hepatocellular-carcinoma. <b>1993</b> , 3, 157-60	
1911	Absence of germline prohibitin mutations in early-onset breast-cancer. <b>1993</b> , 3, 769-72	
1910	Relative paucity of p53 gene-mutations in male breast carcinomas. <b>1993</b> , 2, 739-44	
1909	P53 nuclear overexpression and disease progression in ta-bladder carcinoma. <b>1993</b> , 3, 355-60	28
1908	MUTATIONS IN THE P53 SUPPRESSOR GENE DO NOT CORRELATE WITH C-K-RAS ONCOGENE MUTATIONS IN COLORECTAL-CANCER. <b>1993</b> , 2, 123	1
1907	Expression of the human fetal bac h19 gene in invasive cancers. <b>1993</b> , 2, 753-8	9
1906	Hereditary colorectal-cancer (review). <b>1993</b> , 2, 827-30	1
1905	P53 MUTATIONS ARE INFREQUENT AND DO NOT CORRELATE WITH THE METASTATIC POTENTIAL OF HUMAN-MELANOMA CELLS. <b>1993</b> , 3, 19	1

1904	Reduced tumorigenicity and cell motility of a gastric-carcinoma cell-line by introduction of wild-type p53 gene. <b>1993</b> , 3, 265-71	1
1903	Immunologically defined subclasses of the growth suppressor protein p53 detected with antibodies in sera from tumor patients. <b>1993</b> , 3, 741-7	
1902	Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. <b>1993</b> , 14, 803-10	78
1901	Molecular defects associated with the acute phase CML. <b>1993</b> , 11 Suppl 1, 25-8	16
1900	Analysis of mutational specificity induced by heterocyclic amines in the lacZ gene of Escherichia coli. <b>1993</b> , 14, 1149-53	41
1899	Frequency of RAS and p53 mutations in acute promyelocytic leukemias. <b>1993</b> , 11, 405-10	28
1898	Mutations of the p53 gene in B-cell lymphoma. <b>1993</b> , 11, 21-5	19
1897	Timing of p53 mutations during astrocytoma tumorigenesis. <b>1993</b> , 2, 1687-90	17
1896	p53 gain-of-function mutation in codon 175 is a rare event in human breast cancer. <b>1993</b> , 2, 1501-2	3
1895	The current status of camptothecin analogues as antitumor agents. <b>1993</b> , 85, 271-91	512
1894	p53 mutations in hepatocellular carcinomas induced by a choline-devoid diet in male Fischer 344 rats. <b>1993</b> , 14, 503-10	46
1893	Elevation of cell cycle control proteins during spontaneous immortalization of human keratinocytes. <b>1993</b> , 4, 185-94	58
1892	Molecular biology of colorectal neoplasia. <b>1993</b> , 34, 289-92	26
1891	Mutations induced by saturated aqueous nitric oxide in the pSP189 supF gene in human Ad293 and E. coli MBM7070 cells. <b>1993</b> , 14, 1251-4	96
1890	A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. <b>1993</b> , 7, 2565-74	220
1889	p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen. <b>1993</b> , 46, 1093-6	25
1888	Inherited Breast and Ovarian Cancer. <b>1993</b> , 269, 1975	122
1887	Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. <b>1993</b> , 90, 1013-7	136

1886	Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: a comparison with SSCP analysis. <b>1993</b> , 2, 2155-8	31
1885	No allelic loss at the p53 locus in 1,2-dimethylhydrazine-induced mouse colon tumours: PCR-SSCP analysis with sequence-tagged microsatellite site primers. <b>1993</b> , 14, 1483-6	31
1884	The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. <b>1993</b> , 7, 2556-64	402
1883	Free radical involvement in aging. Pathophysiology and therapeutic implications. <b>1993</b> , 3, 60-80	165
1882	Molecular screening. Prospects for a new approach. <b>1993</b> , 119, 1187-90	28
1881	The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. <b>1993</b> , 119, 1118-22	98
1880	Molecular and biological factors in the pathogenesis of ovarian cancer. <b>1993</b> , 4 Suppl 4, 3-16	9
1879	Cloning of tumor suppressor genes involved in solid tumor development. <b>1993</b> , 119, 1210-6	1
1878	Why a neuro-oncologist?. <b>1993</b> , 8, 287-91	4
1877	Molecular genetic analysis of the mechanism of tumorigenesis in acoustic neuroma. <b>1993</b> , 119, 1222-8	29
1876	Immunohistochemical analysis of p53 expression in anal squamous neoplasia. <b>1993</b> , 46, 507-12	25
1875	Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. <b>1993</b> , 90, 1771-5	302
1874	Free Radical Theory Of Aging. <b>1993</b> , 124-143	
1873	REVIEW. <b>1993</b> , 374, 227-236	9
1872	Mapping of the p53 and mdm-2 interaction domains. <b>1993</b> , 13, 4107-14	611
1871	Overexpression of p53 protein in Barrett's syndrome with malignant transformation. <b>1993</b> , 46, 330-3	59
1870	Platform Presentations. <b>1993</b> , 21, 611-623	
1869	Poster Session. <b>1993</b> , 21, 623-646	



1868	Tandem double CC-->TT mutations are produced by reactive oxygen species. <b>1993</b> , 90, 3904-7	130
1867	Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. <b>1993</b> , 90, 4216-20	631
1866	High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. <b>1993</b> , 67, 1395-7	81
1865	Over-expression of the c-myc proto-oncogene in colorectal carcinoma. <b>1993</b> , 68, 407-13	72
1864	Molecular alterations in a patient with Turcot's syndrome. <b>1993</b> , 68, 519-23	11
1863	Exclusion of constitutional p53 mutations as a cause of genetic susceptibility to colorectal cancer. <b>1993</b> , 68, 712-4	4
1862	p53 expression in incidental prostatic cancer. <b>1993</b> , 305, 275-9	18
1861	Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer. <b>1993</b> , 68, 751-5	34
1860	p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. <b>1993</b> , 104, 1633-9	201
1859	Role of pulse oximetry in the ICU. <b>1993</b> , 104, 330-1	1
1858	Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.. <b>1993</b> , 12, 5057-5064	147
1857	Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. <b>1993</b> , 13, 1456-63	126
1856	Analysis of a protein-binding domain of p53. <b>1993</b> , 13, 3811-20	52
1855	Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. <b>1993</b> , 90, 8586-90	389
1854	A model for tumor suppression using H-1 parvovirus. <b>1993</b> , 90, 8702-6	80
1853	Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. <b>1993</b> , 90, 10529-33	240
1852	The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. <b>1993</b> , 13, 6849-57	56
1851	p53 gene mutations and protein accumulation in human ovarian cancer. <b>1993</b> , 90, 4961-5	252

1850	The APC gene product in normal and tumor cells. <b>1993</b> , 90, 2846-50	353
1849	The tumor suppressor p53 regulates its own transcription. <b>1993</b> , 13, 3415-23	109
1848	Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. <b>1993</b> , 90, 5954-8	90
1847	The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. <b>1993</b> , 13, 301-6	306
1846	Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. <b>1993</b> , 104, 362-5	24
1845	Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. <b>1993</b> , 13, 1378-84	36
1844	Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. <b>1993</b> , 90, 9075-9	161
1843	Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. <b>1993</b> , 90, 2827-31	45
1842	The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. <b>1993</b> , 13, 3291-300	252
1841	Cellular characterization of lung cancer. A caveat. <b>1993</b> , 104, 331	2
1840	p53: a target for new anticancer drugs or a target for old drugs?. <b>1993</b> , 4, 623-9	4
1839	Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. <b>1993</b> , 8, 275-83	94
1838	Molecular genetic changes in human breast cancer. <b>1993</b> , 61, 25-56	47
1837	[The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities]. <b>1993</b> , 53, 742-53	1
1836	New prognostic factors in prostatic carcinoma. <b>1993</b> , 24, 438-49	23
1835	Aberrantes p53 in tumor-benachbarten Schleimh�uten von Kopf-Hals-Tumoren ist eine m�gliche molekulare Grundlage ff die Feldkanzerisierung. <b>1993</b> , 3, 180-187	
1834	mdm2 expression is induced by wild type p53 activity.. <b>1993</b> , 12, 461-468	888
1833	Overview of genetic and molecular events in the pathogenesis of lung cancer. <b>1993</b> , 103, 1S-3S	29

1832	A comparison of the biological activities of wild-type and mutant p53. <b>1993</b> , 7, 855-65	376
1831	Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. <b>1993</b> , 13, 5186-94	116
1830	p53 protein detected by immunohistochemical staining is not always mutant. <b>1993</b> , 11, 239-50	42
1829	Wild-type p53 adopts a mutant-like conformation when bound to DNA.. <b>1993</b> , 12, 1021-1028	143
1828	The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.. <b>1993</b> , 12, 1029-1037	79
1827	8-Methoxypsoralen induced mutations are highly targeted at crosslinkable sites of photoaddition on the non-transcribed strand of a mammalian chromosomal gene.. <b>1993</b> , 12, 397-402	41
1826	Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. <b>1993</b> , 99, 115-22	52
1825	New Molecular Targets and Therapeutic Strategies against Cancer. <b>1993</b> , 8, 1-7	
1824	Characterization of in vivo somatic mutations at the hypoxanthine phosphoribosyltransferase gene of a human control population. <b>1993</b> , 101, 68-74	20
1823	Abnormal chromosome repair and risk of developing cancer. <b>1993</b> , 101 Suppl 3, 303-8	33
1822	Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. <b>1993</b> , 7, 951-6	32
1821	Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation.. <b>1993</b> , 12, 2789-2797	39
1820	Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.. <b>1993</b> , 12, 2799-2808	109
1819	Genetic background alters the spectrum of tumors that develop in p53-deficient mice. <b>1993</b> , 7, 938-43	250
1818	Molecular analysis of mutations induced at the hisD3052 allele of Salmonella by single chemicals and complex mixtures. <b>1993</b> , 101 Suppl 3, 207-12	5
1817	Genetic Events Responsible for Colorectal Tumorigenesis: Achievements and Challenges. <b>1993</b> , 79, 235-243	5
1816	p53-catalyzed annealing of complementary single-stranded nucleic acids.. <b>1993</b> , 12, 2389-2396	153
1815	Frequency of p53 Tumor Suppressor Gene Mutations in Human Primary Brain Tumors. <b>1993</b> , 33, 824-831	32

1814	Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. <b>1993</b> , 99, 107-13	84
1813	Ancient genomes, wise bodies, unhealthy people: limits of a genetic paradigm in biology and medicine. <b>1993</b> , 37, 112-45	77
1812	"Hot spots" mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites. <b>1993</b> , 39, 2186-2191	12
1811	References. <b>1993</b> , 315-343	
1810	The Genetics of Breast Cancer. <b>1994</b> , 8, 15-27	4
1809	Carcinogen-specific mutations in the p53 tumor suppressor gene in lung cancer. <b>1994</b> , 107, 1095-1098	12
1808	Prevalence of p53 mutations in patients with squamous cell carcinoma of the esophagus. <b>1994</b> , 108, 148-152	10
1807	Markers of Risk for Human Malignancies. <b>1994</b> , 8, 471-483	1
1806	The genetics of human cancer: implications for ecotoxicology. <b>1994</b> , 102 Suppl 12, 75-80	7
1805	Molecular mechanisms of transformation of C3H/10T1/2 Cl 8 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. <b>1994</b> , 102 Suppl 3, 119-25	29
1804	Mutagenesis by metal-induced oxygen radicals. <b>1994</b> , 102 Suppl 3, 57-61	32
1803	The role of the cellular antioxidant defense in oxidant carcinogenesis. <b>1994</b> , 102 Suppl 10, 123-9	127
1802	The lack of a role for p53 in astrocytomas in pediatric patients. <b>1994</b> , 34, 967-72; discussion 972-3	34
1801	Epidemiology of Aflatoxin-Related Disease. <b>1994</b> , 233-258	33
1800	Invited commentary--"molecular epidemiology": new pathway or new travelling companion?. <b>1994</b> , 140, 1-11	57
1799	P53 Protein Overexpression in a Case of Conjunctival Micro-Invasive Carcinoma. <b>1994</b> , 4, 184-186	1
1798	Induction of mutation spectra by complex mixtures: approaches, problems, and possibilities. <b>1994</b> , 102 Suppl 4, 127-30	4
1797	Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. <b>1994</b> , 50, 718-31	30

1796	Histochemical studies of progressive p53 mutations during colonic carcinogenesis in Sprague-Dawley rats induced by N-methyl-N-nitro-nitrosoguanidine or azoxymethane. <b>1994</b> , 62, 232-7	13
1795	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.. <b>1994</b> , 13, 3496-3504	150
1794	Pharmacogenetics: detecting sensitive populations. <b>1994</b> , 102 Suppl 11, 81-7	43
1793	Suppression of ras oncogene-mediated transformation. <b>1994</b> , 124, 29-92	6
1792	Genetics of colorectal cancer. <b>1994</b> , 50, 640-55	19
1791	Genetic Tumor Epidemiology. <b>1994</b> , 290-301	
1790	Cell Culture of Lung Cancers. <b>1994</b> , 121-160	2
1789	The Lack of a Role for p53 in Astrocytomas in Pediatric Patients. <b>1994</b> , 34, 967-973	43
1788	Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal.. <b>1994</b> , 13, 1368-1374	113
1787	p53 oligomerization and DNA looping are linked with transcriptional activation.. <b>1994</b> , 13, 6011-6020	88
1786	Oxidative DNA damage correlates with oxygen consumption in humans. <b>1994</b> , 8, 534-7	150
1785	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein.. <b>1994</b> , 13, 5393-5400	27
1784	Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. <b>1994</b> , 12, 925-30	169
1783	p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. <b>1994</b> , 108, 1132-1137	40
1782	Computer program for the analysis of mutational spectra: application to p53 mutations. <b>1994</b> , 15, 2281-5	194
1781	High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. <i>Science</i> , <b>1994</b> , 265, 386-91	33.3 278
1780	Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site. <b>1994</b> , 14, 2651-63	27
1779	Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. <b>1994</b> , 14, 6264-77	546

1778	A de novo p53 germline mutation affecting codon 151 in a six year old child with multiple tumors. <b>1994</b> , 3, 2247-8	21
1777	Abnormalities of p53 Protein Expression in Cutaneous Disorders. <b>1994</b> , 130, 225	25
1776	Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. <b>1994</b> , 22, 1012-7	49
1775	p53 in Low-grade Gliomas. <b>1994</b> , 1, 163-170	9
1774	Liver disease. <b>1994</b> , 70, 162-84	3
1773	Biological implications of the mechanism of action of human DNA (cytosine-5)methyltransferase. <b>1994</b> , 49, 65-111	35
1772	Rates of p16 (MTS1) mutations in primary tumors with 9p loss. <i>Science</i> , <b>1994</b> , 265, 415-7	33-3 397
1771	Mutations of the p53 gene in human functional adrenal neoplasms. <b>1994</b> , 78, 483-91	87
1770	p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. <b>1994</b> , 78, 790-4	140
1769	p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. <b>1994</b> , 150, 528-33	28
1768	Immunohistochemical detection of cripto-1, amphiregulin and transforming growth-factor-alpha in human gastric carcinomas and intestinal metaplasias. <b>1994</b> , 5, 215-23	6
1767	Genetic alterations in p53 and k-ras in lung-cancer in relation to histopathology of the tumor and smoking history of the patient. <b>1994</b> , 5, 1109-17	4
1766	ALLELIC DELETIONS ON CHROMOSOME-17 AND MUTATIONS IN THE P53 GENE IN TUMORS METASTATIC TO BRAIN. <b>1994</b> , 4, 37	
1765	On the interaction of p53 with casein kinase-ii. <b>1994</b> , 4, 491-8	1
1764	Factors associated with p53 nuclear accumulation in prostatic adenocarcinoma. <b>1994</b> , 4, 897-902	
1763	P53 FORMS TIGHT COMPLEXES WITH TMS1 OF FISSION YEAST. <b>1994</b> , 4, 987	
1762	Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals. <b>1994</b> , 4, 1257-63	2
1761	P53 expression in stage iii-iv squamous-cell carcinoma of the larynx - an immunohistochemical study related to clinicopathological, flow-cytometric DNA analysis and prognosis. <b>1994</b> , 5, 495-500	1

1760	Tumor-suppressor genes in colorectal carcinomas - p53 inactivation is highly associated with allelic loss of chromosome 5q. <b>1994</b> , 5, 539-46	
1759	Levels of p53 antigen in the serum of nonsmall cell lung-cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. <b>1994</b> , 5, 553-8	4
1758	T-antigen of sv40 blocks p53 transactivation but not p53 specific binding to DNA. <b>1994</b> , 5, 945-53	1
1757	Frameshift and nonsense p53 mutations in squamous-cell carcinoma of head and neck - non-reactivity with 3 anti-p53 monoclonal-antibodies. <b>1994</b> , 4, 609-14	1
1756	P53 expression in esophageal dysplasia - a possible biomarker for carcinogenesis of esophageal squamous-cell carcinoma. <b>1994</b> , 4, 1061-5	2
1755	Overexpression of the tumor-suppressor gene p53 in human ovarian tumor-tissues and its correlation with clinical stage. <b>1994</b> , 4, 1097-103	1
1754	P53 and rb tumor-suppressor gene alterations in retinoblastoma. <b>1994</b> , 4, 1329-32	
1753	ALLELIC LOSS ON CHROMOSOME-13 CAN PRECEED HISTOLOGICAL-CHANGES IN HEAD AND NECK-CANCER. <b>1994</b> , 5, 205	1
1752	Different patterns of p53 gene-mutations in endometrial carcinomas and endometrioid carcinomas of the ovary. <b>1994</b> , 5, 583-8	4
1751	A new 42-kda protein-binding to the growth suppressor protein-p53. <b>1994</b> , 5, 667-73	2
1750	Nuclear-DNA content and p53 immunostaining in oral squamous-cell carcinoma - an analysis of a consecutive 10-year material. <b>1994</b> , 5, 915-20	1
1749	The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). <b>1994</b> , 4, 277-96	32
1748	Mutations of p53 gene in hepatocellular-carcinoma (hcc) correlate with tumor progression and patient prognosis - a study of 138 patients with unifocal hcc. <b>1994</b> , 4, 1341-7	14
1747	Pathogenesis of ovarian cancers. <b>1994</b> , 1, 181-90	36
1746	p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. <b>1994</b> , 86, 1011-7	85
1745	Physical and functional interaction between wild-type p53 and mdm2 proteins. <b>1994</b> , 14, 1171-8	125
1744	Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy?. <b>1994</b> , 31, 458-61	83
1743	p53 in prostate cancer: frequent expressed transition mutations. <b>1994</b> , 86, 926-33	147

1742	Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. <b>1994</b> , 86, 705-12	351
1741	Genetic heterogeneity of hepatocellular carcinoma. <b>1994</b> , 91, 822-6	138
1740	A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. <b>1994</b> , 91, 3171-5	142
1739	p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. <b>1994</b> , 47, 1073-6	27
1738	p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. <b>1994</b> , 15, 2379-81	20
1737	p53 gene mutations as markers of tumor spread in synchronous oral cancers. <b>1994</b> , 120, 943-7	44
1736	Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. <b>1994</b> , 15, 695-700	15
1735	Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. <b>1994</b> , 15, 771-4	50
1734	Detection of DNA point mutations with DNA mismatch repair enzymes. <b>1994</b> , 15, 1657-62	21
1733	Murine squamous cell carcinoma cell lines produced by a complete carcinogenesis protocol with benzo[a]pyrene exhibit characteristic p53 mutations and the absence of H-ras and cycl 1/cyclin D1 abnormalities. <b>1994</b> , 15, 1613-9	29
1732	Infrequent mutation in tumor suppressor gene p53 in gestational trophoblastic neoplasia. <b>1994</b> , 15, 2221-3	17
1731	Woodchuck hepatitis virus surface antigen induces nitric oxide synthesis in hepatocytes: possible role in hepatocarcinogenesis. <b>1994</b> , 15, 2875-7	56
1730	Application of molecular genetics and cytogenetics to breast cancer and soft tissue sarcomas. <b>1994</b> , 5 Suppl 4, 17-23	2
1729	p53 domains: structure, oligomerization, and transformation. <b>1994</b> , 14, 5182-91	137
1728	p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. <b>1994</b> , 15, 1-3	179
1727	Tissue-specific mutational spectra of 2-amino-3,4-dimethylimidazo[4,5-f]quinoline in the liver and bone marrow of lacI transgenic mice. <b>1994</b> , 15, 2805-9	34
1726	p53 mutations in larynx cancer. <b>1994</b> , 15, 2949-51	16
1725	Structure-activity relationships of chemicals causing endocrine, reproductive, neurotoxic, and oncogenic effects--a public health problem. <b>1994</b> , 10, 163-79	7



1724	High-density multiplex detection of nucleic acid sequences: oligonucleotide ligation assay and sequence-coded separation. <b>1994</b> , 22, 4527-34	110
1723	Apoptosis induced by inhibition of intercellular contact. <b>1994</b> , 125, 403-15	229
1722	Expression of mutant p53 protein in hepatocellular carcinoma. <b>1994</b> , 35, 98-100	17
1721	Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. <b>1994</b> , 47, 453-6	59
1720	Identification of genetic lesions associated with diffuse large-cell lymphoma. <b>1994</b> , 5 Suppl 1, 55-60	50
1719	P53 as a marker of the malignant cell in Hodgkin's disease. <b>1994</b> , 5 Suppl 1, 89-91	6
1718	A unique p53 intragenic deletion flanked by short direct repeats results in loss of mRNA expression in a human esophageal carcinoma. <b>1994</b> , 15, 1653-5	7
1717	Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. <b>1994</b> , 81, 427-36	222
1716	Bcl-2 blocks p53-dependent apoptosis. <b>1994</b> , 14, 2556-63	334
1715	Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. <b>1994</b> , 8, 1300-10	235
1714	Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. <b>1994</b> , 150, 1667-71	22
1713	Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. <b>1994</b> , 35, 1627-31	53
1712	Absence of p53 gene mutations in cutaneous melanoma. <b>1994</b> , 102, 819-21	91
1711	Interactions between papillomavirus proteins and tumor suppressor gene products. <b>1994</b> , 64, 1-24	45
1710	Absence of p53 mutation at codon 249 in duck hepatocellular carcinomas from the high incidence area of Qidong (China). <b>1994</b> , 15, 1353-7	19
1709	Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2. <b>1994</b> , 14, 8315-21	59
1708	p53 status and the efficacy of cancer therapy in vivo. <i>Science</i> , <b>1994</b> , 266, 807-10	33:3 1340
1707	Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells. <b>1994</b> , 14, 251-5	16

1706	Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. <b>1994</b> , 12, 223-31	42
1705	Brief report: molecular biology and the early detection of carcinoma of the bladder—the case of Hubert H. Humphrey. <b>1994</b> , 330, 1276-8	62
1704	Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. <b>1994</b> , 103, 500-3	52
1703	TP53 tumor suppressor gene and skin carcinogenesis. <b>1994</b> , 103, 102S-106S	283
1702	p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. <b>1994</b> , 102, 440-4	90
1701	Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. <b>1994</b> , 330, 597-601	366
1700	Double P53 point mutation in extramedullary blast crisis of chronic myelogenous leukemia. <b>1994</b> , 16, 171-5	3
1699	Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. <b>1994</b> , 15, 257-62	55
1698	Spectroscopic studies of the trans adducts derived from (+)- and (-)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide and the oligonucleotide 5'-d(CCTATAGATATCC). <b>1994</b> , 15, 2207-13	15
1697	Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines. <b>1994</b> , 14, 7604-10	35
1696	p53 mutation is infrequent and might not give a growth advantage in rat bladder carcinogenesis in vivo. <b>1994</b> , 15, 455-8	24
1695	Transformation of human epidermal keratinocytes with fission neutrons. <b>1994</b> , 15, 2867-73	8
1694	Molecular mechanisms of radiation oncogenesis. <b>1994</b> , 65, 57-64	37
1693	Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. <b>1994</b> , 45, 297-323	157
1692	Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. <b>1994</b> , 8, 2227-40	98
1691	p53 mutations in lung cancers from Japanese mustard gas workers. <b>1994</b> , 15, 2075-9	67
1690	Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. <b>1994</b> , 15, 1085-7	52
1689	p53, a potential target for tumor-directed T cells. <b>1994</b> , 40, 171-8	75

1688	Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. <b>1994</b> , 68, 3-7	35
1687	Protective effects of hsp70 in inflammation. <b>1994</b> , 50, 1031-8	198
1686	Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. <b>1994</b> , 87, 225-32	47
1685	Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas. <b>1994</b> , 18, 827-32; discussion 832-3	11
1684	Nucleotide excision repair in yeast. <b>1994</b> , 27, 1-16	17
1683	Significance of P53 in human thyroid tumors. <b>1994</b> , 18, 535-40; discussion 540-1	15
1682	Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas. <b>1994</b> , 286, 417-9	9
1681	Molecular prognostic factors in bladder cancer. <b>1994</b> , 12, 84-8	21
1680	The relationship between aneuploidy and p53 overexpression during genesis of colorectal adenocarcinoma. <b>1994</b> , 424, 343-7	29
1679	p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions. <b>1994</b> , 424, 349-55	17
1678	p53 accumulation in polynuclear-giant-cells. <b>1994</b> , 424, 357-60	4
1677	Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction. <b>1994</b> , 424, 453	11
1676	Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study. <b>1994</b> , 424, 491-4	23
1675	Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. <b>1994</b> , 424, 503-9	51
1674	p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. <b>1994</b> , 424, 187-93	18
1673	Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. <b>1994</b> , 93, 620-4	16
1672	A transcribed polymorphism and sub-localisation of MDM2. <b>1994</b> , 93, 611-2	9
1671	Tumor suppressor genes in molecular medicine. <b>1994</b> , 72, 619-30	8

1670	A presumed B6 strain-specific p53 polymorphism is confined to a B6 cell line and is likely to represent a facilitating mutation. <b>1994</b> , 5, 106-7	1
1669	p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. <b>1994</b> , 4, 371-378	13
1668	Role of p53 and ras genes in radiation-induced transformation of immortalized human epidermal keratinocytes. <b>1994</b> , 2, 119-125	1
1667	Radiation response of human cervical carcinoma cells transfected with sense and antisense p53 retroviral constructs. <b>1994</b> , 2, 212-218	1
1666	Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. <b>1994</b> , 172, 13-8	101
1665	Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. <b>1994</b> , 172, 267-72	55
1664	Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. <b>1994</b> , 174, 23-31	44
1663	p53 expression, mutation, and allelic deletion in ovarian cancer. <b>1994</b> , 174, 159-68	46
1662	On the expression of the p53 protein in human cancer. <b>1994</b> , 19, 23-9	39
1661	p53Val135 temperature sensitive mutant suppresses growth of human breast cancer cells. <b>1994</b> , 30, 167-77	6
1660	Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. <b>1994</b> , 30, 179-95	11
1659	Generation of mutagens during arachidonic acid metabolism. <b>1994</b> , 13, 303-8	71
1658	Tumor suppressor genes and their roles in breast cancer. <b>1994</b> , 32, 19-38	38
1657	The p53 tumor suppressor gene in breast cancer. <b>1994</b> , 32, 39-47	125
1656	Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. <b>1994</b> , 19, 259-68	92
1655	p53 immunoreactivity in oligodendrogliomas. <b>1994</b> , 22, 1-6	16
1654	Absence of MDM-2 gene amplification in experimentally induced tumors regardless of p53 status. <b>1994</b> , 9, 40-5	11
1653	Screening for p53 mutations in C3H/He mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone. <b>1994</b> , 9, 71-5	15

1652	Mutation and altered expression of p53 genes in experimental rat bladder tumor cells. <b>1994</b> , 9, 95-104	11
1651	Characterization of cell lines derived from formaldehyde-induced nasal tumors in rats. <b>1994</b> , 9, 193-9	13
1650	Influence of DNA repair by ada and ogt alkyltransferases on the mutational specificity of alkylating agents. <b>1994</b> , 9, 200-9	13
1649	Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines. <b>1994</b> , 9, 236-44	10
1648	Preferential repair of ultraviolet light-induced DNA damage in the transcribed strand of the human p53 gene. <b>1994</b> , 10, 105-9	30
1647	Ultraviolet B light-induced mutagenesis of p53 hotspot codons 248 and 249 in human skin fibroblasts. <b>1994</b> , 10, 181-8	15
1646	Frequent p53 mutation in mouse tumors induced by repeated beta-irradiation. <b>1994</b> , 11, 236-42	17
1645	Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. <b>1994</b> , 55, 84-91	53
1644	Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. <b>1994</b> , 56, 13-20	11
1643	p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer. <b>1994</b> , 56, 46-50	8
1642	High proliferative rates demonstrated by bromodeoxyuridine labeling index in breast carcinomas with p53 overexpression. <b>1994</b> , 56, 146-52	4
1641	Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. <b>1994</b> , 73, 176-80	98
1640	p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. <b>1994</b> , 73, 181-6	55
1639	Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. <b>1994</b> , 73, 406-15	56
1638	p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. <b>1994</b> , 73, 2147-56	91
1637	K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. <b>1994</b> , 73, 2727-33	91
1636	Low frequency of the p53 gene mutations in neuroblastoma. <b>1994</b> , 73, 3087-93	69
1635	Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. <b>1994</b> , 74, 30-7	48

1634	Dietary carcinogens and mammary carcinogenesis. Induction of rat mammary carcinomas by administration of heterocyclic amines in cooked foods. <b>1994</b> , 74, 1063-9	47
1633	Steroid hormones and risk of breast cancer. <b>1994</b> , 74, 1111-24	106
1632	High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. <b>1994</b> , 74, 3089-96	73
1631	The emerging picture of p53. <b>1994</b> , 26, 145-54	35
1630	p53 mutations in human bladder cancer. <b>1994</b> , 24, 156-60	19
1629	The spectrum of TP53 mutations in bladder carcinoma. <b>1994</b> , 9, 108-18	45
1628	Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. <b>1994</b> , 9, 119-23	72
1627	No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis. <b>1994</b> , 10, 136-8	20
1626	Isochromosomes in neoplasia. <b>1994</b> , 10, 221-30	162
1625	TP53 mutations are frequent in malignant NF1 tumors. <b>1994</b> , 10, 250-5	159
1624	Flow cytometric quantitation of C-myc and P53 proteins in bovine papillomavirus type 1-transformed primary mouse fibroblasts. <b>1994</b> , 17, 237-45	8
1623	Exhaustive analysis of the P53 gene coding sequence by denaturing gradient gel electrophoresis: application to the detection of point mutations in acute leukemias. <b>1994</b> , 3, 126-32	22
1622	A tandem CC-->TT transition in the p53 gene of a breast cancer. <b>1994</b> , 4, 158-60	1
1621	Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. <b>1994</b> , 56, 193-9	63
1620	Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. <b>1994</b> , 56, 487-93	51
1619	Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. <b>1994</b> , 56, 630-3	90
1618	p53 gene mutations in oropharyngeal carcinomas: a comparison of solitary and multiple primary tumours and lymph-node metastases. <b>1994</b> , 56, 807-11	50
1617	Multifactorial analysis of p53 alteration in human cancer: a review. <b>1994</b> , 57, 1-9	250

1616	p53 mutations in human tumors with chimeric EWS/FLI-1 genes. <b>1994</b> , 57, 336-40	46
1615	The regulation of p53 function: Steiner Award Lecture. <b>1994</b> , 57, 623-7	141
1614	Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. <b>1994</b> , 58, 185-91	209
1613	Increased UV-induced SCEs but normal repair of DNA damage in p53-deficient mouse cells. <b>1994</b> , 58, 254-7	53
1612	Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous-cell carcinoma in India. <b>1994</b> , 58, 340-5	92
1611	Cloning of feline p53 tumor-suppressor gene and its aberration in hematopoietic tumors. <b>1994</b> , 58, 602-7	34
1610	Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. <b>1994</b> , 59, 601-6	32
1609	Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma. <b>1994</b> , 19, 122-128	30
1608	Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. <b>1994</b> , 24, 765-8	61
1607	Expression of tumor-associated protein variants in chemically induced rat hepatomas and transformed rat liver cell lines determined by two-dimensional electrophoresis. <b>1994</b> , 15, 372-81	18
1606	Analysis of p53 gene mutations in acute myeloid leukemia. <b>1994</b> , 46, 304-9	32
1605	The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. <b>1994</b> , 28, 7-16	60
1604	Covalent binding of benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxides to DNA: molecular structures, induced mutations and biological consequences. <b>1994</b> , 49, 185-99	75
1603	Cell cycle control and cancer. <i>Science</i> , <b>1994</b> , 266, 1821-8	33.3 1890
1602	DNA Damage and Cytotoxicity Caused by Nitric Oxide. <b>1994</b> , 120-135	29
1601	Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. <b>1994</b> , 120, 737-42	32
1600	Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. <b>1994</b> , 120, 143-8	26
1599	Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer. <b>1994</b> , 120, 678-82	5

1598	The transforming activity of simian virus 40 large tumor antigen. <b>1994</b> , 1198, 65-83	48
1597	p53 and the Li-Fraumeni syndrome. <b>1994</b> , 1198, 197-213	28
1596	Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. <b>1994</b> , 305, 253-64	801
1595	Gene-targeting and the p53 tumor-suppressor gene. <b>1994</b> , 307, 557-72	11
1594	DNA damage, oncogenesis and the p53 tumour-suppressor gene. <b>1994</b> , 307, 573-81	46
1593	International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 6. Estimation of genetic risks of exposure to chemical mutagens: relevance of data on spontaneous mutations and of experience with ionizing radiation. <b>1994</b> , 304, 139-58	15
1592	Rearranged p53 gene with loss of normal allele in a low-grade nonrecurrent glioma. <b>1994</b> , 78, 68-71	5
1591	Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts. <b>1994</b> , 16, 183-310	1
1590	Relationship among p53, stage, and prognosis of large bowel cancer. <b>1994</b> , 37, 527-34	34
1589	p53 mutations in flat- and polypoid-type colorectal tumors detected by temperature-gradient gel electrophoresis. <b>1994</b> , 39, 2043-8	16
1588	Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment. <b>1994</b> , 1, 79-86	6
1587	Altered p53 expression and epidermal cell proliferation is seen in vulval lichen sclerosis. <b>1994</b> , 21, 316-23	46
1586	Lymphocyte apoptosis--mechanisms and implications in disease. <b>1994</b> , 142, 141-56	31
1585	Genetic alterations in non-melanoma skin cancer. <b>1994</b> , 103, 747-50	45
1584	Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. <b>1994</b> , 7, 91-7	270
1583	Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. <b>1994</b> , 8, 171-6	292
1582	Overexpression of p53 and long-term survival in colon carcinoma. <b>1994</b> , 70, 293-6	70
1581	Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. <b>1994</b> , 70, 585-90	115



1580	Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients. <b>1994</b> , 70, 662-7	18
1579	Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. <b>1994</b> , 70, 684-9	47
1578	Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. <b>1994</b> , 70, 914-21	57
1577	TP53 allele loss, mutations and expression in malignant melanoma. <b>1994</b> , 69, 253-9	59
1576	The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. <b>1994</b> , 69, 409-16	358
1575	Solution structure of the tetrameric minimum transforming domain of p53. <b>1994</b> , 1, 877-90	242
1574	Recent advances in the molecular genetics of urogenital tumors. <b>1994</b> , 1, 1-16	9
1573	The clinical relevance of the p53 tumour suppressor gene. <b>1994</b> , 5, 133-45	25
1572	How may clonality be assessed in human tumours?. <b>1994</b> , 24, 287-92	14
1571	Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. <b>1994</b> , 25, 339-47	27
1570	Lower incidence of K-ras codon 12 mutation in flat colorectal adenomas than in polypoid adenomas. <b>1994</b> , 85, 147-51	115
1569	Different roles of 8-hydroxyguanine formation and 2-thiobarbituric acid-reacting substance generation in the early phase of liver carcinogenesis induced by a choline-deficient, L-amino acid-defined diet in rats. <b>1994</b> , 85, 499-505	29
1568	p53 gene mutation in hepatocellular carcinoma induced by 2-amino-3-methylimidazo[4,5-f]quinoline in nonhuman primates. <b>1994</b> , 85, 506-9	18
1567	K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. <b>1994</b> , 85, 1005-14	27
1566	Difference in allelic expression of genes probably associated with tumor progression in murine fibrosarcomas and cell lines. <b>1994</b> , 85, 1015-22	8
1565	High frequency of p53 abnormality in laryngeal cancers of heavy smokers and its relation to human papillomavirus infection. <b>1994</b> , 85, 1087-93	17
1564	Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. <b>1994</b> , 85, 825-30	28
1563	State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. <b>1994</b> , 85, 847-52	41

1562	p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries. <b>1994</b> , 85, 904-10	32
1561	p53: a cellular Achilles' heel revealed. <b>1994</b> , 2, 789-92	1
1560	Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia. <b>1994</b> , 7, 183-233	9
1559	Tumor spectrum analysis in p53-mutant mice. <b>1994</b> , 4, 1-7	1731
1558	Expression of p53 mRNA is proliferation-dependent in the human fibroblast cell line WI-38. <b>1994</b> , 27, 465-473	
1557	Radiation-induced concomitant overexpression of p53, p62c-fos and p21N-fas in mouse epidermis. <b>1994</b> , 27, 517-528	3
1556	p53 gene mutations in pituitary adenomas: rare events. <b>1994</b> , 41, 809-14	130
1555	Differential effect of p53 on the promoters of mouse DNA polymerase beta gene and proliferating-cell-nuclear-antigen gene. <b>1994</b> , 221, 227-37	31
1554	p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. <b>1994</b> , 102, 786-92	26
1553	Germline p53 mutations and heritable cancer. <b>1994</b> , 28, 443-65	61
1552	Historical origins of current concepts of carcinogenesis. <b>1994</b> , 65, 17-111	26
1551	Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. <b>1994</b> , 127, 125-33	19
1550	Evaluation of the yeast DEL assay with 10 compounds selected by the International Program on Chemical Safety for the evaluation of short-term tests for carcinogens. <b>1994</b> , 320, 293-303	49
1549	p53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. <b>1994</b> , 74, 139-43	11
1548	No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis. <b>1994</b> , 76, 47-9	16
1547	Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas. <b>1994</b> , 76, 106-11	17
1546	Lack of germ-line mutations in the p53 gene exons 4 to 8 in patients with late-onset second malignant neoplasms. <b>1994</b> , 76, 148-50	1
1545	Transcriptional activation by p53 correlates with suppression of growth but not transformation. <b>1994</b> , 79, 817-27	219

1544	Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. <b>1994</b> , 77, 829-39	460
1543	p53-dependent apoptosis suppresses tumor growth and progression in vivo. <b>1994</b> , 78, 703-11	801
1542	Characterization of mutagenic activity in cooked-grain-food products. <b>1994</b> , 32, 15-21	30
1541	Effect of cooking time and temperature on the heterocyclic amine content of fried beef patties. <b>1994</b> , 32, 595-603	200
1540	The role of the p53 protein in the apoptotic response. <b>1994</b> , 345, 277-80	50
1539	Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. <b>1994</b> , 5, 1079-88	206
1538	H-ras ribozyme-mediated alteration of the human melanoma phenotype. <b>1994</b> , 716, 242-53; discussion 253-6	25
1537	Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. <b>1994</b> , 716, 265-80; discussion 280-2	18
1536	p53 gene mutations in brain tumors in Taiwan. <b>1994</b> , 78, 25-32	9
1535	Accumulation of nuclear p53 and tumor progression in bladder cancer. <b>1994</b> , 331, 1259-64	656
1534	Cancer and the heat shock response. <b>1994</b> , 30A, 1884-91	110
1533	Functions of human papillomavirus E6 and E7 oncoproteins. <b>1994</b> , 2, 170-4	37
1532	Oncogenes and cell death. <b>1994</b> , 4, 120-9	229
1531	DNA amplification: new insights into its mechanism. <b>1994</b> , 103, 73-81	20
1530	Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. <b>1994</b> , 167, 52-7	67
1529	Potential application of p53 as an intermediate biomarker in Barrett's esophagus. <b>1994</b> , 57, 598-603	49
1528	Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. <i>Science</i> , <b>1994</b> , 265, 346-55	33:3 2093
1527	Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. <b>1994</b> , 168, 429-32	111

1526	p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6. <b>1994</b> , 353, 29-32	10
1525	p53 expression in nitric oxide-induced apoptosis. <b>1994</b> , 355, 23-6	315
1524	The characterisation of p53 binding phage isolated from phage peptide display libraries. <b>1994</b> , 243, 639-52	21
1523	Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. <b>1994</b> , 25, 1075-83	88
1522	Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. <b>1994</b> , 25, 438-42	62
1521	Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. <b>1994</b> , 25, 449-54	23
1520	Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. <b>1994</b> , 25, 92-7	58
1519	Inosine-5'-monophosphate dehydrogenase activity is maintained in immortalized murine cells growth-arrested by serum deprivation. <b>1994</b> , 34, 91-106	6
1518	Cyclins and cancer: wheels within wheels. <b>1994</b> , 343, 931-2	10
1517	A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma. <b>1994</b> , 20, 553-6	17
1516	p53 Protein expression in squamous cell carcinomas from sun-exposed and non-sun-exposed sites. <b>1994</b> , 31, 417-22	15
1515	Apoptosis and programmed cell death in health and disease. <b>1994</b> , 31, 177-246	88
1514	Analysis of the tumor suppressor gene p53 in xeroderma pigmentosum fibroblasts. <b>1994</b> , 85, 9-12	4
1513	Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. <b>1994</b> , 83, 197-200	47
1512	Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations. <b>1994</b> , 86, 59-65	26
1511	Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. <b>1994</b> , 190, 1141-8	25
1510	Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas. <b>1994</b> , 86, 215-21	14
1509	Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. <b>1994</b> , 39, 79-86	61

1508	P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. <b>1994</b> , 30A, 1701-4	31
1507	Maintenance of identical p53 mutations throughout progression of squamous cell carcinomas of the tongue. <b>1994</b> , 30B, 335-7	16
1506	Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus. <b>1994</b> , 190, 767-74	43
1505	Gene replacement strategies for the prevention and therapy of cancer. <b>1994</b> , 30A, 2032-7	7
1504	The pentachlorophenol metabolite tetrachloro-p-hydroquinone induces the formation of 8-hydroxy-2-deoxyguanosine in liver DNA of male B6C3F1 mice. <b>1994</b> , 74, 265-74	46
1503	Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. <b>1994</b> , 30B, 338-45	77
1502	MDM2 gene amplification in human breast cancer. <b>1994</b> , 30A, 982-4	47
1501	A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients. <b>1994</b> , 82, 189-98	19
1500	Neurons from mouse embryos with a null mutation in the tumour suppressor gene p53 undergo normal cell death in the absence of neurotrophins. <b>1994</b> , 182, 112-4	32
1499	Toward the development of an equitable cancer prevention. <b>1994</b> , 83, 139-42	3
1498	Serum p53 auto-antibodies: incidence in familial breast cancer. <b>1994</b> , 30A, 580-4	30
1497	Mutagenesis by Metal-Induced Oxygen Radicals. <b>1994</b> , 102, 57	5
1496	Induction of Mutation Spectra by Complex Mixtures: Approaches, Problems, and Possibilities. <b>1994</b> , 102, 127	4
1495	The Role of the Cellular Antioxidant Defense in Oxidant Carcinogenesis. <b>1994</b> , 102, 123	47
1494	Mechanisms of formation of DNA adducts from ethylene dihalides, vinyl halides, and arylamines. <b>1994</b> , 26, 47-66	19
1493	Sequence of a cDNA encoding the p53 protein in rhesus monkey ( <i>Macaca mulatta</i> ). <b>1994</b> , 138, 223-6	6
1492	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. <b>1994</b> , 170, 246-52	132
1491	The p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. <b>1994</b> , 11, 126-127	3

1490	mRNA and protein expression of p53 mutations in human bladder cancer cell lines. <b>1994</b> , 82, 113-21	22
1489	P53 gene mutations in women with breast cancer and a previous history of benign breast disease. <b>1994</b> , 30A, 808-12	7
1488	Analysis of p53 gene mutations and loss of heterozygosity for loci on chromosome 9q in basal cell carcinoma. <b>1994</b> , 79, 67-72	8
1487	Expression of p53 protein in prostate cancers of different histologic types. <b>1994</b> , 190, 384-8	7
1486	Strand bias in mutation involving 5-methylcytosine deamination in the human hprt gene. <b>1994</b> , 314, 21-6	32
1485	Nuclear accumulation of p53 in response to treatment with DNA-damaging agents. <b>1994</b> , 72, 43-52	23
1484	Gene therapy--its potential in the management of oral cancer. <b>1994</b> , 30B, 143-54	13
1483	Excision of ultraviolet-induced photoproducts of 5-methylcytosine from DNA. <b>1994</b> , 315, 85-94	16
1482	The molecular basis for cell cycle delays following ionizing radiation: a review. <b>1994</b> , 31, 1-13	231
1481	Mutational spectrum of the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. <b>1994</b> , 26, 221-35	10
1480	Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. <b>1994</b> , 11, 318-77	130
1479	Absence of p53 mutation in Japanese patients with malignant thyroid lymphoma. <b>1994</b> , 17, 775-82	2
1478	Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. <b>1994</b> , 8, 2817-30	406
1477	Molecular biology of breast cancer. <b>1994</b> , 5 Suppl 4, 31-7	9
1476	Transgenic Animals in Toxicology. <b>1994</b> , 22, 8-19	4
1475	High Levels of Stable p53 Protein and the Expression of c-myc in Cultured Human Epithelial Tissue after Cobalt-60 Irradiation. <b>1994</b> , 137, 317	12
1474	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. <b>1994</b> , 170, 246-252	120
1473	The relationship between serum p53 autoantibodies and characteristics of human breast cancer. <b>1994</b> , 69, 1115-9	77

1472	Malignant liver disease in alpha 1-antitrypsin deficiency. <b>1994</b> , 393, 27-32	8
1471	Abstracts. <b>1994</b> , 12, 1-64	15
1470	Detection of Human Papillomavirus DNA and State of p53 Gene in Japanese Penile Cancer. <b>1994</b> ,	1
1469	p53 and human cancers. <b>1994</b> , 50, 582-99	137
1468	Identification of p53 mutations in endometrial adenocarcinoma by polymerase chain reaction-single-strand conformation polymorphism. <b>1994</b> , 1, 234-7	5
1467	Mutation of the p53 gene in gallbladder cancer. <b>1994</b> , 172, 283-9	26
1466	p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. <b>1994</b> , 12, 2043-50	117
1465	p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. <b>1994</b> , 106, 1589-95	132
1464	Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. <b>1994</b> , 106, 1645-51	70
1463	TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. <b>1994</b> , 107, 1012-8	153
1462	Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. <b>1994</b> , 69, 809-16	129
1461	p53 mutations and overexpression in locally advanced breast cancers. <b>1994</b> , 69, 1145-50	56
1460	Immune response against tumors. <b>1994</b> , 57, 281-351	55
1459	p53 mutations have no additional prognostic value over stage in bladder cancer. <b>1994</b> , 70, 496-500	41
1458	Dissecting molecular carcinogenesis: development of transgenic mouse models by epidermal gene targeting. <b>1994</b> , 64, 247-96	13
1457	p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. <b>1994</b> , 69, 846-52	89
1456	The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. <b>1994</b> , 69, 943-6	85
1455	Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. <b>1994</b> , 69, 1052-8	61

1454	Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. <b>1994</b> , 70, 1191-7	58
1453	Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia. <b>1994</b> , 111, 758-63	21
1452	Genetics of breast and ovarian cancer. <b>1994</b> , 50, 656-76	18
1451	Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. <b>1994</b> , 152, 388-92	172
1450	Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. <b>1994</b> , 152, 418-23	53
1449	Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. <b>1994</b> , 151, 1276-80	97
1448	Proto-oncogenes and tumor suppressor genes in human urological malignancies. <b>1994</b> , 151, 1479-97	57
1447	Immunohistochemical detection of p53 protein in human prostatic cancer. <b>1994</b> , 152, 1297-301	60
1446	p53 oncogene mutations in human prostate cancer specimens. <b>1994</b> , 151, 492-5	105
1445	Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. <b>1994</b> , 70, 1031-4	38
1444	Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study. <b>1994</b> , 102, 45-54	73
1443	Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. <b>1994</b> , 102, 660-4	31
1442	p53 induction is associated with neuronal damage in the central nervous system. <b>1994</b> , 91, 7525-9	227
1441	The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. <b>1994</b> , 91, 5124-8	184
1440	Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. <b>1994</b> , 91, 8974-8	61
1439	Viruses and human cancer. <b>1994</b> , 50, 560-81	22
1438	Retinoblastoma and p53 genes as prognostic indicators in urological oncology. <b>1994</b> , 53, 1-5	8
1437	Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. <b>1994</b> , 35, 831-7; discussion 837-8	59



1436	Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. <b>1994</b> , 26, 1-5	11
1435	Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. <b>1994</b> , 91, 7036-40	141
1434	Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. <b>1994</b> , 91, 10918-22	643
1433	Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. <b>1994</b> , 91, 3759-63	69
1432	Mutations and altered expression of p16INK4 in human cancer. <b>1994</b> , 91, 11045-9	457
1431	Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. <b>1994</b> , 91, 2230-4	578
1430	Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. <b>1994</b> , 91, 2684-8	243
1429	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. <b>1994</b> , 14, 6764-72	32
1428	Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. <b>1994</b> , 219, 332-41	81
1427	A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. <b>1994</b> , 14, 3683-94	300
1426	p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. <b>1994</b> , 91, 413-7	250
1425	Conformational effects of environmentally induced, cancer-related mutations in the p53 protein. <b>1994</b> , 91, 9262-6	5
1424	Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. <b>1994</b> , 14, 7805-15	102
1423	Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. <b>1994</b> , 14, 1929-38	204
1422	Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. <b>1995</b> , 92, 1008-12	48
1421	Familial brain tumour syndrome associated with a p53 germline deletion of codon 236. <b>1995</b> , 5, 15-23	32
1420	A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. <b>1995</b> , 15, 3450-9	32
1419	Targeting p53 as a general tumor antigen. <b>1995</b> , 92, 11993-7	247

1418	PAK1, a gene that can regulate p53 activity in yeast. <b>1995</b> , 92, 6062-6	22
1417	p53 deficiency does not affect the accumulation of point mutations in a transgene target. <b>1995</b> , 92, 8517-21	74
1416	Expression of the wild-type p53 antioncogene induces guanine nucleotide-dependent stem cell division kinetics. <b>1995</b> , 92, 136-40	58
1415	p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. <b>1995</b> , 92, 8493-7	718
1414	Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. <b>1995</b> , 15, 5849-57	83
1413	Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. <b>1995</b> , 15, 6953-60	59
1412	The p53-mediated G1 checkpoint is retained in tumorigenic rat embryo fibroblast clones transformed by the human papillomavirus type 16 E7 gene and EJ-ras. <b>1995</b> , 15, 1446-54	26
1411	Discrimination of DNA binding sites by mutant p53 proteins. <b>1995</b> , 15, 5196-202	39
1410	p53 mutation in the myelodysplastic syndromes. <b>1995</b> , 89, 61-6	25
1409	Characterization of a mammalian homolog of the Escherichia coli MutY mismatch repair protein. <b>1995</b> , 15, 989-96	183
1408	Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. <b>1995</b> , 71, 215-8	35
1407	DNA damage profiles induced by oxidizing agents. <b>1996</b> , 127, 223-49	68
1406	Lung pathology: the molecular genetics of non-small cell lung cancer. <b>1995</b> , 27, 295-301	4
1405	Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. <b>1995</b> , 92, 5545-9	784
1404	Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. <b>1995</b> , 6, 589-93	18
1403	Immunohistochemical evidence of p53 protein in human placenta and choriocarcinoma cell lines. <b>1995</b> , 10, 983-8	24
1402	Genetics of non-medullary thyroid cancer. <b>1995</b> ,	
1401	Role of cysteine residues in regulation of p53 function. <b>1995</b> , 15, 3892-903	264

1400	Nucleotide sequence of the bovine P53 tumor-suppressor cDNA. <b>1995</b> , 5, 261-4	9
1399	Tumour diagnosis by PCR-based detection of tumour cells. <b>1995</b> , 221, 116-21	4
1398	Cytogenetics and molecular genetics of human solid tumours. <b>1995</b> , 29, 101-10	0
1397	The genetic analysis of ovarian cancer. <b>1995</b> , 72, 521-7	70
1396	Molecular genetics of exocrine pancreatic neoplasms. <b>1995</b> , 75, 857-69	50
1395	p53: DNA damage, DNA repair, and apoptosis. <b>1996</b> , 127, 65-95	36
1394	New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. <b>1995</b> , 108, 246-54	71
1393	p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event. <b>1995</b> , 48, M79-82	10
1392	Biological indices in the assessment of breast cancer. <b>1995</b> , 48, M221-38	11
1391	TP53 abnormalities and genetic instability in breast cancer. <b>1995</b> , 34, 663-7	18
1390	[Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course]. <b>1995</b> , 35 Suppl 1, 93-7	1
1389	[14] Analysis of p53 mutations in human gliomas by RNA single-strand conformational polymorphism. <b>1995</b> , 26, 210-224	
1388	Tumor suppressor p53 mutations and breast cancer: a critical analysis. <b>1995</b> , 66, 71-141	68
1387	Molecular pathogenesis of AIDS-related lymphomas. <b>1995</b> , 67, 113-53	53
1386	V(D)J recombination and double-strand break repair. <b>1995</b> , 58, 29-85	49
1385	The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids. <b>1995</b> , 72, 386-92	24
1384	Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients. <b>1995</b> , 71, 25-9	12
1383	A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. <b>1995</b> , 71, 999-1002	17

1382	[6] Methods to study epstein-barr virus and p53 status in human cells. <b>1995</b> , 89-100	4
1381	The p53 tumor suppressor gene. <b>1995</b> , 3, 55-141	0
1380	MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. <b>1995</b> , 72, 883-8	27
1379	MDM-2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression. <b>1995</b> , 48, M322-5	5
1378	The role of the p53 tumour-suppressor-gene. <b>1995</b> , 8, 99-103	2
1377	p53 mutation and expression in lymphoma. <b>1995</b> , 72, 150-4	34
1376	Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. <b>1995</b> , 17, 209-16	83
1375	Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. <b>1995</b> , 92, 6842-6	25
1374	Molecular and biological factors in the prognosis of non-small cell lung cancer. <b>1995</b> , 8, 1389-97	35
1373	Molecular alterations in head and neck squamous cell carcinoma. <b>1995</b> , 20, 291-8	4
1372	PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid. <b>1995</b> , 103, 404-8	24
1371	Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. <b>1995</b> , 104, 319-24	11
1370	Colon Carcinogenesis in Inflammatory Bowel Disease. <b>1995</b> , 1, 142-158	16
1369	The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. <b>1995</b> , 6, 119-31	12
1368	Adaptive mutations in Escherichia coli as a model for the multiple mutational origins of tumors. <b>1995</b> , 92, 5669-73	35
1367	Increased activity of p53 in senescing fibroblasts. <b>1995</b> , 92, 8348-52	264
1366	Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. <b>1995</b> , 92, 8591-5	123
1365	Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. <b>1995</b> , 15, 6785-93	104

1364	Cytogenetic report of a male breast cancer. <b>1995</b> , 81, 66-71	12
1363	Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. <b>1995</b> , 90, 147-55	7
1362	Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. <b>1995</b> , 91, 625-9	50
1361	Screening for germline mutations of the p53 gene in familial breast cancer patients. <b>1995</b> , 25, 132-7	7
1360	High-frequency developmental abnormalities in p53-deficient mice. <b>1995</b> , 5, 931-6	390
1359	Management of pancreatic carcinoma. <b>1995</b> , 4, 61-74	28
1358	p53 and disease progression in patients with non-small cell lung cancer. <b>1995</b> , 4, 157-61	5
1357	Human papillomavirus DNA and abnormal p53 expression in carcinoma of the urinary bladder. <b>1995</b> , 103, 331-8	24
1356	Transgenic mouse models for tumour-suppressor genes. <b>1995</b> , 238, 233-8	13
1355	p53 gene mutations and photocarcinogenesis. <b>1995</b> , 62, 218-30	129
1354	Reversion profiles of coolwhite fluorescent light compared with far ultraviolet light: homologies and differences. <b>1995</b> , 61, 353-9	8
1353	Ras oncogene and p53 gene hotspot mutations in colorectal cancers. <b>1995</b> , 10, 119-24	2
1352	Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. <b>1995</b> , 10, 250-5	29
1351	Primary liver cancer is of multifactorial origin: importance of hepatitis B virus infection and dietary aflatoxin. <b>1995</b> , 10, 604-8	11
1350	Small hepatocellular carcinoma: its relationship to multistep hepatocarcinogenesis. <b>1995</b> , 45, 175-84	29
1349	Immunohistochemical detection of p53 and the recurrence of rectal adenocarcinoma. <b>1995</b> , 65, 740-2	
1348	DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. <b>1995</b> , 75, 26-32	21
1347	Phosphorylation studies on rat p53 using the baculovirus expression system. Manipulation of the phosphorylation state with okadaic acid and influence on DNA binding. <b>1995</b> , 228, 625-39	37

1346	Early detection of ovarian cancer. <b>1995</b> , 45, 71-87	36
1345	p53 allelic imbalance in astrocytoma detected using fluorescent PCR of microsatellite repeat polymorphisms. <b>1995</b> , 21, 344-51	1
1344	Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner. <b>1995</b> , 234, 827-31	11
1343	p53 expression in multicentric squamous cell carcinoma and surrounding squamous epithelium of the upper aerodigestive tract. Immunohistochemical analysis of 95 lesions. <b>1995</b> , 75, 1657-62	41
1342	p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. <b>1995</b> , 75, 2037-44	72
1341	Mutations of the p53 gene in male breast cancer. <b>1995</b> , 75, 2233-8	65
1340	p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. <b>1995</b> , 76, 57-66	26
1339	Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. <b>1995</b> , 76, 72-8	60
1338	The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. <b>1995</b> , 76, 314-8	31
1337	Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. <b>1995</b> , 76, 618-25	32
1336	Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. <b>1995</b> , 76, 1187-96	44
1335	p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. <b>1995</b> , 76, 1201-8	106
1334	Molecular basis of endometrial cancer. <b>1995</b> , 76, 2034-40	84
1333	Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. <b>1995</b> , 76, 2457-63	68
1332	Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer. <b>1995</b> , 76, 2504-9	20
1331	Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. <b>1995</b> , 46, 178-88	101
1330	A p53 mutation in exon 5 associated with adenovirus transformation. <b>1995</b> , 12, 1-6	2
1329	Lack of concordant p53 mutations in some paired primary and metastatic mouse squamous cell carcinomas induced by chemical carcinogenesis. <b>1995</b> , 12, 77-81	8

1328	Does telomere shortening drive selection for p53 mutation in human cancer?. <b>1995</b> , 12, 119-23	35
1327	No involvement of Ki-ras or p53 gene mutations in colitis-associated rat colon tumors induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate. <b>1995</b> , 12, 193-7	20
1326	Benzo[a]pyrene-induced mutagenesis of p53 hot-spot codons 248 and 249 in human hepatocytes. <b>1995</b> , 13, 15-20	25
1325	Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. <b>1995</b> , 13, 104-11	14
1324	p53 mutations in matched primary and metastatic human tumors. <b>1995</b> , 13, 166-72	25
1323	p53 gene mutational spectra in hepatocellular carcinomas induced by 2-acetylaminofluorene and N-nitroso-2-acetylaminofluorene in rats. <b>1995</b> , 13, 182-90	15
1322	p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. <b>1995</b> , 13, 266-71	23
1321	Frameshift mutation in codon 176 of the p53 gene in rat esophageal epithelial cells transformed by benzo[a]pyrene dihydrodiol. <b>1995</b> , 14, 84-93	13
1320	Analysis of oncogenes, tumor suppressor genes, autocrine growth-factor production, and differentiation state of human osteosarcoma cell lines. <b>1995</b> , 14, 170-8	25
1319	A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. <b>1995</b> , 14, 227-32	14
1318	High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. <b>1995</b> , 14, 286-93	27
1317	p53 gene mutations in pediatric brain tumors. <b>1995</b> , 25, 431-6	60
1316	Prognostic value of p53 protein in esophageal adenocarcinoma. <b>1995</b> , 60, 5-11	20
1315	Giant leap for p53, small step for drug design. <b>1995</b> , 17, 3-7	14
1314	Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. <b>1995</b> , 17, 501-8	279
1313	Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. <b>1995</b> , 25, 1765-9	81
1312	Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. <b>1995</b> , 5, 48-57	52
1311	Colon carcinogenesis in inflammatory bowel disease. <b>1995</b> , 1, 142-158	17

1310	A mutational hot spot in the p53 gene is associated with hepatoblastomas. <b>1995</b> , 60, 786-90	17
1309	Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aero-digestive tract. <b>1995</b> , 60, 872-6	24
1308	Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. <b>1995</b> , 61, 316-20	17
1307	Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. <b>1995</b> , 61, 397-401	34
1306	Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcinomas in Thailand. <b>1995</b> , 63, 381-6	19
1305	p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. <b>1995</b> , 64, 47-51	34
1304	p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. <b>1995</b> , 64, 52-9	61
1303	Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. <b>1995</b> , 64, 83-91	72
1302	ras, p53 and HPV status in benign and malignant prostate tumors. <b>1995</b> , 64, 124-9	43
1301	p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. <b>1995</b> , 64, 176-81	69
1300	Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. <b>1995</b> , 64, 223-8	49
1299	p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. <b>1995</b> , 64, 298-303	12
1298	Molecular nature of spontaneous mutations at the hypoxanthine-guanine phosphoribosyltransferase (hprt) locus in Chinese hamster ovary cells. <b>1995</b> , 26, 127-38	29
1297	Analysis of mutations induced by replication of UV-damaged plasmid DNA in HeLa cell extracts. <b>1995</b> , 26, 139-46	10
1296	Deletion of chromosome arm 17p DNA sequences in pediatric high-grade and juvenile pilocytic astrocytomas. <b>1995</b> , 12, 165-72	32
1295	Molecular analysis of genetic changes in ependymomas. <b>1995</b> , 13, 272-7	64
1294	The p53 gene and its role in human brain tumors. <b>1995</b> , 15, 308-27	156
1293	Molecular pathways in the formation of gliomas. <b>1995</b> , 15, 328-38	209



1292	p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. <b>1995</b> , 22, 774-779	72
1291	Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. <b>1995</b> , 22, 1279-1288	38
1290	p53 Proteins and aflatoxin B1: The good, the bad, and the ugly. <b>1995</b> , 22, 1330-1332	2
1289	The clinical significance of p53 gene mutation in hepatocellular carcinomas from japan. <b>1995</b> , 22, 1702-1707	67
1288	Retrovirally mediated wild-type p53 restores S-phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53. <b>1995</b> , 59, 537-44	4
1287	Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. <b>1995</b> , 96, 173-94	81
1286	Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. <b>1995</b> , 101, 125-56	128
1285	Glioblastoma multiforme in four siblings: a cytogenetic and molecular genetic study. <b>1995</b> , 24, 251-8	14
1284	Familial breast cancer and genes involved in breast carcinogenesis. <b>1995</b> , 34, 171-83	11
1283	Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53. <b>1995</b> , 14, 125-48	16
1282	Apoptosis, cancer and the p53 tumour suppressor gene. <b>1995</b> , 14, 149-61	133
1281	P53, cell cycle control and apoptosis: implications for cancer. <b>1995</b> , 14, 3-15	392
1280	Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. <b>1995</b> , 14, 17-29	88
1279	Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. <b>1995</b> , 14, 323-38	94
1278	Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. <b>1995</b> , 426, 563-9	23
1277	Molecular biology of testicular germ cell tumors: current status. <b>1995</b> , 73, 355-67	7
1276	Frequency and spectrum of p53 mutations in gastric cancer--a molecular genetic and immunohistochemical study. <b>1995</b> , 426, 447-55	26
1275	Genetic alterations associated with the evolution and progression of astrocytic brain tumours. <b>1995</b> , 427, 113-8	120

1274	HPV DNA and p53 alterations in oropharyngeal carcinomas. <b>1995</b> , 427, 153-7	21
1273	The clinical significance of p53 aberrations in human tumours. <b>1995</b> , 427, 229-41	65
1272	Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. <b>1995</b> , 427, 271-6	37
1271	Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. <b>1995</b> , 427, 19-26	99
1270	Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. <b>1995</b> , 427, 27-32	31
1269	Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours. <b>1995</b> , 96, 684-90	23
1268	Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. <b>1995</b> , 23, 293-300	43
1267	Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. <b>1995</b> , 19, 216-20	44
1266	Distribution of the p53 pseudogene among mouse species and subspecies. <b>1995</b> , 6, 360-2	6
1265	Role of tumor suppressor genes in determining radiation-induced G1 arrest and transformation in human cells. <b>1995</b> , 3, 268-271	
1264	Immortalization of human uroepithelial cells by human papillomavirus 16 E6 or E7. <b>1995</b> , 3, 368-376	5
1263	Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. <b>1995</b> , 175, 175-80	69
1262	p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. <b>1995</b> , 175, 181-8	51
1261	PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. <b>1995</b> , 175, 189-94	24
1260	Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. <b>1995</b> , 175, 397-401	56
1259	p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. <b>1995</b> , 176, 45-53	61
1258	Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. <b>1995</b> , 176, 243-7	24
1257	TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue. <b>1995</b> , 176, 299-308	15

1256	p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. <b>1995</b> , 176, 361-72	11
1255	MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. <b>1995</b> , 177, 27-34	33
1254	p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. <b>1995</b> , 177, 65-70	54
1253	p53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. <b>1995</b> , 26, 63-8	30
1252	T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. <b>1995</b> , 42, 98-103	22
1251	Intracranial germ cell tumors: detection of p53 gene mutations by single-strand conformation polymorphism analysis. <b>1995</b> , 86, 555-61	14
1250	Changes in radiation sensitivity of human osteosarcoma cells after p53 introduction. <b>1995</b> , 86, 711-3	6
1249	p53 mutations occur in clinical, but not latent, human prostate carcinoma. <b>1995</b> , 86, 57-63	33
1248	Detection of p53 gene mutations in aspiration biopsy specimens from suspected breast cancers by polymerase chain reaction-single strand conformation polymorphism analysis. <b>1995</b> , 86, 140-5	3
1247	Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. <b>1995</b> , 86, 174-81	73
1246	Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. <b>1995</b> , 86, 333-5	21
1245	Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. <b>1995</b> , 86, 819-27	58
1244	Absence of ras mutations and low incidence of p53 mutations in renal cell carcinomas induced by ferric nitrilotriacetate. <b>1995</b> , 86, 1143-9	10
1243	Tumor suppressor genes: prospects for cancer therapies. <b>1995</b> , 13, 127-31	3
1242	The dominating effect of mutant p53. <b>1995</b> , 9, 221-2	44
1241	A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. <b>1995</b> , 9, 305-11	204
1240	A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. <b>1995</b> , 10, 181-7	224
1239	Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. <b>1995</b> , 71, 1003-7	172

1238	p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. <b>1995</b> , 71, 1008-12	26
1237	Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. <b>1995</b> , 71, 1013-7	49
1236	p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. <b>1995</b> , 71, 1248-52	51
1235	Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. <b>1995</b> , 72, 146-9	13
1234	Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. <b>1995</b> , 72, 720-7	10
1233	Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study. <b>1995</b> , 72, 976-80	21
1232	The role of p53 inactivation in human cervical cell carcinoma development. <b>1995</b> , 71, 219-26	28
1231	Molecular and immunohistochemical analysis of P53 in pheochromocytoma. <b>1995</b> , 72, 1211-3	21
1230	Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. <b>1995</b> , 72, 1259-66	115
1229	Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. <b>1995</b> , 72, 1389-96	26
1228	Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer?. <b>1995</b> , 71, 357-62	31
1227	A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. <b>1995</b> , 71, 451-5	58
1226	Refined solution structure of the oligomerization domain of the tumour suppressor p53. <b>1995</b> , 2, 321-33	190
1225	High prevalence of hepatitis C virus antibody and RNA in patients with oral cancer. <b>1995</b> , 24, 354-60	60
1224	The pineal neurohormone melatonin prevents in vivo and in vitro apoptosis in thymocytes. <b>1995</b> , 19, 178-88	114
1223	Cell cycle regulators in the keratinocyte (cyclin-cdk). <b>1995</b> , 4, 1-8	7
1222	Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. <b>1995</b> , 104, 928-32	44
1221	Tobacco and cancer: an update. <b>1995</b> , 18, 103-10	5

1220	Familial polyposis: recent advances. <b>1995</b> , 19, 1-31	44
1219	Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. <b>1995</b> , 40, 2587-94	27
1218	p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. <b>1995</b> , 38, 1176-81	18
1217	Chemotherapy-induced nuclear alterations of morphologic and genomic characteristics in a human colon cancer grafted onto nude mice. <b>1995</b> , 38, 853-65	2
1216	DNA ploidy and proliferating cell nuclear antigen in colonic adenomas and adenocarcinomas. <b>1995</b> , 40, 996-1004	6
1215	Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. <b>1995</b> , 19, 869-75	15
1214	Factors affecting somatic mutation frequencies in vivo. <b>1995</b> , 338, 189-201	43
1213	Induction of 8-hydroxy-2-deoxyguanosine and single-strand breaks in DNA of V79 cells by tetrachloro-p-hydroquinone. <b>1995</b> , 329, 29-36	31
1212	Potential genotoxicity of chronically elevated nitric oxide: a review. <b>1995</b> , 339, 73-89	282
1211	Constitutional p53 mutations associated with brain tumors in young adults. <b>1995</b> , 82, 106-15	57
1210	Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation. <b>1995</b> , 84, 105-12	11
1209	Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem. <b>1995</b> , 51, 43-53	24
1208	Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. <b>1995</b> , 1263, 275-80	35
1207	P53 accumulation and proliferating-cell nuclear antigen expression in human lung cancer. <b>1995</b> , 121, 371-7	22
1206	Induction of apoptosis by tumor suppressor genes and oncogenes. <b>1995</b> , 6, 17-25	70
1205	Clinicopathological findings and p53 expression of thyroid cancer in children. <b>1995</b> , 25, 217-21	3
1204	Biologic indicators of exposure: are markers associated with oncogenesis useful as biologic markers of effect?. <b>1995</b> , 13 Suppl 1, 326-38	4
1203	Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigaret smoking. <b>1995</b> , 17, 237-42	6

1202	Recessive oncogenes: current status. <b>1995</b> , 1, 7-22	7
1201	Direct solid-phase sequence analysis of the human p53 gene by use of multiplex polymerase chain reaction and alpha-thiotriphosphate nucleotides. <b>1995</b> , 41, 1461-1466	29
1200	Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. <b>1995</b> , 41, 644-657	43
1199	p53 Mutations and Tumor Progression in Well-differentiated Liposarcoma and Dermatofibrosarcoma Protuberans. <b>1995</b> , 3, 35-41	11
1198	Suppression of the yeast mutation rft1-1 by human p53. <b>1995</b> , 270, 22556-64	13
1197	Tobacco and cancer: epidemiology and the laboratory. <b>1995</b> , 103, 156-60	65
1196	Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. <b>1995</b> , 15, 425-32	138
1195	Multiple genetic lesions in laryngeal squamous cell carcinomas. <b>1995</b> , 75, 1292-301	24
1194	Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. <b>1995</b> , 13, 1893-903	130
1193	Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. <b>1995</b> , 103, 942-50	210
1192	A direct effect of activated human p53 on nuclear DNA replication.. <b>1995</b> , 14, 2099-2105	57
1191	Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. <b>1995</b> , 37, 246-54	30
1190	Apoptosis and inflammation. <b>1995</b> , 4, 5-15	93
1189	Growth pattern and p53 overexpression in patients with early gastric cancer. <b>1995</b> , 75, 1454-9	27
1188	Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. <b>1995</b> , 75, 1327-38	109
1187	Immunohistochemical detection of p53 protein expression in mammary carcinoma: a study of 80 cases. <b>1995</b> , 27, 365-9	3
1186	Genetics of Colorectal and Breast Cancer. <b>1995</b> , 15, 957-971	4
1185	Genetic Alterations in Prostate Adenocarcinoma. <b>1995</b> , 4, 241-255	4

1184	Differential in situ hybridization for determination of mutational specific expression of the p53 gene in human hepatoma cell lines. <b>1995</b> , 27, 191-6	6
1183	Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway. <b>1995</b> , 1, 506-526	221
1182	Biomarkers and mechanistic approaches in environmental epidemiology. <b>1995</b> , 16, 83-103	27
1181	A p53-dependent mouse spindle checkpoint. <i>Science</i> , <b>1995</b> , 267, 1353-6	33-3 625
1180	X-gene product antagonizes the p53-mediated inhibition of hepatitis B virus replication through regulation of the pregenomic/core promoter. <b>1995</b> , 270, 31405-12	28
1179	Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). <b>1995</b> , 92, 3264-8	103
1178	Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells. <b>1995</b> , 6, 1443-58	116
1177	Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. <b>1995</b> , 16, 993-1002	115
1176	Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. <b>1995</b> , 4, 1089-92	96
1175	The Genetics of Cancer. <b>1995</b> ,	2
1174	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. <b>1995</b> , 23, 3710-7	125
1173	Nucleotide sequence of exons 5 to 9 of the p53 tumour-suppressor gene of the donkey ( <i>Equus asinus</i> ). <b>1995</b> , 6, 61-3	3
1172	p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. <i>Science</i> , <b>1995</b> , 267, 100-4	33-3 407
1171	Molecular genetics of familial breast-ovarian cancer. <b>1995</b> , 48, 789-95	3
1170	p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. <b>1995</b> , 270, 5511-8	188
1169	Disease heterogeneity: does it impact our ability to detect dietary associations with breast cancer?. <b>1995</b> , 24, 213-20	12
1168	Nucleotide sequence of the ovine P53 tumor-suppressor cDNA and its genomic organization. <b>1995</b> , 5, 255-9	12
1167	p53 Protein and Proliferating Cell Nuclear Antigen (PCNA) Expression in Small Round Cell Tumors of Bone and Adjacent Soft Tissue: A Study of 60 Cases. <b>1995</b> , 2, 259-267	1

1166	The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. <b>1995</b> , 9, 2143-56	195
1165	Frequent p53 alterations but low incidence of ras mutations in UV-B-induced skin tumors of hairless mice. <b>1995</b> , 16, 1141-7	70
1164	p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. <b>1995</b> , 23, 362-9	151
1163	Regulation of p53-Dependent Apoptosis by E1A and E1B. <b>1995</b> , 33-58	6
1162	Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. <b>1995</b> , 48, 218-22	32
1161	p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. <b>1995</b> , 48, 236-8	6
1160	Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome. <b>1995</b> , 58, 711-4	17
1159	Mechanisms of Toxicity and Carcinogenesis. <b>1995</b> , 23, 775-827	
1158	Loss of wild-type p53 and C-erbB2 amplification correlates with high-grade breast carcinomas. <b>1995</b> , 6, 181-6	
1157	Rodent p53 suppresses the transforming activity of the activated Neu oncogene by modulating the Basal promoter activity of Neu. <b>1995</b> , 6, 1087-92	1
1156	P53 and its implication in apoptosis (review). <b>1995</b> , 6, 1129-35	10
1155	Modulation of urokinase-type plasminogen-activator expression by the wild-type and mutated p53 tumor-suppressor gene. <b>1995</b> , 7, 143-6	
1154	The p53 tumor-suppressor gene is overexpressed but not mutated in human atherosclerotic tissue. <b>1995</b> , 7, 399-402	1
1153	Prevalence of p53 overexpression or mutations, but not k-ras mutations, in recurrent patients affected by colorectal-carcinoma. <b>1995</b> , 7, 1319-25	5
1152	Different subnuclear localization of wild-type and mutant p53 in human prostate-cancer cells. <b>1995</b> , 7, 1355-60	1
1151	K-RAS MUTATION IN COLORECTAL CARCINOMAS FROM SINGAPORE. <b>1995</b> , 6, 191	
1150	IN FRAME DELETION OF INTRON-7 IN THE P53 GENE IN A HUMAN TONSIL TUMOR. <b>1995</b> , 6, 27	
1149	Early detection of cancer-associated gene alterations in DNA isolated from rat feces during intestinal tumor-induction with 1,2-dimethylhydrazine. <b>1995</b> , 6, 437-45	



1148	MUTATIONS IN DNA-POLYMERASE-BETA OCCUR IN BREAST, PROSTATE AND COLORECTAL TUMORS. <b>1995</b> , 6, 459		1
1147	Status of the mdm-2 and waf-1 genes in mouse epidermal jb6 variants harboring wild-type p53 - a p53-independent induction of waf-1. <b>1995</b> , 6, 465-71		1
1146	The aberrant p53 protein (review). <b>1995</b> , 6, 1209-26		2
1145	Role of p53 in mcf-10f cell immortalization and chemically-induced neoplastic transformation. <b>1995</b> , 7, 1289-96		2
1144	Modulation of proliferation and tumorigenic potential of cervical-carcinoma cells by the expression of sense and antisense p53. <b>1995</b> , 7, 883-8		
1143	Mutation analysis in two newly identified rat p53 pseudogenes. <b>1995</b> , 10, 123-8		5
1142	The pharmacology of T cell apoptosis. <b>1995</b> , 58, 211-96		55
1141	Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. <b>1995</b> , 15, 4489-96		97
1140	Response. <i>Science</i> , <b>1995</b> , 268, 445-7	33-3	14
1139	Cancer Predisposition, Radiosensitivity and the Risk of Radiation-Induced Cancers. I. Background. <b>1995</b> , 143, 121		39
1138	Accumulation of p53 protein in chemically induced oval cells during early stages of rodent hepatocarcinogenesis. <b>1995</b> , 16, 697-701		13
1137	Reduced growth factor requirements and accelerated cell-cycle kinetics in adult human melanocytes transformed with SV40 large T antigen. <b>1995</b> , 104, 755-62		12
1136	Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. <b>1995</b> , 133, 513-22		46
1135	P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. <b>1995</b> , 17, 211-21		73
1134	Tumor suppressor genes and clonal evolution in B-CLL. <b>1995</b> , 18, 41-9		14
1133	Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. <b>1995</b> , 17, 13-8		38
1132	Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. <b>1995</b> , 19, 213-21		29
1131	17p anomalies in lymphoid malignancies: diagnostic and prognostic implications. <b>1995</b> , 17, 271-9		10

1130	Using multistage models to describe radiation-induced leukaemia. <b>1995</b> , 15, 315-334	6
1129	Low frequency of alterations in p53, K-ras, and mdm2 in rat lung neoplasms induced by diesel exhaust or carbon black. <b>1995</b> , 16, 1215-21	33
1128	DNA-damaging potency and genotoxicity of aflatoxin M1 in somatic cells in vivo of <i>Drosophila melanogaster</i> . <b>1995</b> , 10, 161-4	19
1127	Molecular analysis of mutations in thyroid tumors with TGGE. <b>1995</b> , 103, 275-9	1
1126	Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. <b>1995</b> , 160, 221-66	36
1125	p53 Overexpression in laryngeal squamous cell carcinoma and dysplasia. <b>1995</b> , 48, M194-7	8
1124	Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. <b>1995</b> , 87, 1400-7	114
1123	Recent advances in the pathogenesis of adrenocortical tumours. <b>1995</b> , 133, 133-44	56
1122	Genotypic analysis of multiple loci in somatic cells by whole genome amplification. <b>1995</b> , 23, 3488-92	33
1121	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. <b>1995</b> , 36, 455-8	37
1120	Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in F1 hybrid mice. <b>1995</b> , 16, 2659-66	27
1119	Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. <b>1995</b> , 45, 1533-9	33
1118	The P53 Tumor Suppressor Protein. <b>1995</b> , 407-418	2
1117	p53 protein accumulation in oesophageal squamous cell carcinomas and precancerous lesions. <b>1995</b> , 48, 531-4	13
1116	The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. <b>1995</b> , 17, 335-9	24
1115	Immunohistochemical evidence of p53 protein in human placenta and choriocarcinoma cell lines. <b>1995</b> , 1, 63-68	1
1114	p53 Oncoprotein Expression in Cutaneous Lymphoproliferations. <b>1995</b> , 131, 1019	11
1113	Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. <b>1995</b> , 87, 1146-53	68

1112	Tamoxifen experimental carcinogenicity studies: implications for human effects. <b>1995</b> , 208, 141-3	4
1111	Effect of dietary restriction on aging in an update. <b>1995</b> , 5, 247-258	26
1110	Nitric oxide and ethylnitrosourea: relative mutagenicity in the p53 tumor suppressor and hypoxanthine-phosphoribosyltransferase genes. <b>1995</b> , 16, 2069-74	34
1109	Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. <b>1995</b> , 16, 1181-9	98
1108	p53: a cell cycle regulator activated by DNA damage. <b>1995</b> , 66, 143-80	87
1107	p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. <b>1995</b> , 128, 1185-96	153
1106	Bcl-2 protects murine erythroleukemia cells from p53-dependent and -independent radiation-induced cell death. <b>1995</b> , 16, 1761-7	32
1105	Biochemical and molecular aspects of mammalian susceptibility to aflatoxin B1 carcinogenicity. <b>1995</b> , 208, 213-27	110
1104	Identification of an upstream region of the mouse p53 promoter critical for transcriptional expression. <b>1995</b> , 23, 663-9	29
1103	High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons. <b>1995</b> , 4, 137-9	28
1102	Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. <b>1995</b> , 16, 2363-8	39
1101	N-MYC Oncogene Amplification: A Consequence of Genomic Instability in Human Neuroblastoma. <b>1995</b> , 1, 277-285	20
1100	Effect of Cell Cycle Stage, Dose Rate and Repair of Sublethal Damage on Radiation-Induced Apoptosis in F9 Teratocarcinoma Cells. <b>1995</b> , 144, 90	16
1099	Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. <b>1995</b> , 332, 429-35	603
1098	K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. <b>1995</b> , 16, 2487-92	47
1097	p53 gene mutations in skin cancers with underlying disorders. <b>1995</b> , 9, 209-14	11
1096	Different regulation of p53 stability in UV-irradiated normal and DNA repair deficient human cells. <b>1995</b> , 336, 169-80	15
1095	The effects of hydrogen peroxide on DNA repair activities. <b>1995</b> , 336, 193-201	66

1094	Apoptosis and the cell cycle. <b>1995</b> , 7, 825-34	272
1093	Detection of TP53 gene mutations in human sarcomas. <b>1995</b> , 31A, 735-8	33
1092	Molecular genetics of dysplasia in ulcerative colitis. <b>1995</b> , 31A, 1171-3	43
1091	Screening for clonal genetic alterations. <b>1995</b> , 31A, 1127-9	5
1090	TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. <b>1995</b> , 31A, 1856-61	41
1089	Presence of human papillomavirus sequences in tumour-derived human oral keratinocytes expressing mutant p53. <b>1995</b> , 31B, 136-43	45
1088	p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract. <b>1995</b> , 31B, 53-7	24
1087	Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. <b>1995</b> , 31B, 384-91	53
1086	Terms and techniques: New approach to hot-start polymerase chain reaction using Taq DNA polymerase antibody. <b>1995</b> , 1, 42-6	17
1085	Selective neuronal vulnerability in the hippocampus--a role for gene expression?. <b>1995</b> , 18, 446-51	86
1084	Protein phosphorylation in apoptosis. <b>1995</b> , 1269, 187-99	81
1083	Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. <b>1995</b> , 63, 31-6	10
1082	p53 tumor suppressor gene protein expression in cervical cancer: relationship to prognosis. <b>1995</b> , 63, 55-9	22
1081	Transcriptional repression in normal human keratinocytes by wild-type and mutant p53. <b>1995</b> , 91, 85-92	3
1080	Preferential promutagenic lesions at exons 7-8 of human p53 genomic DNA induced by the direct-acting hepatocarcinogens N-nitroso-2-acetylaminofluorene and N-acetoxy-2-acetylaminofluorene. <b>1995</b> , 95, 39-47	
1079	Lack of p53 point mutations in chemically induced mouse hepatoblastomas: an end-stage, highly malignant hepatocellular tumor. <b>1995</b> , 95, 175-80	10
1078	Overexpression of genes in health and sickness. A bird's eye view. <b>1995</b> , 112, 1-13	22
1077	Transgenic models and cancer treatment. <b>1996</b> , 21, 565-76	1

1076	Diagnosis of micrometastases by the amplification of tissue-specific genes. <b>1995</b> , 159, 43-7	93
1075	The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review. <b>1995</b> , 159, 83-96	230
1074	Cloning and characterization of two processed p53 pseudogenes from the rat genome. <b>1995</b> , 156, 183-9	9
1073	A splice donor site mutation results in the insertion of five extra amino acids into P53 from SEWA mouse sarcoma cells. <b>1995</b> , 162, 231-4	1
1072	Cloning and sequence of a processed p53 pseudogene from rat: a potential source of false 'mutations' in PCR fragments of tumor DNA. <b>1995</b> , 166, 317-22	15
1071	A stochastic model for multistage tumorigenesis in developing and adult mice. <b>1995</b> , 129, 95-110	9
1070	p53 expression and DNA ploidy of cartilage lesions. <b>1995</b> , 26, 620-4	61
1069	Site-specific comparison of p53 immunostaining in squamous cell carcinomas. <b>1995</b> , 26, 531-3	17
1068	Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. <b>1995</b> , 82, 675-84	1875
1067	Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. <b>1995</b> , 80, 293-9	3503
1066	Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. <b>1995</b> , 248, 58-78	172
1065	Identification of a human hepatocellular carcinoma-associated tumor suppressor gene by differential display polymerase chain reaction. <b>1995</b> , 57, 1077-85	5
1064	Clinical applications of the p53 tumor suppressor gene. <b>1995</b> , 237, 79-90	11
1063	The second intron of the human galectin-3 gene has a strong promoter activity down-regulated by p53. <b>1995</b> , 363, 165-9	36
1062	Induction of p53 and apoptosis by delta 12-PGJ2 in human hepatocarcinoma SK-HEP-1 cells. <b>1995</b> , 368, 348-52	29
1061	Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. <b>1995</b> , 371, 86-8	297
1060	TP53 mutations in upper aerodigestive squamous cell carcinomas from a group of Brazilian patients. <b>1995</b> , 170, 492-4	9
1059	Frequency and characterization of p53 mutations in clinically localized prostate cancer. <b>1995</b> , 45, 470-5	57

1058	Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. <b>1995</b> , 46, 334-40	36
1057	Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells. <b>1995</b> , 173, 1477-82	24
1056	Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis. <b>1995</b> , 768, 205-9	10
1055	Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. <b>1995</b> , 23, 412-9	28
1054	Loss of heterozygosity in liver tumours. <b>1995</b> , 22, 230-8	26
1053	Analysis of mutagenesis in UV-sensitive mouse lymphoma L5178Y-R cells with a polyomavirus-based shuttle vector. <b>1995</b> , 344, 31-9	2
1052	Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. <b>1995</b> , 6, 1403-16	160
1051	P53 polymorphisms and haplotypes in lung cancer. <b>1995</b> , 16, 2233-6	110
1050	A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. <b>1995</b> , 14, 983-90	39
1049	Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. <b>1995</b> , 332, 712-7	503
1048	p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. <b>1995</b> , 75, 1339-42	40
1047	Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. <b>1995</b> , 35, 423-31	25
1046	p53 Gene Mutation in Recurrent Superficial Bladder Cancer. <b>1995</b> , 153, 1711-1715	30
1045	The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. <b>1995</b> , 36, 218-24	28
1044	Chicken anaemia virus infection: molecular basis of pathogenicity. <b>1995</b> , 24, 11-31	89
1043	Biopathologic features of Hodgkin's disease. <b>1995</b> , 16, 385-95	8
1042	Genetic changes in ovarian cancer. <b>1995</b> , 27, 73-8	54
1041	Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. <b>1995</b> , 18, 140-2	30

1040	Cell proliferation markers and growth factors in ovarian cancer. <b>1995</b> , 27, 87-94	9
1039	p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. <b>1995</b> , 14, 153-7	9
1038	Genetic and environmental factors in the etiology of human brain tumors. <b>1995</b> , 82-83, 601-5	15
1037	Transgenic approaches to understanding the mechanisms of chemical carcinogenesis in mouse skin. <b>1995</b> , 82-83, 123-30	12
1036	Molecular epidemiology and human risk monitoring. <b>1995</b> , 82-83, 763-9	11
1035	Expression of p53 in oesophageal squamous cell carcinoma in Hong Kong Chinese. <b>1995</b> , 21, 242-7	14
1034	Induction of mutations by replication of malondialdehyde-modified M13 DNA in Escherichia coli: determination of the extent of DNA modification, genetic requirements for mutagenesis, and types of mutations induced. <b>1995</b> , 16, 93-9	80
1033	p53 mutations and overexpressions in Japanese breast cancer. <b>1995</b> , 21, 595-600	3
1032	Expression of p53 and its relationship with human papillomavirus in penile carcinomas. <b>1995</b> , 21, 613-6	32
1031	Molecular pathogenesis of pituitary tumours. <b>1995</b> , 9, 203-23	16
1030	Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. <b>1995</b> , 191, 1122-32	11
1029	Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. <b>1995</b> , 191, 881-7	10
1028	Immunohistochemical expression of p53 protein and proliferating cell nuclear antigen in hepatocellular carcinoma. <b>1995</b> , 191, 1208-13	12
1027	Early initiating and promoting effects in 2-AAF-induced rat liver carcinogenesis: an immunohistochemical study. <b>1995</b> , 98, 39-46	8
1026	1995 Deichmann Lecture--p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. <b>1995</b> , 82-83, 1-7	37
1025	Cell type-specific expression of human 8-oxo-7,8-dihydroguanosine triphosphatase in normal breast and skin tissues in vivo. <b>1995</b> , 16, 277-83	8
1024	Alterations of the p16 (MTS1) Gene in Testicular, Ovarian, and Endometrial Malignancies. <b>1995</b> , 154, 1954-1957	36
1023	Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. <b>1995</b> , 22, 1279-88	35

1022	Cell-cycle dependent biosynthesis and localization of p53 protein in untransformed human cells. <b>1995</b> , 84, 167-73	24
1021	The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. <b>1995</b> , 22, 1702-1707	10
1020	Molecular events in lung cancer. <b>1995</b> , 12 Suppl 2, S3-15	9
1019	P53 germ line haplotypes associated with increased risk for colorectal cancer. <b>1995</b> , 16, 1461-4	86
1018	The Process of Leukemogenesis. <b>1996</b> , 104, 1239	16
1017	p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Cancer Risk Assessment. <b>1996</b> , 104, 435	17
1016	Utilization of Biomarker Data for Clinical and Environmental Intervention. <b>1996</b> , 104, 921	4
1015	p53 Immunohistochemical and Genetic Alterations are Associated at High Incidence with Post-Irradiated Locally Persistent Prostate Carcinoma. <b>1996</b> , 155, 1685-1692	56
1014	Molecular biology of human oral cancer. <b>1996</b> , 7, 319-28	62
1013	Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. <b>1996</b> , 10, 1081-109	64
1012	Genomic In Situ Hybridization for Whole Chromosome and Genome Analysis. 1-23	5
1011	p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. <b>1996</b> , 48, 261-8	18
1010	The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?. <b>1996</b> , 48, 971-9	47
1009	Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. <b>1996</b> , 47, 366-9	39
1008	Relationships between proliferative activity and oncogene expression in human breast cancer. <b>1996</b> , 784, 555-63	1
1007	Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. <b>1996</b> , 77, 1707-10	66
1006	DNA-protein crosslinks, a biomarker of exposure to formaldehyde--in vitro and in vivo studies. <b>1996</b> , 17, 121-5	87
1005	Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. <b>1996</b> , 88, 1442-55	528



1004	Analysis of the K-ras and p53 Pathways in X-Ray-Induced Lung Tumors in the Rat. <b>1996</b> , 145, 449	18
1003	Synthesis and characterization of adducts derived from the syn-diastereomer of benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxide and the 5'-d(CCTATAGATATCC) oligonucleotide. <b>1996</b> , 9, 188-96	14
1002	p21--negative regulator of the cell cycle. <b>1996</b> , 213, 138-49	276
1001	p53 mutations in gastric cancers from Taiwan. <b>1996</b> , 100, 107-13	15
1000	Lack of p16/CDKN2 alterations in thyroid carcinomas. <b>1996</b> , 101, 85-92	15
999	Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. <b>1996</b> , 101, 137-42	17
998	Establishment and characterization of a human-papillomavirus negative, p53-mutation negative human cervical cancer cell line. <b>1996</b> , 102, 173-81	12
997	Effects of sodium saccharin and linoleic acid on mRNA levels of Her2/neu and p53 in a human breast epithelial cell line. <b>1996</b> , 102, 91-9	4
996	p53 gene mutation in cerebral primitive neuroectodermal tumor in Taiwan. <b>1996</b> , 104, 103-13	15
995	Studies of the p53 gene mutation in Saudi non-Hodgkin's lymphoma. <b>1996</b> , 104, 225-31	0
994	Expression of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. <b>1996</b> , 105, 139-46	64
993	p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine. <b>1996</b> , 105, 105-12	21
992	Analysis of the equine tumor suppressor gene p53 in the normal horse and in eight cutaneous squamous cell carcinomas. <b>1996</b> , 107, 125-30	25
991	Excitotoxic lesion of rat brain with quinolinic acid induces expression of p53 messenger RNA and protein and p53-inducible genes Bax and Gadd-45 in brain areas showing DNA fragmentation. <b>1996</b> , 74, 1143-60	100
990	Analysis of intron 4 of the p53 gene in human cutaneous melanoma. <b>1996</b> , 176, 259-62	13
989	Causal thinking, biomarkers, and mechanisms of carcinogenesis. <b>1996</b> , 49, 951-6	27
988	Heat-shock enhanced reactivation of a UV-damaged reporter gene in human cells involves the transcription coupled DNA repair pathway. <b>1996</b> , 363, 125-35	22
987	Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer. <b>1996</b> , 32A, 335-41	15

986	Expression of p53 protein as a prognostic factor in patients with gastric cancer. <b>1996</b> , 32A, 215-20	38
985	Transfection of wild-type TP53 induces differentiation in human gingival carcinoma cells. <b>1996</b> , 32A, 533-9	4
984	A new germline TP53 gene mutation in a family with Li-Fraumeni syndrome. <b>1996</b> , 32A, 1359-65	17
983	Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. <b>1996</b> , 32A, 1963-7	29
982	The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. <b>1996</b> , 2, 32-7	48
981	Apoptosis--molecular mechanisms and biomedical implications. <b>1996</b> , 17, 1-110	84
980	Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. <b>1996</b> , 367, 65-72	51
979	Predominant p53 mutations in enzootic bovine leukemic cell lines. <b>1996</b> , 52, 53-63	14
978	Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. <b>1996</b> , 16, 517-544	174
977	p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. <b>1996</b> , 60, 72-80	40
976	p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. <b>1996</b> , 60, 339-44	34
975	p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. <b>1996</b> , 61, 167-74	103
974	Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. <b>1996</b> , 63, 216-8	15
973	The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline. <b>1996</b> , 258, 240-50	56
972	How phosphorylation regulates the activity of p53. <b>1996</b> , 263, 103-13	85
971	Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. <b>1996</b> , 25, 10-2	5
970	ADP-ribosylation of wild-type p53 in vitro: binding of p53 protein to specific p53 consensus sequence prevents its modification. <b>1996</b> , 224, 96-102	71
969	p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. <b>1996</b> , 88, 1580-6	189

968	Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. <b>1996</b> , 74, 35-42	97
967	Cancer risk and oxidative DNA damage in man. <b>1996</b> , 74, 297-312	701
966	Molecular oncology in pancreatic cancer. <b>1996</b> , 74, 313-20	28
965	p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. <b>1996</b> , 27, 360-5	91
964	p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. <b>1996</b> , 27, 389-95	72
963	p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. <b>1996</b> , 27, 542-6	25
962	The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. <b>1996</b> , 27, 567-72	47
961	p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. <b>1996</b> , 27, 586-9	51
960	p53 mutations in solar keratoses. <b>1996</b> , 27, 1180-4	35
959	Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. <b>1996</b> , 27, 1336-40	21
958	Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. <b>1996</b> , 31, 1-133	7
957	p53 Protein exhibits 3'-to-5' exonuclease activity. <b>1996</b> , 85, 1089-99	234
956	The role of DNA repair in the prevention of cancer. <b>1996</b> , 17, 235-283	5
955	Tumour suppressor gene p53 in the horse: identification, cloning, sequencing and a possible role in the pathogenesis of equine sarcoid. <b>1996</b> , 61, 114-9	22
954	Nitric oxide donors induce apoptosis in glomerular mesangial cells, epithelial cells and endothelial cells. <b>1996</b> , 317, 137-49	83
953	Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. <b>1996</b> , 120, 45-53	28
952	Multiple synchronous primaries of the gastrointestinal tract: a molecular case report. <b>1996</b> , 110, 1-9	5
951	Assessment of p53 and Ki-67 expression in snuff-induced lesions. <b>1996</b> , 34, 409-13	13

950	Decreasing p53 overexpression in sequential, recurrent, oral squamous cell carcinomas. <b>1996</b> , 34, 225-9	1
949	On the origin of cancer. <b>1996</b> , 46, 581-3	6
948	p53 expression in hepatocellular carcinoma in Greece. Correlation with epidemiological and histopathological data. <b>1996</b> , 192, 1100-6	4
947	Role of induced genetic instability in the mutagenic effects of chemicals and radiation. <b>1996</b> , 367, 11-23	41
946	Detection of DNA damage induced by human carcinogens in acellular assays: potential application for determining genotoxic mechanisms. <b>1996</b> , 368, 235-48	19
945	Control of gene expression by proteolysis. <b>1996</b> , 8, 340-7	132
944	Biochemistry of cell death. <b>1996</b> , 6, 71-80	43
943	Détection de métastases de tumeurs solides dans la circulation sanguine par PCR. <b>1996</b> , 11, 361-371	
942	Abnormal centrosome amplification in the absence of p53. <i>Science</i> , <b>1996</b> , 271, 1744-7	333 720
941	Apoptosis in ocular disease: a molecular overview. <b>1996</b> , 17, 145-65	76
940	Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. <b>1996</b> , 74, 203-209	28
939	Human papilloma virus and P53 overexpression in carcinomas of the uterine cervix, lower uterine segment and endometrium. <b>1996</b> , 28, 28-31	16
938	Implications of p53 protein expression in clear cell sarcoma of the kidney. <b>1996</b> , 28, 229-31	8
937	. <b>1996</b> ,	
936	The Molecular Progression of Bladder Cancer. <b>1996</b> , 97-112	
935	Biological and clinical importance of the p53 tumor suppressor gene. <b>1996</b> , 42, 858-868	156
934	Dominant-negative p53 mutations selected in yeast hit cancer hot spots. <b>1996</b> , 93, 4091-5	135
933	p53 mutations in non-small cell lung carcinomas in Hong Kong. <b>1996</b> , 109, 718-26	13

932	Effect of p53 alleles on placental weight. <b>1996</b> , 46, 290-7	4
931	The Role of Biomarkers in Detecting Early Changes Relating to Exposure to Occupational Carcinogens. <b>1996</b> , 38, 170-178	4
930	The process of leukemogenesis. <b>1996</b> , 104 Suppl 6, 1239-46	34
929	Anti-apoptotic activity of low levels of wild-type p53.. <b>1996</b> , 15, 4566-4573	81
928	p53 Protein overexpression in verrucous carcinoma of the skin. <b>1996</b> , 192, 12-5	10
927	p53 immunoreaction in hepatocellular carcinoma and its relationship to etiologic factors. A fine needle aspiration study. <b>1996</b> , 40, 1148-53	6
926	Functional interactions between p53 and the TFIID complex are affected by tumour-associated mutations.. <b>1996</b> , 15, 1615-1624	116
925	Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis.. <b>1996</b> , 15, 3693-3701	165
924	p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. <b>1996</b> , 93, 4781-6	101
923	Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. <b>1996</b> , 93, 3953-7	140
922	Converting cancer genes into killer genes. <b>1996</b> , 93, 4192-6	35
921	Identification of a region of p53 that confers lability. <b>1996</b> , 271, 4447-51	24
920	Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer. <b>1996</b> , 53, 233-40	6
919	Utilization of biomarker data for clinical and environmental intervention. <b>1996</b> , 104 Suppl 5, 921-5	12
918	The role of individual susceptibility in cancer burden related to environmental exposure. <b>1996</b> , 104 Suppl 3, 569-77	91
917	p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells. <b>1996</b> , 40, 855-60	22
916	p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. <b>1996</b> , 104 Suppl 3, 435-9	67
915	Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. <b>1996</b> , 93, 1093-6	118

914	Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. <b>1996</b> , 14, 2646-52	105
913	P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. <b>1996</b> , 104, 1324-31	29
912	Identification of a novel p53 functional domain that is necessary for efficient growth suppression. <b>1996</b> , 93, 15335-40	374
911	Cigarette smoking and p53 mutations in lung cancer and bladder cancer. <b>1996</b> , 104 Suppl 3, 553-6	28
910	Tumor suppressor p53 gene mutation in squamous cell carcinoma of the larynx. <b>1996</b> , 5, 201-5	11
909	The Author's Reply. <b>1996</b> , 105, 132.3-133	
908	Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis. <b>1996</b> , 106, 487-92	34
907	P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease. <b>1996</b> , 106, 728-38	38
906	[Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system]. <b>1996</b> , 75, 53-6	3
905	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. <b>1996</b> , 16, 6009-19	159
904	mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. <b>1996</b> , 16, 2445-52	318
903	Epidemiology and mechanisms relating diet to risk of colorectal cancer. <b>1996</b> , 9, 197-239	34
902	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. <b>1996</b> , 16, 4961-71	276
901	Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay. <b>1996</b> , 5, 271-8	16
900	Carcinogenesis of cutaneous malignancies. <b>1996</b> , 22, 209-15	11
899	Role of low-level ionizing radiation in multi-step carcinogenic process. <b>1996</b> , 70, 812-22	28
898	MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. <b>1996</b> , 5, 65-73	55
897	17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. <b>1996</b> , 93, 7081-4	277

896	Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. <b>1996</b> , 73, 1193-200	79
895	Isolation and characterization of the versicolorin B synthase gene from <i>Aspergillus parasiticus</i> . Expansion of the aflatoxin b1 biosynthetic gene cluster. <b>1996</b> , 271, 13600-8	48
894	Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. <b>1996</b> , 73, 144-7	68
893	TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. <b>1996</b> , 74, 555-61	30
892	The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. <b>1996</b> , 73, 261-9	93
891	p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions. <b>1996</b> , 38, 765-771	225
890	The relationship between smoking exposure and p53 overexpression in colorectal cancer. <b>1996</b> , 73, 902-8	33
889	Casein kinase 2 inhibits the renaturation of complementary DNA strands mediated by p53 protein. <b>1996</b> , 316 ( Pt 1), 331-5	20
888	Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. <b>1996</b> , 93, 8318-23	326
887	p53 gene alterations and protein accumulation in colorectal cancer. <b>1996</b> , 49, M85-90	7
886	Effects of IFN-beta and 1,25-dihydroxyvitamin D3 on cellular proliferation, induction of 2',5'-oligoadenylate (2-5A) synthetase and changes in immunoreactive pRB/p53 in human prostatic JCA-1 cells. <b>1996</b> , 39, 1085-92	
885	Cancer cell cycles. <i>Science</i> , <b>1996</b> , 274, 1672-7	333 4404
884	Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. <i>Science</i> , <b>1996</b> , 274, 430-2	333 1408
883	Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. <b>1996</b> , 39, 1269-74	14
882	Appendiceal mucocele with concomitant colonic cancer. Report of two cases. <b>1996</b> , 39, 232-6	19
881	Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. <b>1996</b> , 3, 136-43	20
880	Detection of point mutation of p53 gene by silver staining PCR-SSCP in paraffin-embedded malignant fibrous histiocytoma. <b>1996</b> , 8, 192-195	
879	Suppression of tumorigenicity and overexpression of cell adhesion molecules in AK-5 cells transfected with wild-type p53 gene. <b>1996</b> , 21, 445-454	

878	Midgut Carcinoids and Solid Carcinomas of the Intestine: Differences in Endocrine Markers and p53 Mutations. <b>1996</b> , 7, 273-279	12
877	Assignment of the TP53 orthologue to a new linkage group (LG XIV) in fish of the genus Xiphophorus (Teleostei: Poeciliidae). <b>1996</b> , 88, 144-50	10
876	Multi-mutation screening using PCR and ligation--principles and applications. <b>1996</b> , 14, 112-4	1
875	Redox regulation of transcriptional activators. <b>1996</b> , 21, 335-48	562
874	Chromosome changes caused by alterations of p53 expression. <b>1996</b> , 354, 129-38	41
873	A mutation in the p53 tumor suppressor gene of AHH-1 tk+/- human lymphoblastoid cells. <b>1996</b> , 356, 129-34	14
872	p53 in growth control and neoplasia. <b>1996</b> , 1287, 77-102	198
871	In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. <b>1996</b> , 1288, F9-19	5
870	Pterygia and limbal epithelial cells: Relationship and molecular mechanisms. <b>1996</b> , 15, 297-329	10
869	Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. <b>1996</b> , 122, 489-94	31
868	Analysis of the cellular origin of hepatocellular carcinoma by p53 genotype. <b>1996</b> , 122, 763-6	12
867	Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. <b>1996</b> , 122, 541-8	59
866	The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. <b>1996</b> , 122, 360-5	95
865	Proliferative (MIB1, mdm2) Versus Anti-Proliferative (p53) Markers in Head and Neck Cancer. An Immunohistochemical Study. <b>1996</b> , 2, 37-42	5
864	The role of anti-p53-autoantibodies in pancreatic disorders. <b>1996</b> , 19, 171-8	23
863	The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis. <b>1996</b> , 52, 1001-7	61
862	Gene expression in synchronous tumors in different organs: Pancreas and other organs. <b>1996</b> , 3, 167-171	1
861	Prolonged nuclear accumulation of p53 in xeroderma pigmentosum complementation group A cells after ultraviolet irradiation. <b>1996</b> , 288, 249-51	



860	Genomic instability in MycER-activated Rat1A-MycER cells. <b>1996</b> , 4, 365-71	84
859	Apoptosis: molecular regulation of cell death. <b>1996</b> , 236, 1-26	467
858	Alteration of the p53 gene of lung carcinomas with sarcomatous transformation (spindle cell carcinoma): analysis of four cases. <b>1996</b> , 46, 38-45	14
857	Primary adenocarcinoma of the renal pelvis with special reference to histochemical observations. <b>1996</b> , 46, 791-6	6
856	Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. <b>1996</b> , 46, 953-61	30
855	The relationship between the gene mutation of p53 and the protein expression of p53 and Ki-67 in non-Hodgkin's lymphomas. <b>1996</b> , 46, 130-6	1
854	APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. <b>1996</b> , 46, 333-40	75
853	Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status. <b>1996</b> , 46, 417-25	13
852	Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. <b>1996</b> , 46, 486-90	24
851	P53 tumour suppressor gene expression in hyperparathyroidism. <b>1996</b> , 66, 302-4	7
850	Cytologic changes in two cervical carcinoma cell lines after transfection of the wild-type p53 gene. <b>1996</b> , 75, 797-803	5
849	Established cell lines transformed by E2F-1 overexpression contain wild-type p53. <b>1996</b> , 29, 579-88	7
848	Transgene expression in the rhesus cervix mediated by an adenovirus expressing beta-galactosidase. <b>1996</b> , 174, 1094-101	12
847	Apoptosis and gastrointestinal pharmacology. <b>1996</b> , 72, 149-69	60
846	Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. <b>1996</b> , 366, 23-44	118
845	Future approaches to genetic toxicology risk assessment. <b>1996</b> , 365, 191-204	11
844	Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. <b>1996</b> , 111, 323-31; discussion 331-3	95
843	Oncogenes and tumor suppressor genes in photocarcinogenesis. <b>1996</b> , 63, 428-32	16

842	Molecular pathophysiology of acromegaly. <b>1996</b> , 417, 45-8	1
841	Epithelial growth fraction and expression of p53 tumour suppressor gene in oral submucous fibrosis. <b>1996</b> , 41, 91-6	19
840	Vaccine strategies in non-Hodgkin's lymphomas. <b>1996</b> , 9, 799-817	2
839	Teratogen-induced eye defects mediated by p53-dependent apoptosis. <b>1996</b> , 6, 60-9	64
838	Synergistic interactions between XPC and p53 mutations in double-mutant mice: neural tube abnormalities and accelerated UV radiation-induced skin cancer. <b>1996</b> , 6, 1691-4	60
837	Gene replacement strategies for lung cancer. <b>1996</b> , 6, 105-109	5
836	Radiation-mediated gene expression in the pathogenesis of the clinical radiation response. <b>1996</b> , 6, 250-267	27
835	Molecular biology of the cell cycle: Potential for therapeutic applications in radiation oncology. <b>1996</b> , 6, 284-294	19
834	A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. <b>1996</b> , 26, 2635-9	19
833	Lead acetate mutagenicity and mutational spectrum in the hypoxanthine guanine phosphoribosyltransferase gene of Chinese hamster ovary K1 cells. <b>1996</b> , 17, 181-91	17
832	A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. <b>1996</b> , 61, 20-6	36
831	Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer. <b>1996</b> , 62, 253-7	2
830	p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers. <b>1996</b> , 63, 87-90	4
829	p53 tumor suppressor gene: Implications for iatrogenic cancer and cancer therapy. <b>1996</b> , 27, 2-11	3
828	Regulation of cellular proliferation effects on alteration of normal signaling pathways. <b>1996</b> , 27, 20-24	
827	Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. <b>1996</b> , 178, 53-8	35
826	Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. <b>1996</b> , 178, 133-9	22
825	Prognostic influence of p53 expression in gastric cancer. <b>1996</b> , 178, 255-8	23

824	p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. <b>1996</b> , 178, 415-21	39
823	MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. <b>1996</b> , 180, 58-64	21
822	Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. <b>1996</b> , 180, 364-70	40
821	Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. <b>1996</b> , 28, 318-24	40
820	Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. <b>1996</b> , 77, 321-9	64
819	Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. <b>1996</b> , 77, 490-8	176
818	Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer. <b>1996</b> , 77, 1688-93	36
817	Hereditary cancer susceptibility. <b>1996</b> , 78, 553-7	7
816	p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. <b>1996</b> , 78, 1203-10	53
815	Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. <b>1996</b> , 78, 1248-53	68
814	Ionizing radiation and the cell cycle: A review. <b>1996</b> , 4, 147-158	1
813	EMF and current cancer concepts. <b>1996</b> , 17, 339-57	27
812	Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. <b>1996</b> , 78, 2288-2299	17
811	Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. <b>1996</b> , 65, 466-72	25
810	p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. <b>1996</b> , 69, 28-33	75
809	Early detection research program at the NCI. <b>1996</b> , 69, 35-7	24
808	Detection and evaluation of p53 intron 2 polymorphism in lung carcinomas in Hong Kong. <b>1996</b> , 69, 120-4	6
807	Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. <b>1996</b> , 69, 125-30	23

806	Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. <b>1996</b> , 69, 152-8	48
805	Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. <b>1996</b> , 69, 259-64	23
804	Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. <b>1996</b> , 69, 317-23	33
803	Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA. <b>1996</b> , 67, 898-902	32
802	Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. <b>1996</b> , 68, 501-5	39
801	Immunohistochemical detection of p53 in non-malignant and malignant oral lesions associated with snuff dipping in the Sudan and Sweden. <b>1996</b> , 68, 749-53	13
800	A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. <b>1996</b> , 24, 131-9	377
799	Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cells. <b>1996</b> , 25, 21-31	4
798	Risk biomarkers and current strategies for cancer chemoprevention. <b>1996</b> , 63, 1-14	124
797	K-ras mutation in sputum of patients with or without lung cancer. <b>1996</b> , 63, 172-176	13
796	Application of molecular epidemiology to lung cancer chemoprevention. <b>1996</b> , 63, 63-68	6
795	Normal and transforming Ras are differently regulated for posttranslational modifications. <b>1996</b> , 61, 172-81	2
794	ADP-ribosylation of p53 tumor suppressor protein: mutant but not wild-type p53 is modified. <b>1996</b> , 62, 90-101	62
793	Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. <b>1996</b> , 7, 109-13	11
792	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. <b>1996</b> , 15, 48-53	9
791	Microsatellite analysis of childhood brain tumors. <b>1996</b> , 15, 54-63	35
790	Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. <b>1996</b> , 15, 77-88	133
789	Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. <b>1996</b> , 15, 187-90	18

788	Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. <b>1996</b> , 16, 1-14	141
787	Molecular heterogeneity of B-lineage diffuse large cell lymphoma. <b>1996</b> , 16, 21-30	30
786	Detection of numerical chromosome anomalies in interphase cells of ovarian carcinomas using fluorescence in situ hybridization. <b>1996</b> , 16, 120-9	7
785	TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. <b>1996</b> , 16, 170-9	58
784	Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. <b>1996</b> , 17, 37-44	94
783	Correlation of p53 immunoreactivity and sequencing in patients with glioma. <b>1996</b> , 15, 1-4	26
782	A possible role in chemical carcinogenesis for epigenetic, heritable changes in gene expression. <b>1996</b> , 15, 241-50	32
781	Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. <b>2000</b> , 14, 981-993	247
780	The transcriptional program following p53 activation. <b>2000</b> , 65, 475-82	26
779	Coexpression of p21Waf1/Cip1 and p53 in sun-exposed normal epidermis, but not in neoplastic epidermis. <b>1996</b> , 135, 717-720	14
778	EGF effects on p53 in MDA-468 human breast cancer cells: implications for G1 arrest. <b>1997</b> , 30, 81-94	7
777	Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression. <i>Science</i> , <b>1992</b> , 256, 827-830	333 180
776	Gastric Cancer. 481-498	4
775	Introduction to DNA Tumor Viruses: Adenovirus, Simian Virus 40, and Polyomavirus. 51-86	9
774	Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. <b>1992</b> , 66, 6164-70	134
773	Transformation of a continuous rat embryo fibroblast cell line requires three separate domains of simian virus 40 large T antigen. <b>1992</b> , 66, 2780-91	84
772	Inhibition of viral and cellular promoters by human wild-type p53. <b>1992</b> , 66, 4757-62	149
771	Wild-type p53 is not a negative regulator of simian virus 40 DNA replication in infected monkey cells. <b>1993</b> , 67, 886-93	13

770	Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. <b>1993</b> , 67, 3111-7	102
769	Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct roles in cell transformation. <b>1993</b> , 67, 5226-34	29
768	Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. <b>1994</b> , 68, 103-10	37
767	Functional characterization of <i>Xenopus laevis</i> p53: evidence of temperature-sensitive transactivation but not of repression. <b>1994</b> , 68, 7178-87	8
766	Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. <b>1994</b> , 68, 8028-34	83
765	Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. <b>1994</b> , 68, 1309-15	38
764	The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells. <b>1994</b> , 68, 1334-41	60
763	Stabilization of the tumor suppressor p53 during cellular transformation by simian virus 40: influence of viral and cellular factors and biological consequences. <b>1994</b> , 68, 2869-78	34
762	The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. <b>1994</b> , 68, 4302-13	74
761	Cooperation of simian virus 40 large and small T antigens in metabolic stabilization of tumor suppressor p53 during cellular transformation. <b>1995</b> , 69, 6115-21	35
760	A herpesvirus saimiri protein required for interleukin-2 independence is associated with membranes of transformed T cells. <b>1995</b> , 69, 4495-9	20
759	Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. <b>1996</b> , 70, 8653-9	198
758	Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. <b>1996</b> , 70, 8691-700	36
757	Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?. <b>1996</b> , 70, 2095-100	22
756	High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. <b>1996</b> , 70, 4509-16	144
755	Cellular aging is a critical determinant of primary cell resistance to v-src transformation. <b>1997</b> , 71, 237-47	8
754	Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. <b>1997</b> , 71, 2905-12	139
753	Perturbation of the p53 response by human papillomavirus type 16 E7. <b>1997</b> , 71, 3710-8	41

752	Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. <b>1998</b> , 72, 9470-8	257
751	p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. <b>1998</b> , 72, 2033-9	103
750	A mammalian cell line deficient in activity of the DNA repair enzyme 5-hydroxymethyluracil-DNA glycosylase is resistant to the toxic effects of the thymidine analog 5-hydroxymethyl-2'-deoxyuridine. <b>1992</b> , 12, 5536-5540	24
749	Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. <b>1992</b> , 12, 5581-5592	166
748	Human p53 and CDC2Hs genes combine to inhibit the proliferation of <i>Saccharomyces cerevisiae</i> . <b>1992</b> , 12, 1357-1365	44
747	The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. <b>1993</b> , 13, 301-306	115
746	p53-mediated cell death: relationship to cell cycle control. <b>1993</b> , 13, 1415-1423	103
745	Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. <b>1993</b> , 13, 1456-1463	55
744	The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. <b>1993</b> , 13, 3291-3300	111
743	The tumor suppressor p53 regulates its own transcription. <b>1993</b> , 13, 3415-3423	43
742	Analysis of a protein-binding domain of p53. <b>1993</b> , 13, 3811-3820	25
741	Mapping of the p53 and mdm-2 interaction domains. <b>1993</b> , 13, 4107-4114	303
740	Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. <b>1993</b> , 13, 5186-5194	42
739	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. <b>1994</b> , 14, 6764-6772	8
738	Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. <b>1994</b> , 14, 7805-7815	35
737	Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2. <b>1994</b> , 14, 8315-8321	31
736	Physical and functional interaction between wild-type p53 and mdm2 proteins. <b>1994</b> , 14, 1171-1178	40
735	Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. <b>1994</b> , 14, 1929-1938	100

734	Bcl-2 blocks p53-dependent apoptosis. <b>1994</b> , 14, 2556-2563	83
733	Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site. <b>1994</b> , 14, 2651-2663	14
732	A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. <b>1994</b> , 14, 3683-3694	98
731	p53 domains: structure, oligomerization, and transformation. <b>1994</b> , 14, 5182-5191	55
730	Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. <b>1994</b> , 14, 6264-6277	181
729	Molecular pathogenesis of oral squamous carcinoma. <b>2000</b> , 53, 165-72	143
728	Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. <b>2011</b> , 1, 275-300	65
727	Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. <b>2018</b> , 3,	19
726	CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. <b>1998</b> , 101, 120-7	26
725	Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. <b>1992</b> , 90, 653-8	27
724	Cancer risks from germline p53 mutations. <b>1992</b> , 90, 1637-41	61
723	High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. <b>1993</b> , 91, 179-84	466
722	Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. <b>1993</b> , 91, 1753-60	274
721	p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine. <b>1994</b> , 93, 2206-14	51
720	Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. <b>1995</b> , 95, 1606-11	149
719	p53-dependent ceramide response to genotoxic stress. <b>1998</b> , 102, 329-39	132
718	Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. <b>2007</b> , 117, 1019-28	115
717	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. <b>1998</b> , 91, 3995-4019	5



716	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. <b>1998</b> , 91, 4342-4349	4
715	Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy. <b>1998</b> , 92, 802-809	2
714	Allelotype Analysis of Adult T-Cell Leukemia. <b>1998</b> , 92, 2113-2117	1
713	Regulated Genomic Instability and Neoplasia in the Lymphoid Lineage. <b>1999</b> , 94, 3997-4010	3
712	Abundance of cyclin B1 regulates $\gamma$ radiation-induced apoptosis. <b>2000</b> , 95, 2645-2650	4
711	Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. <b>1993</b> , 33, 824-30; discussion 830-1	34
710	Analysis of HPV16 E6 and mutant p53-transfected keratinocytes in reconstituted epidermis suggests that wild-type p53 inhibits cytokeratin 19 expression. <b>1994</b> , 107, 435-441	10
709	The p53/p63/p73 family of transcription factors: overlapping and distinct functions. <b>2000</b> , 113, 1661-1670	373
708	Detection of circulating anti-p53 antibodies in esophageal cancer patients. <b>2000</b> , 67, 110-7	13
707	Tongue Carcinogenic Susceptibility of p53 Deficient Mice to Methyl-n-amylnitrosamine. <b>2002</b> , 15, 209-214	4
706	Susceptibility of Heterozygous and Nullizygous p53 Knockout Mice to Chemical Carcinogens: Tissue Dependence and Role of p53 Gene Mutations. <b>2005</b> , 18, 121-134	2
705	Corp Regulates P53 in <i>Drosophila melanogaster</i> via a Negative Feedback Loop. <b>2015</b> , 11, e1005400	17
704	Cyclin B1/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. <b>2010</b> , 5, e12341	40
703	The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. <b>2011</b> , 6, e24468	30
702	An aqueous extract of <i>Fagonia cretica</i> induces DNA damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression. <b>2012</b> , 7, e40152	60
701	Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53. <b>2012</b> , 7, e46148	11
700	Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. <b>2012</b> , 7, e48992	16
699	Global effect of inauhzin on human p53-responsive transcriptome. <b>2012</b> , 7, e52172	16

698	Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. <b>2013</b> , 8, e56912	23
697	A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect. <b>2014</b> , 9, e87492	2
696	The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. <b>2014</b> , 9, e95724	11
695	Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display. <b>2014</b> , 9, e109163	13
694	The p53R172H mutant does not enhance hepatocellular carcinoma development and progression. <b>2015</b> , 10, e0123816	5
693	Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. <b>2015</b> , 10, e0128807	19
692	Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. <b>2015</b> , 10, e0135101	24
691	A Temperature Sensitive Variant of p53 Drives p53-Dependent MicroRNA Expression without Evidence of Widespread Post-Transcriptional Gene Silencing. <b>2016</b> , 11, e0148529	9
690	MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. <b>2016</b> , 11, e0156422	12
689	Stabilization of HIF-1 $\alpha$ and HIF-2 $\beta$ up-regulation of MYCC and accumulation of stabilized p53 constitute hallmarks of CNS-PNET animal model. <b>2017</b> , 12, e0173106	3
688	Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. <b>2017</b> , 12, e0174326	3
687	SOX14 activates the p53 signaling pathway and induces apoptosis in a cervical carcinoma cell line. <b>2017</b> , 12, e0184686	11
686	Dual expression of immunoreactive estrogen receptor $\beta$ and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. <b>2017</b> , 12, e0188641	10
685	TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression. <b>2006</b> , 11, 343-55	13
684	Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma. <b>2021</b> , 36, 305-315	2
683	Inhibits SW480 Cells Growth by Apoptosis Induction. <b>2018</b> , 8, 675-682	3
682	Detection of mutant p53 protein in workers occupationally exposed to benzidine. <b>2007</b> , 49, 279-84	12
681	Effect of the Interaction Between Selenium and Zinc on DNA Repair in Association With Cancer Prevention. <b>2019</b> , 24, 146-154	32

680	Expression of p53, bcl-2, and Ki-67 proteins in the inflammatory regenerative and dysplastic epithelial lesions of flat colonic mucosa. <b>2006</b> , 6, 39-45	4
679	cep-1/p53-dependent dysplastic pathology of the aging <i>C. elegans</i> gonad. <b>2012</b> , 4, 256-69	29
678	Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. <b>2019</b> , 11, 2512-2540	57
677	microRNAs: short non-coding bullets of gain of function mutant p53 proteins. <b>2014</b> , 1, 427-33	17
676	TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. <b>2016</b> , 7, 46203-46218	15
675	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <b>2016</b> , 7, 62676-62686	6
674	Targeting Zfp148 activates p53 and reduces tumor initiation in the gut. <b>2016</b> , 7, 56183-56192	6
673	Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism. <b>2016</b> , 7, 71378-71389	11
672	The p53 status can influence the role of Sam68 in tumorigenesis. <b>2016</b> , 7, 71651-71659	5
671	Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. <b>2016</b> , 7, 71937-71950	9
670	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <b>2016</b> , 7, 76362-76373	18
669	TP53 mutations, expression and interaction networks in human cancers. <b>2017</b> , 8, 624-643	63
668	Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated and MDM2 up-regulation. <b>2017</b> , 8, 82123-82143	21
667	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. <b>2010</b> , 1, 639-650	60
666	Usp7 protects genomic stability by regulating Bub3. <b>2014</b> , 5, 3728-42	15
665	Melatonin as a potential inhibitory agent in head and neck cancer. <b>2017</b> , 8, 90545-90556	20
664	Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction. <b>2010</b> , 1, 685-690	35
663	Testicular cancer from diagnosis to epigenetic factors. <b>2017</b> , 8, 104654-104663	36

662	Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis. <b>2017</b> , 8, 102361-102370	14
661	The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. <b>2017</b> , 8, 112245-112257	1
660	Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. <b>2018</b> , 9, 1114-1129	16
659	Potential therapeutic targets of gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. <b>2018</b> , 9, 16234-16247	15
658	Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. <b>2011</b> , 2, 378-92	44
657	Elevated telomere dysfunction in cells containing the African-centric Pro47Ser cancer-risk variant of TP53. <b>2019</b> , 10, 3581-3591	2
656	EBNA3C regulates p53 through induction of Aurora kinase B. <b>2015</b> , 6, 5788-803	25
655	DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. <b>2011</b> , 2, 1094-108	39
654	Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target. <b>2015</b> , 6, 22706-23	20
653	p53 and rapamycin are additive. <b>2015</b> , 6, 15802-13	24
652	The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. <b>2015</b> , 6, 19228-45	21
651	p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3. <b>2015</b> , 6, 15842-56	22
650	Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing. <b>2015</b> , 6, 44660-74	38
649	ER $\alpha$ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. <b>2016</b> , 7, 13599-611	32
648	Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. <b>2016</b> , 7, 23933-46	33
647	Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway. <b>2016</b> , 7, 27350-62	13
646	Homeobox protein VentX induces p53-independent apoptosis in cancer cells. <b>2016</b> , 7, 39719-39729	8
645	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. <b>2013</b> , 4, 705-14	87

644	Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma. <b>2016</b> , 7, 45225-45236	13
643	Renewable Standard Reference Material for the Detection of TP53 Mutations. <b>2003</b> , 7, 85-97	16
642	Use of TP53 reference materials to validate mutations in clinical tissue specimens by single-strand conformational polymorphism analysis. <b>2004</b> , 8, 123	1
641	Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population. <b>2018</b> , 19, 395-410	3
640	Targeting tumor suppressor networks for cancer therapeutics. <b>2014</b> , 15, 2-16	56
639	Synthesis and Reactivity of 6,8-Dibromo-2-ethyl-4H-benzo[d][1,3]oxazin-4-one Towards Nucleophiles and Electrophiles and Their Anticancer Activity. <b>2019</b> , 19, 538-545	3
638	Predictive Role of p53 Protein as a Single Marker or Associated to Ki67 Antigen in Oral Carcinogenesis. <b>2008</b> , 2, 24-9	7
637	Predictive Role of p53 Protein as a Single Marker or Associated with ki67 Antigen in Oral Leukoplakia: A Retrospective Longitudinal Study. <b>2015</b> , 9, 41-5	20
636	DNA damage formation and p53 accumulation in mammalian cells exposed to the space environment. <b>1999</b> , 13, 82-7	8
635	[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarian carcinomas]. <b>2006</b> , 63, 813-8	1
634	p53 immunocytochemistry and TP53 gene mutations in patients with chronic hepatitis C virus (HCV) infection. <b>2009</b> , 47, 35-42	8
633	p53 expression in laryngeal carcinoma. <b>1993</b> , 25, 394-7	7
632	Loss of heterozygosity at 1p, 7q, 17p, and 22q in meningiomas. <b>2010</b> , 48, 14-9	6
631	Targeted Gene Delivery Therapies for Cervical Cancer. <b>2020</b> , 12,	14
630	Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. <b>2009</b> , 15, 1381-7	20
629	Potential role of p53 mutation in chemical hepatocarcinogenesis of rats. <b>2004</b> , 10, 46-52	7
628	Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. <b>2004</b> , 10, 3634-8	83
627	Mutations of p53 gene exons 4-8 in human esophageal cancer. <b>2005</b> , 11, 2998-3001	7

626	Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. <b>2005</b> , 11, 3834-41	59
625	Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. <b>2007</b> , 13, 3714-20	82
624	Specific intronic p53 mutation in esophageal squamous cell carcinoma in Southern Thailand. <b>2010</b> , 16, 5359-66	3
623	Alterations of tumor-related genes do not exactly match the histopathological grade in gastric adenocarcinomas. <b>2010</b> , 16, 1129-37	6
622	Clonality analysis of neuroendocrine cells in gastric adenocarcinoma. <b>2013</b> , 19, 5340-6	8
621	Apoptotic pathway induced by diallyl trisulfide in pancreatic cancer cells. <b>2014</b> , 20, 193-203	36
620	Strategies for early detection of resectable pancreatic cancer. <b>2014</b> , 20, 11230-40	32
619	Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. <b>2016</b> , 22, 7342-52	13
618	and mutations predict overall survival of stage II/III colorectal cancer patients. <b>2018</b> , 24, 631-640	10
617	Overexpression of P53 and its risk factors in esophageal cancer in urban areas of Xi'an. <b>1998</b> , 4, 57-60	18
616	Codon 249 mutations of p53 gene in development of hepatocellular carcinoma. <b>1998</b> , 4, 125-127	21
615	Molecular biology of Barrett's esophagus and esophageal cancer:role of p53. <b>1998</b> , 4, 277-279	9
614	Sequencing of p53 mutation in established human hepatocellular carcinoma cell line of HHC4 and HHC15 in nude mice. <b>1998</b> , 4, 506-510	8
613	Codon 249 mutations of p53 gene in non-neoplastic liver tissues. <b>1999</b> , 5, 324-326	7
612	Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks. <b>1999</b> , 5, 470-476	22
611	Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma?. <b>2003</b> , 9, 1202-7	31
610	Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review). <b>2018</b> , 18, 5307-5316	11
609	Bergapten induces G1 arrest of non-small cell lung cancer cells, associated with the p53-mediated cascade. <b>2019</b> , 19, 1972-1978	7

608	p53 mutation in patients with ulcerative colitis in rectal biopsy. <b>1998</b> , 13, 110-6	6
607	Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients. <b>2007</b> , 10, 3350-5	6
606	Reduced P53 Staining in Actinic Keratosis is Associated with Squamous Cell Carcinoma: A Preliminary Study. <b>2013</b> , 58, 325	8
605	Molecular concept in human oral cancer. <b>2015</b> , 6, 9-15	19
604	C-deletion in exon 4 codon 63 of p53 gene as a molecular marker for oral squamous cell carcinoma: A preliminary study. <b>2015</b> , 6, S227-34	5
603	The influence of sleep deprivation on expression of apoptosis regulatory proteins p53, bcl-2 and bax following rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. <b>2013</b> , 10, 247-53	4
602	Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients. <b>2016</b> , 5, 33-6	2
601	Medicinal Plants, Effective Plant Compounds (Compositions) and their Effects on Stomach Cancer. <b>2017</b> , 8, 96	5
600	Yield of p53 expression in esophageal squamous cell cancer and its relationship with survival. <b>2017</b> , 23, 281-286	3
599	Expression of c-kit and p53 in non-small cell lung cancers. <b>2004</b> , 36, 167-72	5
598	p53 prevents immature escaping from cell cycle G2 checkpoint arrest through inhibiting cdk2-dependent NF-Y phosphorylation. <b>2006</b> , 38, 224-8	6
597	Mutations of TP53 Gene and Oxidative Stress in Alzheimer's Disease Patients. <b>2014</b> , 03, 24-32	7
596	Characterization and Prognostic Value of Mutations in Exons 5 and 6 of the p53 Gene in Patients with Colorectal Cancers in Central Iran. <b>2013</b> , 7, 295-302	4
595	Role of copper transporters in platinum resistance. <b>2016</b> , 7, 106-13	65
594	Association of oxidative stress with mortality: the Beaver Dam Eye Study. <b>2012</b> , 1, 161-167	4
593	Molecular pathology and clinicopathologic features of penile tumors: with special reference to analyses of p21 and p53 expression and unusual histologic features. <b>1999</b> , 123, 895-904	25
592	p53, ErbB2, and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuys system. <b>2000</b> , 124, 234-9	8
591	Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium. <b>2001</b> , 125, 872-9	24

590	Male versus female breast cancers. A population-based comparative immunohistochemical analysis. <b>2003</b> , 127, 36-41	106
589	Distinguishing pseudoepitheliomatous hyperplasia from squamous cell carcinoma in mucosal biopsy specimens from the head and neck. <b>2005</b> , 129, 1032-6	51
588	Genetic instability of mouse embryonic germinative G1 cell line and dysfunction of the mitotic checkpoint and p53. <b>2007</b> , 23, 338-346	2
587	Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. <b>2012</b> , 13, 5155-9	33
586	Absence of p53 gene mutations in exons 5 - 7 among breast cancer patients of Bengalee Hindu caste females, West Bengal, India. <b>2012</b> , 13, 4477-9	2
585	Oleuropein induces apoptosis via the p53 pathway in breast cancer cells. <b>2014</b> , 14, 6739-42	63
584	Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. <b>2014</b> , 15, 3065-70	9
583	Prognostic significance of p53 in gastric cancer: a meta- analysis. <b>2015</b> , 16, 327-32	34
582	How elephants beat cancer. <b>2016</b> , 5,	10
581	The evolutionary plasticity of chromosome metabolism allows adaptation to constitutive DNA replication stress. <b>2020</b> , 9,	16
580	Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser. <b>2020</b> , 9,	5
579	Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for Li-Fraumeni syndrome. <b>2021</b> , 20, 18	0
578	Construction of a New Tumor Immunity-Related Signature to Assess and Classify the Prognostic Risk of Colorectal Cancer. <b>2021</b> , 14, 6661-6676	1
577	p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. <b>2021</b> , 26,	2
576	A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications. <b>2021</b> ,	0
575	A Structural Model for the P53 Complex with DNA Response Elements: Implications for P53 Function and Future Research Directions. <b>2000</b> , 257-272	
574	Pharmacological Gene Therapy for Experimental Brain Tumors. <b>2000</b> , 303-314	
573	Use of p53 as Cancer Cell Target for Gene Therapy. <b>2000</b> , 235-255	



- 572 Occupational Skin Cancer and Tumors. **2000**, 248-253 3
- 571 Andere Therapien. **2000**, 595-615
- 570 NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. **2000**, 630 1
- 569 OUTCOME PREDICTION WITH p53 IMMUNOSTAINING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER. **2000**, 1756-1760
- 568 Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. **2000**, 164, 814-9 9
- 567 Susceptibility of Heterozygous p53 Deficient CBA Mice to Induction of Liver Proliferative Lesions by Phenobarbital after Dimethylnitrosamine Initiation.. **2001**, 14, 273-278 1
- 566 Adrenocortical Tumors and Oncogenes. **2001**, 219-230
- 565 p53 Expression in non-small cell and small cell lung carcinomas: relationship with proliferating cell nuclear antigen and cigarette smoking. **2001**, 21, 84-7
- 564 Genetics of Prolactinomas. **2001**, 119-137
- 563 p53 Mutation Load. **2001**, 333-346
- 562 Pulmonary Malignancies: Pathophysiology and Treatment. **2001**, 406-432
- 561 IDENTIFICATION OF EFFECTIVE RETINOIDS FOR INHIBITING GROWTH AND INDUCING APOPTOSIS IN BLADDER CANCER CELLS. **2001**, 986-992
- 560 VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS. **2001**, 304-310 1
- 559 Role of Oxidative Stress in Chemical Carcinogenesis. **2001**,
- 558 Inactivation of Negative Growth Regulators During Neoplastic Transformation. **2002**, 81-111
- 557 Molecular Genetics of Gastrointestinal Tract Cancers. **2002**, 177-192
- 556 Molekulare Pathologie b̄artiger pulmonaler und pleuraler Tumoren. **2002**, 27-86
- 555 Pankreaskarzinom. **2002**, 187-206

- 554 Gene Therapy Strategies for Colorectal Cancer. **2002**, 811-835
- 553 Oncolytic Viruses. **2002**, 1-30
- 552 Superficial Esophageal Carcinomas Associated with Multiple Lesions that Do Not Stain with Iodine. **2002**, 126-131
- 551 Validation of exposure and risk biomarkers. **2002**,
- 550 Cellular Senescence. **2003**,
- 549 Mouse models in the recognition of tumor antigens. **2003**, 3-19
- 548 Prediction of lymph node metastasis based on p53 and nm23-H1 expression in muscle invasive grade III transitional cell carcinoma of bladder. **2003**, 539, 67-85
- 547 Genetic Changes and Their Prognostic Significance in Prostate Cancer. **2003**, 101-112
- 546 TP53 in Carcinogenesis and Cancer Prevention. **2003**, 57-81
- 545 Use of Transgenic Animals in Regulatory Carcinogenicity Evaluations. **2003**,
- 544 Detection of p53 Mutation in Colorectal Cancer Using PCR-SSCP and DHPLC. **2003**, 47, 460-465
- 543 Potential Function of the Werner Syndrome Homologue in the African Clawed Frog and the Mouse. **2004**, 107-122
- 542 Blockierung der spontanen Tumorgenese in p53-defizienten Mäusen nach wiederholter oraler Applikation von attenuierten Salmonella typhimurium-Bakterien. **2004**, 143-145
- 541 Epidemiology, Genetics, and Molecular Biology of Gestational Trophoblastic Disease. **2004**, 544-554
- 540 The p53 Transcription Factor as Therapeutic Target in Cancer. **2004**, 209-258
- 539 Genetische Grundlagen der Kanzerogenese. **2004**, 75-145 1
- 538 Immunophenotypic Differential Diagnosis and Cell Cycle Analysis. **2004**, 145-161
- 537 Inducible Nitric Oxide Synthase as a Target for Chemoprevention. **2004**, 133-151 1

536 Zervixkarzinom. **2004**, 1113-1151

535 Tumorimmunologie. **2004**, 355-380

534 Analysis of p53 Somatic Mutation in Head and Neck Cancer Using Denaturing High Performance Liquid Chromatography(DHPLC). **2004**, 48, 33-38

533 Smokeless Tobacco, Oxidative Stress, and Oral Cancer. **2004**,

532 Testing for association in genetic studies. **2005**, 49-52

531 Molecular Mechanisms of Carcinogenesis. **2005**,

530 Molecular Pathogenesis of Thyroid Cancer. **2006**, 15-32

529 Osteosarcoma: Biologic Markers in Its Treatment. **2006**, 49, 1082

528 Analysis of distribution of mobile genetic elements within the human TP53 gene and its 5'-flanking region. **2006**, 22, 75-81

527 The anti-tumor mechanisms of p53 through the regulation of expression and glycosylation of insulin-like growth factor binding protein-3. **2006**, 49, 431

526 Specificity of Glutathione S-Transferases in the Glutathione Conjugation of Carcinogenic Diol Epoxides. **2006**, 103-128

525 Exposure to Radiation from the Sun. **2007**, 351-371

524 Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. **2007**, 183-207

523 Immunology and Molecular Oncology in Gynecologic Cancer. **2007**, 731-741

522 TP53 Mutation and Li-Fraumeni Syndrome. **2007**, 251-261

1

521 Molecular Biology of Liver Carcinogenesis and Hepatitis. **2007**, 153-163

520 Expressão do p53 no carcinoma epidermide do lbio. **2007**, 34, 92-97

519 Molecular Genetics of Lung and Pleural Neoplasms. **2008**, 47-157

1

- 518 Roles of Mutation and Epimutation in the Development of Lung Disease. **2008**, 53-61
- 517 Carcinoma of Unknown Primary. **2008**, 2057-2074
- 516 MOLECULAR BIOLOGY OF COLORECTAL CANCER. **2008**, 867-896
- 515 Malignancy. **2008**, 832-848
- 514 Other Syndromes. **2008**, 195-218
- 513 Color Plates. **2008**, 107-111
- 512 p53 Tumor Suppressor Opens Gateways for Cancer Therapy. **2008**,
- 511 Transformation by Polyomaviruses. **2009**, 25-52 1
- 510 The Future of Molecular Neuro-Oncology. **2009**, 3201-3228
- 509 Expression of pro-apoptotic signalling molecules mRNA in lung cancer. **2009**, 22, 129-134
- 508 TP53 Mutation and Li-Fraumeni Syndrome. **2009**, 247-257
- 507 Targeting HAUSP: Killing Two Birds with One Stone. **2009**, 31-43
- 506 TP53 Mutation and Li-Fraumeni Syndrome. **2009**, 85-96
- 505 Detection of Extravesical Disease: A Lack of Bladder Cancer Markers. **2009**, 55-65
- 504 Tumors of the Pituitary Gland. **2009**, 27-39 0
- 503 Primary Liver Cancer: Chemical Carcinogenesis. **2009**, 55-107
- 502 Replicative Senescence as an Intrinsic Tumor-Suppressor Mechanism. **2010**, 201-217
- 501 Endocrine Lung. **2010**, 429-445

500 Carcinogenesis and Carcinogens that are also Genotoxic.

499 Pathogenesis of Adrenocortical Tumors. **2010**, 41-52

498 Clinical Significance of Measuring Serum p53 Antibodies in Colorectal Cancer Patients. **2010**, 43, 996-1001 1

497 Tumorbiologische und molekulargenetische Aspekte. **2010**, 38-51

496 Epidemiologie, Biologie und Pathogenese. **2010**, 14-37

495 Cyclin D1, p16, and p21 gene product expression as a predictor of outcomes in tongue cancer. **2010**, 56, 401-408

494 Bee Venom Inhibits Prostate Cancer Growth in LNCaP Xenografts via Apoptosis. **2010**, 13, 15-35 1

493 Translesion Synthesis and Mutagenic Pathways in Escherichia coli Cells. 353-380

492 The Biological Impact of Radiation Exposure on Breast Cancer Development. **2011**, 185-203

491 Adrenocortical Carcinoma. **2011**, 195-220

490 Diffuse Low-Grade Astrocytomas: P53-Mediated Inhibition of Angiogenesis. **2012**, 135-142

489 DNA Damage Checkpoint Signaling Pathways in Human Cancer. **2012**, 23-37

488 Advances in Liposome-Based Targeted Gene Therapy of Cancer. **2012**, 113-133 2

487 Evaluation of Anti-p53 Antibodies as a Molecular Marker for Breast Carcinoma. **2012**, 58, 173-177

486 Malignant Transformation of Melanocytic Nevi. **2012**, 137-144

485 A Clinical Study of Serum p53 Antibodies in Patients with Surgically Treated Colorectal Cancer. **2012**, 65, 249-252

484 Preimplantation Diagnosis for Single-Gene Disorders. **2012**, 45-170

483 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16

- 482 Webbasierte Sequenzanalyse und Datenbankabfragen. **2012**, 557-587
- 481 Larynx and Hypopharynx Cancer. **2012**, 639-663 2
- 480 p53 Immunotherapy of Cancer. **2013**, 275-287
- 479 Inferring the Association Network from p53 Sequence Alignment Using Granular Evaluations. **2013**, 220-230
- 478 Adrenal Tumors. **2013**, 143-170
- 477 Molecular Oncology in Gynecologic Cancer. **2013**, 623-633 1
- 476 Apoptosis and Autophagy. **2013**, 57-77 1
- 475 CHAPTER 4. Recent Progress in the Electrochemical Detection of Disease-Related Diagnostic Biomarkers. **2013**, 89-128
- 474 Forward Mutation Tests. **2013**, 96-98
- 473 Fluorescence Study Gives a Hint to Understand How the p53 DNA Binding Domain Recognizes Its Specific Binding Site on DNA Fragments. **2013**, 34, 1300-1302
- 472 Allgemeine Grundsätze der toxikologischen Risikoabschätzung und der präventiven Gefährdungsminimierung bei Lebensmitteln. 1-74
- 471 Breast Cancer Gene Therapy. **2014**, 519-534
- 470 DNA Damage Response Pathways and Cancer. **2014**, 142-153.e3 1
- 469 Network Biomarker Construction for Molecular Investigation and Diagnosis of Lung Cancer via Microarray Data. **2014**, 3-29
- 468 Prediction of recurrence for non-small cell lung cancer by combined analysis of molecular markers and 18F 2-fluoro-2-deoxy-D-glucose positron emission tomography. **2014**, 60, 47-56
- 467 p53 in Head and Neck Cancer. **2014**, 227-258
- 466 Carcinoma of Unknown Primary. **2014**, 1792-1803.e2
- 465 Translational Cancer Research. 1-20

- 464 Effects of Ionizing Radiation on Human Papillomavirus Immortalized Human Bronchial Epithelial Cells. **1991**, 113-117
- 463 Cancer. **1992**, 121-156
- 462 Predictive Value for Cancer Risk Assessment of Cell- and Tissue- Specific Formation of Carcinogen-DNA Adducts. **1992**, 31-42
- 461 The Secrets of Crypticity and its Relationship to Medical Problems: Autoimmune Disease, Transplantation and Cancer. **1992**, 411-424
- 460 Gene Localization By Linkage Analysis. **1992**, 25, 907-922 2
- 459 Biological Phenotypes of Tumor-Derived Human p53 Mutants. **1993**, 231-236
- 458 p53: Oncogene, Tumor Suppressor, or Both?. **1993**, 27-39 2
- 457 Practical Applications of Biomarkers in the Study of Environmental Liver Disease. **1993**, 517-546
- 456 Concepts and strategies for human gene therapy. **1993**, 165-179
- 455 ?????????p53. **1993**, 60, 216-216
- 454 Transcriptional Control of Gene Expression in Hepatic Cells. **1993**, 162-242 2
- 453 Bedeutung der medizinischen Molekularbiologie in der Diagnose, Therapie und Prognose von Tumorerkrankungen unter besonderer Berücksichtigung der Schilddrüsentumoren. **1993**, 21-26
- 452 Free Radicals and Active States of Oxygen in Human Cancer Due to Environmental Pollutants: Public Health Optimism and Scientific Skepticism. **1993**, 226-240
- 451 Tumour suppressor genes and molecular chaperones. **1993**, 113-117
- 450 Ataxia-Telangiectasia: Defective in a P53-Dependent Signal Transduction Pathway. **1993**, 163-173
- 449 Mutationen des p53 Tumor-suppressor-Gens beim Mammakarzinom und Suppression des neoplastischen Phänotyps durch Wildtyp p53. **1993**, 834-836
- 448 Cancer Forecasting: Cohort Models of Disease Progression and Mortality. **1993**, 109-136 1
- 447 PATHOGENESIS AND PATHOLOGY. **1993**, 14, 17-30 19

- 446 Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. **1993**, 13, 1378-1384 14
- 445 The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. **1993**, 13, 6849-6857 19
- 444 Molecular Controls of Cell Cycle Progression Following DNA Damage: Roles of P53 and Ataxia-Telangiectasia Gene Products. **1994**, 117-135
- 443 Molecular Biology and Bladder Cancer. **1994**, 19-45
- 442 Transgenic Animals and the Study of Gonadal Function. **1994**, 253-271
- 441 Oxidative Damage and Carcinogenesis. **1994**, 17-29
- 440 Genetic Alterations. **1994**, 226-237
- 439 Importance of genetic alterations in tumour development. **1994**, 16, 253-60 5
- 438 The Two Amino Terminal Transforming Functions of the SV40 Large T-Antigen are Required to Overcome P53 Mediated Growth Arrest. **1994**, 311-317
- 437 Molekularbiologische Charakterisierung von Tumoren durch frñzeitige Identifizierung von Mutationen in Onkogenen und Tumorsuppressorgenen. **1994**, 339-343
- 436 The Antibody Response Against P53 in Cancer Patients. **1994**, 1-7
- 435 Molecular Biology. **1994**, 1173-1198
- 434 Molecular Biology. **1994**, 257-264
- 433 Molecular Biology of Brain Tumors. **1994**, 5, 127-133
- 432 Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines. **1994**, 14, 7604-7610 10
- 431 RISK FACTORS. **1994**, 21, 561-586 2
- 430 Die Bedeutung von P53 Mutationen fñ das maligne Potential des Barrett-Epithels und die Pathogenese des Barrett-Carcinoms. **1995**, 289-292
- 429 Involvement of Nitric Oxide(NO) to disease state.. **1995**, 57, 1127-1131



428 Transfer and Expression of Antioncogenes and Paraneoplastic Genes in Normal and Neoplastic Cells in Vitro and in Vivo. **1995**, 275-VIII

427 The Role of p53 in Cancer. **1995**, 1-11

426 The genetics of prostate cancer. **1995**, 67-83

425 Cellular nitrogen oxide production: Its role in endogeneous mutation and carcinogenesis. **1995**, 45-52 1

424 Potential Clinical Significance of the p53 Tumor Suppressor Gene in Cancer Patients. **1995**, 113-125

423 Genetic Alterations in Colon Cancer. **1995**, 139-189

422 Mechanisms of Mutagenicity and Tumour Formation. **1995**, 261-302

421 Target of breeding and canceration of keratinocytes.Cyclin and cdk complex.. **1995**, 57, 687-695 1

420 Biophysical and Biochemical Properties of the p53 Protein. **1995**, 55-72

419 Lymphocyte death, p53, and the problem of the "undead" cell. **1995**, 200, 123-35 2

418 The role of the p53 protein in the apoptotic response. **1995**, 41-44 1

417 Cell Death by Apoptosis: Morphological, Genetic and Biochemical Features and Toxicological Implications. **1995**, 241-255

416 Regulation and Modulation of the Function of p53. **1995**, 73-112

415 Towards understanding the molecular basis of thyroid cancer. **1995**, 15, 252-75

414 Molecular medicine makes its way to the bedside. **1995**, 162, 567-568

413 A Model for the Molecular Pathogenesis of Astrocytic Gliomas. **1996**, 173-186

412 p16 Family Inhibitors of Cyclin-Dependent Kinases. **1996**, 57-82

411 Genetics of Breast Cancer. **1996**, 197-224

410 DNA Topoisomerases as Drug Targets and Cell Cycle Checkpoint Effector Molecules. **1996**, 143-153

409 Pathology of Prostatic Carcinoma. **1996**, 27-50

408 Mechanisms of activation and inactivation of dominant oncogenes and tumour suppressor genes. **1996**, 16-26

407 Molecular Mechanism of Apoptosis and Its Significance in Pathogenesis and Therapeutic Strategy in Neurosurgical Disease. **1996**, 5, 103-110

406 Homeostatic Mechanisms Governing the Go Phase as Defined by the gas Genes. **1996**, 201-214

405 Regulation of p53-Dependent Apoptosis in Human Neuroblastoma Cells by Isoquinolines. **1997**, 71-77

404 Clinical Applicability of Molecular Procedures in the Diagnosis of Pancreatic Cancer. **1997**, 411-423

403 Neoplastic Progression in Barrett's Esophagus. **1997**, 195-214

402 Tiermodelle in der biomedizinischen Forschung. **1997**, 338-358

401 Molecular Genetics of Hepatocellular Carcinoma. **1997**, 219-243

400 Medical Background: Human DNA Damage Recognition and Processing Disorders. **1997**, 1-30

399 Nuclear Reactivity Relationship Among p53 and Some of its Downstream Proteins is Predictive of p53 Functional State. **1997**, 715-722

398 The Role of Structure in Complexes Between the p53 DNA Binding Domain and DNA Response Elements. **1997**, 173-207

397 Consequences of Mutations that Alter Telomeres in the Yeast *K. lactis*. **1997**, 111-131

3

396 References. **1997**, 215-326

395 p53-Dependent Signaling in Response to DNA Damage or Arrest of DNA Synthesis and its Role in Cell Cycle Control. **1997**, 69-81

394 The Genetics of Actinic Keratoses. **1997**, 700-708

393 The Use of HLA Transgenic Mice in Identifying and Targeting Human Tumor Cell Antigens. **1997**, 41-48

392 p53-Alterations in Thymic Epithelial Tumors. **1997**, 35-40

391 Patenting transcription factors for drug discovery and therapeutics. **1997**, 7, 225-231

390 Preliminary study on the loss of heterozygosity at 17p13 in gastric and colorectal cancers. **1997**, 3, 160-2 2

389 Regulation of RNA Polymerase III Transcription. **1998**, 213-251

388 Adaptive mutagenesis: a process that generates almost exclusively beneficial mutations. **1998**, 109-125

387 Proteins that Modulate the Rate of RNA Polymerase III Transcription. **1998**, 191-212 1

386 The Role for ink4a in Melanoma Pathogenesis. **1998**, 1-14

385 The use of genetically engineered cells in drug discovery. **1998**, 20, 249-66

384 The molecular genetics of colonic cancer. **1998**, 98, 351-82 1

383 Poly(ADP-Ribose) Polymerase in Response to DNA Damage. **1998**, 487-515 1

382 Recent Developments in the Molecular Biology of Human Brain Tumors. **1998**, 191-205

381 The role of p53 in apoptosis. **1998**, 5-35 0

380 Phosphorylation of the p53 tumour suppressor protein by stress- and DNA damage-activated protein kinases. **1998**, 109-115

379 Tumor Suppressor Gene Therapy for Brain Tumors. **1998**, 205-229

378 DNA methylation and carcinogenesis in digestive neoplasms. **1998**, 4, 174-177 5

377 Screening for Pancreatic Cancer Using Techniques to Detect Altered Gene Products. **1998**, 113-136

376 Transcriptional Responses to Damage Created by Ionizing Radiation. **1998**, 223-262

375 Mechanismen der Entstehung fremdstoffbedingter Krebsformen. **1998**, 27-49

- 374 Tumorantigene und ihre Nutzung für eine Therapie mit Antikörpern. **1998**, 160-185
- 373 Krebsprävention durch Vakzination. **1998**, 201-217
- 372 Prognostic Factors in Bladder Cancer: Emphasis on Immunohistochemical Analysis. **1998**, 23-35
- 371 Klinische Bedeutung von p53 Tumor-Suppressor-Gen Mutationen beim Adenocarcinom im Barrett-Ösophagus. **1998**, 495-499
- 370 Transgenic Animal Models. **1998**, 209-221
- 369 Immune response to p53 and HPV-16 E6 proteins in patients with cervical cancer. **1998**, 8, 328-335
- 368 Molecular and cellular pathology of hepatocellular carcinoma. **1998**, 13, S299-S303 2
- 367 Biologically Based Models of Carcinogenesis. **1999**, 205-241 1
- 366 Onkogenese und Neoplasien. **1999**, 71-78
- 365 Biological Functions of the BRCA1 and BRCA2 Proteins. **1999**, 225-246 1
- 364 Cellular proliferation and cell-cell cycle regulatory proteins as prognostic markers for transitional cell carcinoma of the bladder. **1999**, 462, 425-35 1
- 363 Use of Biochemical and Molecular Biomarkers for Cancer Risk Assessment in Humans. **1999**, 81-182 2
- 362 Cell Cycle and Apoptosis. **1999**, 131-169
- 361 Carcinogenesis and Pathological Classification of Hepatocellular Carcinoma. **1999**, 21-38
- 360 Expression von E-Cadherin und p53, sowie Ki-67 Zellproliferation in der Metaplasie-Dysplasie-Karzinom Sequenz des Barrett Ösophagus. **1999**, 93-98
- 359 Protein kinase CK2-dependent regulation of p53 function: Evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. **1999**, 187-199
- 358 Mutationen des Tumorsuppressor Gens p53 spielen in der Genese maligner neuroendokriner Tumoren keine Rolle. **1999**, 201-204
- 357 Progress in the Molecular Medicine of Cancer. 129-152

356 Inflammation. **2014**, 29-114

355 *Helicobacter pylori* infection and a P53 codon 72 single nucleotide polymorphism: a reason for an unexplained Asian enigma. **2014**, 15, 9171-6

4

354 Bladder Cancer.

353 Osteosarcoma.

352 Copy Number Changes in Carcinomas: Applications. **2015**, 95-104

351 Triple-Negative Breast Cancer: Subtypes with Clinical Implications. **2015**, 157-175

350 Apoptosis. **2015**, 29-46

349 Molekulare Grundlagen der malignen Transformation. **2015**, 1-16

348 Immunohistochemistry Study of and Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy. **2016**, 9, e4115

1

347 The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers. **2016**, 30, 441-451

6

346 An Overview of Cancer Genes. **2017**, 121-142

345 Molecular Pathology of Lung Tumors. **2017**, 611-638

344 A Surgical Case of Metachronous Double Cancer of the Gallbladder and the Common Bile Duct. **2017**, 50, 812-822

343 Biomarkers for Predicting Neoplastic Progression in Barrett's Esophagus. **2017**, 251-269

342 HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA. **2017**, 1, 52-57

341 Genome-scale mutational signatures of aflatoxin in cells, mice and human tumors.

340 SQUID: Transcriptomic Structural Variation Detection from RNA-seq.

339 Simulation Analysis of the Homologous Recombination Repair Distribution over the Cell Cycle. **2018**, 218-229

- 338 Metastatic Prostate Cancer. **2018**, 279-295 0
- 337 Human Papillomavirus and Head and Neck Cancer. **2018**, 349-364
- 336 CURE 2000. **2018**, 123-139
- 335 The Impact of Endothelial Transcription Factors in Sprouting Angiogenesis. **2018**, 1-18
- 334 Case Studies. **2018**, 1069, 135-209
- 333 Review on the Research of Cell-Penetrating Peptides. **2018**, 05, 29-37
- 332 Empirical single-cell tracking and cell-fate simulation reveal dual roles of p53 in tumor suppression. 2
- 331 TP53 mutations promote immunogenic activity in breast cancer.
- 330 Prediction of Deleterious Single Nucleotide Polymorphisms in Human p53 Gene. 0
- 329 Activation of Multiple Signalling Pathways by P152Lp53 Mutant Reveals New Gain-of-function Implicating Tumorigenesis.
- 328 The research progress of p53 tumour suppressor activity controlled by Numb in triple-negative breast cancer. 0
- 327 CLL with Del (17p)/TP53 Mutation. **2019**, 97-106
- 326 The Impact of Endothelial Transcription Factors in Sprouting Angiogenesis. **2019**, 73-90 0
- 325 Specifics 1: Head and Neck Cancer and Esophageal Cancer. **2019**, 63-77
- 324 Apoptosis. **2019**, 33-53
- 323 Recent Advances in the au NP Treatment Strategies of Lung Cancers. **2019**, 701-729
- 322 HSP90-Based Heterocomplex as Essential Regulator for Cancer Disease. **2019**, 19-45
- 321 MicroRNA-26a targets the mdm2/p53 loop directly in response to liver regeneration. **2019**, 44, 1505-1514 1

320	In Vitro Analysis of Protein:Protein Interactions in the Human Cancer-Pertinent rp.eL42-p53-Mdm2 Pathway. <b>2019</b> , 13, 64-80	1
319	Probability of Change in Life: amino acid changes in single nucleotide substitutions.	
318	The evolutionary plasticity of chromosome metabolism allows adaptation to DNA replication stress.	0
317	PTPN2 deletion in T cells promotes anti-tumour immunity and CAR T cell efficacy in solid tumours.	0
316	Astragaloside accelerates fracture healing via modulating miR-122/p53 and miR-221/RUNX2 signaling pathways. <b>2020</b> , 16, 119	
315	Introduction to Genes, Oncogenes, and Anti-oncogenes. <b>2020</b> , 1-40	
314	Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?. <b>2020</b> , 21, 293-302	1
313	Extracting the phylogenetic dimension of coevolution reveals hidden functional signal.	0
312	Somatic Hypomethylation of Pericentromeric SST1 Repeats and Tetraploidization in Human Colorectal Cancer Cells. <b>2021</b> , 13,	1
311	Myricetin Apoptotic Effects on T47D Breast Cancer Cells is a P53-Independent Approach. <b>2020</b> , 21, 3697-3704	4
310	Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity. <b>2020</b> , 20, 2019-2035	6
309	Statistical characterization and classification of colon microarray gene expression data using multiple machine learning paradigms. <b>2020</b> , 273-317	
308	Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer. <b>2020</b> , 40,	2
307	Varlitinib Mediates Its Activity Through Down Regulating MAPK/EGFR Pathway in Oral Cancer. <b>2020</b> , 17, 51-58	
306	Strategies and Indications for Preimplantation Genetic Testing for Monogenic Disorders (PGT-M). <b>2020</b> , 49-181	
305	Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis. <b>2020</b> , 19, 1533033820983081	2
304	Effect of topotecan and zinc oxide nanoparticles combination on cytotoxicity and P53 gene expression against breast cancer (MCF-7) cell line. <b>2020</b> , 22, 192-197	
303	Analysis of Mutations in K-ras and p53 Genes in Sputum and Plasma Samples. <b>2020</b> , 2102, 373-394	1

- 302 Assessment of cervical lymph node metastasis based on total RNA from saliva and tumor tissue in patients with oral squamous cell carcinoma: An observational study. **2020**, 24, 230-236
- 301 Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases. **2020**, 6, 30
- 300 Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser.
- 299 WITHDRAW WITHDRAW WITHDRAW (Preprint).
- 298 The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time. **2021**, 12, 760039 3
- 297 Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer. **2021**, 1
- 296 CRISPR/Cas9-induced DNA damage enriches for mutations in a p53-linked interactome: implications for CRISPR-based therapies. **2021**, 3
- 295 A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. **2021**, 0
- 294 Clinical and Immunological Effects of p53-Targeting Vaccines. **2021**, 9, 762796 1
- 293 R248W Mutations in p53 Gene are Rare Among Indian Patients with Head-and-Neck Cancer. **2020**, 41, 519-522
- 292 RNA/DNA Based Detection of Minimal Residual Head and Neck Cancer. **2003**, 19-45
- 291 Immunophenotypic Characterization of Infiltrating Poly- and Mononuclear Cells in Childhood Brain Tumors. **2005**, 13-161
- 290 Hamlet; A Novel Tool to Identify Apoptotic Pathways in Tumor Cells. **2005**, 223-245
- 289 Preimplantation Genetic Diagnosis for Single Gene Disorders. **2005**, 29-110
- 288 RNA/DNA Based Detection of Minimal Residual Head and Neck Cancer. **2003**, 19-45
- 287 Smoking and Lung Cancer. **2008**, 219-239
- 286 Reovirus as an Oncolytic Agent. **2005**, 249-260
- 285 Gene Therapy for Patients With Head and Neck Cancer. **2005**, 263-278 1



- 284 Combination of Gene Therapy with Radiation. **2007**, 243-256
- 283 Molecular Markers in Epithelial Ovarian Cancer. **2007**, 29-47
- 282 Prognostic factors. **2007**, 89-105
- 281 Bedrock radioactivity influences the rate and spectrum of mutation. **2020**, 9, 4
- 280 Database and software for the analysis of mutations at the human p53 gene. **1994**, 22, 3549-50 23
- 279 Database of p53 gene somatic mutations in human tumors and cell lines. **1994**, 22, 3551-5 561
- 278 Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. **2000**, 14, 981-93 299
- 277 Cooperative effects of genes controlling the G(2)/M checkpoint. **2000**, 14, 1584-8 67
- 276 Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. **1994**, 13, 1368-74 50
- 275 A temperature-sensitive mutant of human p53. **1994**, 13, 2535-44 40
- 274 Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. **1994**, 13, 3496-504 61
- 273 Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. **1994**, 13, 5393-400 11
- 272 p53 oligomerization and DNA looping are linked with transcriptional activation. **1994**, 13, 6011-20 45
- 271 A direct effect of activated human p53 on nuclear DNA replication. **1995**, 14, 2099-105 22
- 270 8-Methoxypsoralen induced mutations are highly targeted at crosslinkable sites of photoaddition on the non-transcribed strand of a mammalian chromosomal gene. **1993**, 12, 397-402 15
- 269 mdm2 expression is induced by wild type p53 activity. **1993**, 12, 461-8 429
- 268 Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. **1993**, 12, 1021-8 59
- 267 The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. **1993**, 12, 1029-37 27

266	p53-catalyzed annealing of complementary single-stranded nucleic acids. <b>1993</b> , 12, 2389-96	73
265	Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. <b>1993</b> , 12, 2789-97	24
264	Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. <b>1993</b> , 12, 2799-808	52
263	Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. <b>1993</b> , 12, 5057-64	73
262	Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. <b>1996</b> , 15, 1615-24	37
261	Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. <b>1996</b> , 15, 3693-701	59
260	Anti-apoptotic activity of low levels of wild-type p53. <b>1996</b> , 15, 4566-73	27
259	MDMX: a novel p53-binding protein with some functional properties of MDM2. <b>1996</b> , 15, 5349-57	268
258	p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. <b>1992</b> , 11, 1383-90	97
257	Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. <b>1992</b> , 11, 2115-21	35
256	Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. <b>1992</b> , 11, 3513-20	37
255	Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. <b>1992</b> , 11, 3935-40	34
254	The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. <b>1992</b> , 11, 5013-20	129
253	Strategies for manipulating the p53 pathway in the treatment of human cancer. <b>2000</b> , 352 Pt 1, 1-17	28
252	The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. <b>1995</b> , 88, 35P-39P	4
251	Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. <b>1999</b> , 36, 610-4	82
250	Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. <b>1995</b> , 56, 608-15	136
249	Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. <b>1995</b> , 56, 1132-9	97

248	Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. <b>1997</b> , 150, 993-1007	324
247	Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. <b>1997</b> , 151, 461-70	22
246	Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis. <b>1998</b> , 152, 63-74	20
245	Differentiation-dependent p53 regulation of nucleotide excision repair in keratinocytes. <b>1997</b> , 150, 1457-64	46
244	Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. <b>1997</b> , 150, 1141-57	164
243	Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. <b>1998</b> , 152, 1091-8	94
242	Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. <b>1998</b> , 152, 1057-63	18
241	Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis. <b>1998</b> , 152, 1407-13	25
240	Prognostic significance of the proliferative activity in neuroblastoma. <b>1997</b> , 150, 133-45	22
239	Tumors associated with p53 germline mutations: a synopsis of 91 families. <b>1997</b> , 150, 1-13	283
238	p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. <b>1997</b> , 150, 177-85	245
237	Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. <b>1996</b> , 148, 1113-23	74
236	Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. <b>1996</b> , 148, 1531-41	112
235	The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. <b>1996</b> , 148, 1381-5	54
234	Prognostic significance of Bcl-2 in clinically localized prostate cancer. <b>1996</b> , 148, 1557-65	97
233	Germ cell tumors of the testis overexpress wild-type p53. <b>1996</b> , 149, 1221-8	57
232	Exon-specific DNA hypomethylation of the p53 gene of rat colon induced by dimethylhydrazine. Modulation by dietary folate. <b>1996</b> , 149, 1129-37	61
231	Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. <b>1996</b> , 149, 2143-51	121

230	Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. <b>1995</b> , 146, 1170-7	36
229	Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. <b>1995</b> , 147, 92-101	86
228	p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. <b>1995</b> , 147, 790-8	100
227	Somatic mitochondrial mutation in gastric cancer. <b>1995</b> , 147, 1105-11	57
226	p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. <b>1995</b> , 147, 884-8	83
225	Overexpression of p53 protein in basal cell carcinomas of human skin. <b>1992</b> , 141, 25-9	61
224	Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. <b>1993</b> , 142, 907-15	37
223	Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. <b>1993</b> , 142, 725-32	62
222	p53 expression in colorectal adenomas. <b>1993</b> , 142, 87-93	58
221	Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. <b>1993</b> , 142, 1163-72	81
220	p53 alterations in human squamous cell carcinomas and carcinoma cell lines. <b>1993</b> , 142, 1131-9	60
219	Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. <b>1993</b> , 142, 1347-51	51
218	Pancreatic adenocarcinomas frequently show p53 gene mutations. <b>1993</b> , 142, 1534-43	225
217	Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. <b>1993</b> , 143, 381-9	150
216	p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. <b>1993</b> , 143, 1398-405	44
215	High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. <b>1993</b> , 143, 845-56	73
214	K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. <b>1994</b> , 144, 767-75	77
213	Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. <b>1994</b> , 145, 287-93	41

212	p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. <b>1994</b> , 145, 338-44	33
211	Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. <b>1994</b> , 144, 1312-9	46
210	Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age. <b>1994</b> , 145, 1444-9	15
209	Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. <b>1994</b> , 145, 702-14	83
208	Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. <b>1996</b> , 156, 238-45	158
207	Prognostic Values of microRNAs in Colorectal Cancer. <b>2006</b> , 2, 113-121	215
206	Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. <b>2006</b> , 3, 317-324	138
205	Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. <b>1995</b> , 1, 506-26	76
204	Soft tissue sarcomas and p53 mutations. <b>1998</b> , 4, 365-72	14
203	New advances in the molecular biology of musculoskeletal neoplasms. <b>1997</b> , 17, 115-20	2
202	Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database. <b>2007</b> , 2, 277-87	1
201	Databases and QSAR for cancer research. <b>2007</b> , 2, 99-111	4
200	Biomarkers in bladder cancer: present status and perspectives. <b>2007</b> , 2, 95-105	3
199	Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. <b>1996</b> , 12, 2267-78	45
198	Targeted therapies in the management of metastatic bladder cancer. <b>2007</b> , 1, 393-406	7
197	An association between BPDE-like DNA adduct levels and CYP1A1 and GSTM1 polymorphisms in pterygium. <b>2010</b> , 16, 623-9	10
196	CYP1A1 gene polymorphisms as a risk factor for pterygium. <b>2010</b> , 16, 1054-8	5
195	CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. <b>2010</b> , 3, 515-21	9

194	Skin cancer in asians: part 1: nonmelanoma skin cancer. <b>2009</b> , 2, 39-42	43
193	Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. <b>2011</b> , 11, 2	6
192	Tobacco smoke: chemical carcinogenesis and genetic lesions. <b>1999</b> , 1, 130-5	2
191	Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. <b>2010</b> , 1, 685-90	23
190	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. <b>2010</b> , 1, 639-50	52
189	High levels of Hdmx promote cell growth in a subset of uveal melanomas. <b>2012</b> , 2, 492-507	9
188	What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia. <b>2004</b> , 11, 37-43	
187	MDM2 and MDMX: Alone and together in regulation of p53. <b>2012</b> , 1, 88-89	80
186	Serum Survivin and TP53 Gene Expression in Children with Acute Lymphoblastic Leukemia. <b>2012</b> , 41, 37-44	1
185	Socioeconomic status, p53 abnormalities, and colorectal cancer. <b>2013</b> , 4, 40-4	3
184	Somatic alterations in brain tumors. <b>2008</b> , 20, 203-10	3
183	Possible prognostic significance of p53, cyclin D1 and Ki-67 in the second primary malignancy of patients with double primary malignancies. <b>2014</b> , 7, 3975-83	4
182	Increased expression of prothymosin- $\alpha$ independently or combined with TP53, correlates with poor prognosis in colorectal cancer. <b>2014</b> , 7, 4867-76	12
181	IGFBP-3 mediates p53-induced apoptosis during serum starvation. <b>2002</b> , 21, 327-35	19
180	Implications of miRNAs in Colorectal Cancer Chemoresistance. <b>2011</b> , 2011,	8
179	The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients. <b>2014</b> , 43, 453-9	6
178	Clinicopathologic significance and survival of TIP30 expression in laryngeal squamous cell carcinoma. <b>2015</b> , 8, 6024-31	2
177	LAMP3 and TP53 overexpression predicts poor outcome in laryngeal squamous cell carcinoma. <b>2015</b> , 8, 5519-27	17

176	Association of OPN overexpression with tumor stage, differentiation, metastasis and tumor progression in human laryngeal squamous cell carcinoma. <b>2015</b> , 8, 7116-24	6
175	The silence of p66(Shc) in HCT8 cells inhibits the viability via PI3K/AKT/Mdm-2/p53 signaling pathway. <b>2015</b> , 8, 9097-104	2
174	Prognostic value of ISG15 mRNA level in drinkers with esophageal squamous cell cancers. <b>2015</b> , 8, 10975-84	8
173	Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas. <b>2015</b> , 8, 13978-86	4
172	The Evolution of Mutations: From Loss-of-Function to Separation-of-Function Mutants. <b>2016</b> , 4,	13
171	Mathematical Modeling of E6-p53 interactions in Cervical Cancer. <b>2017</b> , 18, 1057-1061	3
170	Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods. <b>2017</b> , 11, 250-261	14
169	No Evaluation of Serum P53 Levels in Iraqi Female Breast Cancer Patients. <b>2017</b> , 18, 2551-2553	1
168	Pan-cancer analysis of expressed somatic nucleotide variants in long intergenic non-coding RNA. <b>2018</b> , 23, 512-523	1
167	p53 domains: suppression, transformation, and transactivation. <b>1993</b> , 3, 95-107	30
166	p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites. <b>1995</b> , 5, 19-33	6
165	DNA Repair Footprint Uncovers Contribution of DNA Repair Mechanism to Mutational Signatures. <b>2020</b> , 25, 262-273	2
164	Expression of EZH2 and P53 and their correlation in ovarian cancer tissues. <b>2020</b> , 13, 456-464	1
163	Clinical significance of CCN5 and mutant p53 in primary and recurrent lesions of breast cancer. <b>2021</b> , 13, 8433-8437	
162	Cooperative effects of genes controlling the G2/M checkpoint. <b>2000</b> , 14, 1584-1588	174
161	Sensitivity to tumor development by TALEN-mediated Trp53 mutant genes in the susceptible FVB/N mice and the resistance C57BL/6 mice. <b>2021</b> , 37, 32	0
160	Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms. <b>2021</b> , 10,	3
159	DREAM: a database of experimentally supported protein-coding RNAs and drug associations in human cancer. <b>2021</b> , 20, 148	2

- 158 Noscipine, an Emerging Medication for Different Diseases: A Mechanistic Review. **2021**, 2021, 8402517 2
- 157 TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers.. **2021**, 12, 764749 0
- 156 A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma.. **2021**, 10, 1
- 155 Targeting disorders in unstructured and structured proteins in various diseases.. **2021**, 281, 106742 2
- 154 Biocompatible silver(I) complexes with heterocyclic thioamide ligands for selective killing of cancer cells and high antimicrobial activity - A combined in vitro and in silico study.. **2021**, 228, 111695 0
- 153 Polymorphism of TP53 gene and the risk of high human papillomavirus load in cervical epithelial cells. **2022**, 26, 101456
- 152 Genterapie ¶or zur Zukunft?. **2000**, 32, 264-269
- 151 An¶sis mutacional de los genes de la familiaTP53 en oligodendrogliomas. **2004**, 6, 37-40
- 150 Modeling of the Lipid Bilayer Mimicking the Inner Mitochondrial Membrane. **2021**, 66, 1006-1009
- 149 The co-mutation of and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients.. **2022**, 14, 185-193 1
- 148 MEK Inhibition Suppresses Metastatic Progression of KRAS-Mutated Gastric Cancer.. **2021**, 1
- 147 Extracting phylogenetic dimensions of coevolution reveals hidden functional signals.. **2022**, 12, 820 2
- 146 The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.. **2022**, 108910 1
- 145 Relevance of gene mutations and methylation to the growth of pancreatic intraductal papillary mucinous neoplasms based on pyrosequencing.. **2022**, 12, 419 0
- 144 Measurement of deaminated cytosine adducts in DNA using a novel hybrid thymine DNA glycosylase.. **2022**, 101638 0
- 143 Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression.. **2022**, 23, 1
- 142 Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.. **2022**, 14, 0
- 141 Deep muscularis propria tumor invasion without lymph node metastasis as a unique subclassification of stage IB gastric cancer: a retrospective study.. **2022**, 22, 30 0



140	Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study.. <b>2022</b> ,	1
139	microRNA-Mediated Encoding and Decoding of Time-Dependent Signals in Tumorigenesis.. <b>2022</b> , 12,	
138	Investigation of the Anticancer Effect of -Aminophosphonates and Arylidine Derivatives of 3-Acetyl-1-aminoquinolin-2()-one on the DMBA Model of Breast Cancer in Albino Rats with In Silico Prediction of Their Thymidylate Synthase Inhibitory Effect.. <b>2022</b> , 27,	3
137	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. <b>2021</b> ,	0
136	Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis.. <b>2022</b> , 436, 115883	
135	Biochemical and biophysical characterization of PADI4 supports its involvement in cancer.. <b>2022</b> , 717, 109125	1
134	Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients' Stratification.. <b>2021</b> , 11, 811486	0
133	Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.. <b>2022</b> , 174807	3
132	UXT, a novel DNMT3b-binding protein, promotes breast cancer progression via negatively modulating lncRNA MEG3/p53 axis.. <b>2022</b> , 24, 497-506	1
131	Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction. <b>1994</b> , 424, 453-7	5
130	Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. <b>1999</b> , 191, 187-99	17
129	Molecular mechanisms of metal toxicity and carcinogenesis. <b>2001</b> , 222, 3-9	31
128	Introduction. <b>2021</b> , 1-29	
127	GSEnet: feature extraction of gene expression data and its application to Leukemia classification.. <b>2022</b> , 19, 4881-4891	
126	Identification of Four Metabolic Subtypes of Glioma Based on Glycolysis-Cholesterol Synthesis Genes.. <b>2022</b> , 2022, 9448144	1
125	Non-Targeted Effects of Synchrotron Radiation: Lessons from Experiments at the Australian and European Synchrotrons. <b>2022</b> , 12, 2079	0
124	Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC.. <b>2022</b> , 12,	1
123	The metabolism of cells regulates their sensitivity to NK cells depending on p53 status.. <b>2022</b> , 12, 3234	0

122	Detection and Quantification of Tp53 and p53-Anti-p53 Autoantibody Immune Complex: Promising Biomarkers in Early Stage Lung Cancer Diagnosis.. <b>2022</b> , 12,	
121	Systematic Analysis of Molecular Characterization and Clinical Relevance of Liquid-Liquid Phase Separation Regulators in Digestive System Neoplasms.. <b>2021</b> , 9, 820174	0
120	TP53 mutations in head and neck cancer.. <b>2022</b> ,	2
119	Protecting the Rights of Persons in Case of Injury Due to the Use of Gene Therapy. <b>2022</b> , 1, 151-159	
118	The Role of Mutations in -Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.. <b>2022</b> , 14,	0
117	The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer.. <b>2022</b> , 23,	1
116	Bromelain mediates apoptosis in HeLa cells via ROS-independent pathway. 1	
115	Review on Gene Therapy on Cancer. <b>2022</b> , 37-42	
114	Structural diversity of p63 and p73 isoforms.. <b>2022</b> ,	0
113	The p53 network: cellular and systemic DNA damage responses in cancer and aging.. <b>2022</b> ,	5
112	SPATA18 Expression Predicts Favorable Clinical Outcome in Colorectal Cancer.. <b>2022</b> , 23,	0
111	Dynamic transcriptome profiling reveals essential roles of the Receptor Tyrosine Kinases (RTK) family in feather development of duck.. <b>2022</b> ,	
110	promotes the proliferation and differentiation of primary chicken myoblasts.. <b>2022</b> ,	
109	Chenodeoxycholic acid inhibits lung adenocarcinoma progression via the integrin $\beta 1$ /FAK/p53 signaling pathway.. <b>2022</b> , 923, 174925	0
108	Transcriptomics, molecular docking, and cross-resistance profiling of nobiletin in cancer cells and synergistic interaction with doxorubicin upon SOX5 transfection.. <b>2022</b> , 100, 154064	
107	Fatty acids and their lipid mediators in the induction of cellular apoptosis in cancer cells.. <b>2022</b> , 106637	1
106	Multiple Time Delays Induced Dynamics of p53 Gene Regulatory Network. <b>2021</b> , 31,	
105	MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines.. <b>2021</b> , 11,	1

104	p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways.. <b>2022,</b>	3
103	idpr: A package for profiling and analyzing Intrinsically Disordered Proteins in R.. <b>2022,</b> 17, e0266929	0
102	The oral cavity. 1597-1706	
101	Deregulated signaling networks in lung cancer. 421-442	
100	The First Twenty-Five Years of p53 Research. <b>2007,</b> 1-25	
99	Patterns of TP53 Mutations in Human Cancer: Interplay between Mutagenesis, DNA Repair and Selection. <b>2007,</b> 293-319	
98	Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX. <b>2007,</b> 73-113	
97	Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. <b>2007,</b> 183-207	
96	Image_1.pdf. <b>2020,</b>	
95	Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. <b>2004,</b> 3, 93-100	10
94	, a p53-downstream gene, is associated with suppression of breast cancer cell proliferation and better survival.. <b>2021,</b> 11, 6060-6073	
93	A Prognostic Gene Signature for Hepatocellular Carcinoma.. <b>2022,</b> 12, 841530	1
92	Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.. <b>2022,</b>	0
91	Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma.. <b>2022,</b> 13, 888250	0
90	A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma.. <b>2022,</b> 2022, 3194996	0
89	Cytotoxicity, genotoxicity, and immunohistochemical expression of p53 in the oral mucosal epithelium of adults following cone-beam computed tomography. <b>2022,</b> 503496	0
88	Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer.. <b>2022,</b>	0
87	MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides. <b>2004,</b> 2, 29-35	36

86	Kaposi Sarcoma, a Trifecta of Pathogenic Mechanisms. <b>2022</b> , 12, 1242	1
85	Accurate and sensitive mutational signature analysis with MuSiCal.	
84	Molecular Gymnastics Required for Mdmx Inhibition of P53 DNA Binding Activity.	
83	TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma. <b>2022</b> , 23,	1
82	Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity. <b>2022</b> , 120650	0
81	Molecular Investigation of the Dual Inhibition Mechanism for Targeted P53 Regulator MDM2/MDMX Inhibitors.	0
80	Identification of cancer-keeping genes as therapeutic targets by finding network control hubs.	
79	Isotypic analysis of anti-p53 serum autoantibodies and p53 protein tissue phenotypes in colorectal cancer. <b>2022</b> ,	
78	Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations. <b>2022</b> , 110401	1
77	P63 and P73 Activation in Cancers with p53 Mutation. <b>2022</b> , 10, 1490	1
76	Peptide and protein chemistry approaches to study the tumor suppressor protein p53.	
75	p53 Isoforms as Cancer Biomarkers and Therapeutic Targets. <b>2022</b> , 14, 3145	0
74	p53 Binding Sites in Long Terminal Repeat 5Hs (LTR5Hs) of Human Endogenous Retrovirus K Family (HML-2 Subgroup) Play Important Roles in the Regulation of LTR5Hs Transcriptional Activity.	3
73	Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1.	0
72	High-Resolution Imaging of Human Cancer Proteins Using Microprocessor Materials.	0
71	Ribosomopathies and cancer: pharmacological implications. 1-18	
70	Benzo(a)pyrene Diolepoxide (BPDE)-DNA Adduct Levels in Leukocytes of Smokers in Relation to Polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. <b>2004</b> , 13, 1342-1348	25
69	Epigallocatechin-3-gallate induces apoptosis in estrogen receptorβnegative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. <b>2005</b> , 4, 81-90	42

68	p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate Cancer. <b>2004</b> , 13, 2217-2224	13
67	Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. <b>2004</b> , 3, 1459-1466	26
66	Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis.	2
65	Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non-Small Cell Lung Carcinoma. <b>2005</b> , 11, 232-241	9
64	Identify non-mutational p53 loss of function in human cancers.	
63	Decreased RNA-binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B-cell lymphoma cells by regulating the p53 signaling pathway. <b>2022</b> , 26,	
62	The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. 11, 853	
61	The Interaction of Human Papillomavirus Infection and Prostaglandin E2 Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics. <b>2022</b> , 11, 2528	1
60	Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53. 9,	2
59	Research progress in toxicological effects and mechanism of aflatoxin B1 toxin. 10, e13850	2
58	Oral Papillomatosis: Its Relation with Human Papilloma Virus Infection and Local Immunity An Update. <b>2022</b> , 58, 1103	1
57	Visualization of Endogenous p53-Mediated Transcription In vivo Using Sodium Iodide Symporter. <b>2005</b> , 11, 123-128	7
56	CHOROBA NOWOTWOROWA PIERSI I NOWE ZWIŹKI O AKTYWNOŚCI PRZECIWNOWOTWOROWEJ. <b>2005</b> , 3, 10-18	0
55	Evaluation of TP53 and HER-2/neu Genes Expression Levels in Gestational Trophoblastic Diseases Cases and Determining Their Predictive Value in Diagnosis of Malignancy and Disease Progression. <b>2022</b> , 15,	0
54	Genetic Factors Contributing ROS-Driven Chemotherapy and Drug Resistance in Cancer. <b>2022</b> , 3345-3361	0
53	Cell Division/Death: Cell Cycle Cellular Senescence. <b>2022</b> ,	0
52	Oxidative Stress Player in Head and Neck Cancer Therapy Response. <b>2022</b> ,	0
51	Combating pancreatic cancer with ovarian cancer cells.	0

- 50 Introductory Chapter: p53 - The Miracle Protein That Holds the Distinction of Being Guardian of the Genome
- 49 Empirical single-cell tracking and cell-fate simulation reveal dual roles of p53 in tumor suppression. **2022**, 11,
- 48 Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase-7. **2022**, 61,
- 47 Two short linear motifs in the MDMX acidic domain bind overlapping sites on MDMX and p53. **2022**, 167844
- 46 Computational modeling of TP63-TP53 interaction and rational design of inhibitors: Implications for therapeutics.
- 45 Genetic Factors Contributing ROS-Driven Chemotherapy and Drug Resistance in Cancer. **2021**, 1-17
- 44 PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study. **2022**, 22,
- 43 p53 coordinates ECM-driven morphogenesis and gene expression in 3-dimensional mammary epithelial acini.
- 42 Chemical Carcinogenesis. 1-23
- 41 Novel Expression of Thymine Dimers in Renal Cell Carcinoma, Demonstrated through Immunohistochemistry. **2022**, 10, 2673
- 40 Characterization of full-length p53 aggregates and their kinetics of formation. **2022**,
- 39 Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo. **2022**, 11, 3614
- 38 PTC124 Rescues Nonsense Mutation of Two Tumor Suppressor Genes NOTCH1 and FAT1 to Repress HNSCC Cell Proliferation. **2022**, 10, 2948
- 37 Phylogenetic analysis of the MCL1 BH3 binding groove and rBH3 sequence motifs in the p53 and INK4 protein families.
- 36    
 **2022**, 236-245
- 35 Optical tweezers for drug discovery. **2022**, 103443
- 34 Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. **2022**, 13,
- 33 Ribosomal protein RPL11 haploinsufficiency causes anemia in mice via activation of the RP-MDM2-p53 pathway. **2023**, 299, 102739

32	Screening for Pancreatic Cancer: Current Status and Future Directions. 59-67	0
31	p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations. <b>2022</b> , 17,	0
30	Modeling and Predicting Cancer Clonal Evolution with Reinforcement Learning.	0
29	Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia.	0
28	Complete Models of p53 Better Inform the Impact of Hotspot Mutations. <b>2022</b> , 23, 15267	0
27	Generation of Anti-p53 Fab Fragments from Individuals with Colorectal Cancer Using Phage Display. <b>1999</b> , 163, 2276-2283	3
26	Epigenetics in Cancer Biology. <b>2022</b> ,	0
25	P53 protein and the diseases in central nervous system. 13,	0
24	Mechanism of andrographis paniculata on lung cancer by network pharmacology and molecular docking. <b>2023</b> , 1-21	0
23	Residue communities reveal evolutionary signatures of $\alpha$ -Cell receptor.	0
22	Novel Strategies for the Bioavailability Augmentation and Efficacy Improvement of Natural Products in Oral Cancer. <b>2023</b> , 15, 268	1
21	Therapeutic Strategies to Activate p53. <b>2023</b> , 16, 24	0
20	Molecular Pathology of Lung Tumors. <b>2021</b> , 633-669	0
19	Metabolic Health, Mitochondrial Fitness, Physical Activity, and Cancer. <b>2023</b> , 15, 814	0
18	A Look at Emerging Therapeutic Targets for Gallbladder Cancer: A Multi-Omics Approach. <b>2023</b> , 161-175	0
17	Metabolism-Guided Optimization of Tryptophan-Derived Isoindolinone p53 Activators. <b>2023</b> , 16, 146	0
16	Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation.	0
15	In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. <b>2023</b> , 387-415	0

- 14 Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207
- 13 Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. **2023**, 161, 114452
- 12 LiFraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death. OF1-OF24
- 11 Phylogenetic analysis of the MCL1 BH3 binding groove and rBH3 sequence motifs in the p53 and INK4 protein families. **2023**, 18, e0277726
- 10 Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. Publish Ahead of Print,
- 9 Effect of Nutlin-3a on stability of p53-MDM2 complex. **2023**, 72, 068702
- 8 Mutation pattern of cancer suppressor p53 gene in factory workers exposed to polypropylene and impact on their reproductive hormones.
- 7 P53 genotype-independent anticancer effects of 11-keto-beta-boswellic acid on human colorectal cancer cells.
- 6 lncRNA TRHDE-AS1 correlated with genomic landscape and clinical outcome in glioma.
- 5 Anticancer Activity of Diosgenin and Its Molecular Mechanism.
- 4 Positron emission tomography imaging sheds new light on hypoxia and antitumor therapies.
- 3 p53 Deficiency-Dependent Oncogenicity of Runx3. **2023**, 12, 1122
- 2 SPEADI: Accelerated Analysis of IDP-Ion Interactions from MD-Trajectories. **2023**, 12, 581
- 1 Synonymous alterations of cancer-associated Trp53 CpG mutational hotspots cause fatal developmental jaw malocclusions but no tumors in knock-in mice. **2023**, 18, e0284327